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Abstract 
Junctional adhesion molecule C (JAM-C) is a component of endothelial cell (EC) tight 
junctions that has been implicated in a number of endothelial functions, such as 
angiogenesis and trafficking of leukocytes through the endothelium during 
inflammation. Work within our lab has identified that loss of JAM-C at EC junctions 
results in increased reverse transendothelial migration (rTEM) of neutrophils back into 
the circulation, a response that has been associated with the dissemination of 
inflammation to distant organs. Whilst the mechanism by which JAM-C is lost or 
redistributed away from EC junctions has begun to be elucidated, little is known about 
how loss of endothelial JAM-C impacts the functions of ECs. As such, this thesis aimed 
to investigate the effect of JAM-C deficiency on EC functions to unravel possible 
molecular and cellular mechanisms of mediating neutrophil rTEM. 
To address the effect of JAM-C deficiency on EC functions, an in vitro RNA interference 
(RNAi) approach was used to efficiently knock-down (KD) JAM-C in human umbilical 
vein ECs (HUVECs). Importantly, KD of JAM-C did not affect expression of other key EC 
junctional markers such as JAM-A and VE-Cadherin and cell proliferation and apoptosis 
were similarly unaffected. Gene expression profiling using microarrays revealed that 
JAM-C depleted HUVECs exhibited a pro-inflammatory phenotype under basal 
conditions that was characterised by increased expression of pro-inflammatory genes 
such as ICAM1 and IL8. 
Following IL-1β-induced inflammation, no difference in expression of pro-inflammatory 
genes was detected between control and JAM-C KD HUVECs. However, protein levels 
of secreted chemokines such as IL-8 were reduced in JAM-C KD HUVECs following 
stimulation with IL-1β. This was corroborated by in vivo studies demonstrating reduced 
levels of secreted chemokines in the plasma of mice where JAM-C was conditionally 
deleted from ECs. 
A novel finding of this work is the demonstration that JAM-C KD HUVECs exhibit 
increased autophagy under basal conditions. This might provide a potential 
mechanism for the reduced chemokine secretion that is observed in this system, 
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whereby chemokines are preferentially trafficked for autophagosome-mediated 
degradation. 
Taken together, these findings indicate a multi-functional role for JAM-C in regulating 
EC homeostasis under basal conditions. JAM-C KD ECs respond aberrantly to 
inflammatory stimuli by secreting reduced chemokine levels, a consequence that could 
provide novel insights into the mechanisms of neutrophil rTEM under conditions of 
endothelial JAM-C loss. 
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1 General Introduction 
1.1 Inflammation 
Inflammation is the first line response of the body to injury or pathogens. 
Inflammation is commonly acute, where the end result is tissue healing and removal of 
the inflammatory trigger. By contrast, chronic inflammation is a prolonged and 
excessive response that goes beyond healing and can become detrimental to the host 
(Murakami and Hirano, 2012). This involves tissue destruction combined with 
unresolved active inflammation. As such, chronic inflammation is associated with 
many human diseases, including atherosclerosis, arthritis and cancer among others 
(Maskrey et al., 2011). Inflammation itself is characterised by the classical symptoms of 
redness, swelling, heat and pain. These are caused by an increase in blood flow to the 
affected area (redness), leakage of plasma and proteins into tissues causing oedema 
(swelling), and release of inflammatory mediators by tissue resident cells and 
infiltrating leukocytes. This process is tightly regulated, and dysregulation results in 
chronic inflammation and complications thereof (Medzhitov, 2008). 
 
1.1.1 Leukocyte adhesion cascade 
Leukocytes circulating in the blood are the defence armoury of the host and hence 
need to find a way to migrate from the blood into sites of tissue inflammation. 
Pathogen associated molecular patterns (PAMPs) and damage associated molecular 
patterns (DAMPs) stimulate sentinel cells such as tissue macrophages and dendritic 
cells (e.g. Kupffer cells, Langerhans cells) in the damaged tissue to release a range of 
pro-inflammatory mediators that initiates the process of attracting circulating 
leukocytes (e.g. neutrophils and monocytes) (Davies et al., 2013, Chen et al., 2016).  
These mediators include vasoactive amines, cytokines, chemokines, lipid mediators 
and enzymes, all of which promote rapid leukocyte recruitment and migration.  
The leukocyte adhesion cascade is a multistep process by which circulating cells 
adhere to blood vessel walls and eventually migrate into inflamed tissues. This cascade 
can be split into four principal steps: rolling, adhesion, crawling and extravasation (See 
Figure 1.1; (Ley et al., 2007)). 
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Initial leukocyte capture and rolling is mediated by selectin molecules expressed on 
both leukocytes (L-selectin) and the endothelium (P- and E-selectin). For example, 
neutrophil rolling on endothelial E-selectin is mediated through the P-selectin 
glycoprotein ligand-1 (PSGL1), which is also the dominant ligand for both E-selectin 
and L-selectin also. These selectin-ligand interactions enable leukocytes to adhere to 
the endothelium under conditions of flow. Selectins actually require shear to support 
leukocyte attachment due to their catch bond character, where the strength of each 
bond increases as shear is applied. Selectin-ligand engagement and initial leukocyte 
rolling leads to downstream signalling events in the leukocyte such as through p38 
MAPK in neutrophils that are bound to E-selectin on the endothelium, which in turn 
induces integrin activation.  Indeed, integrins also participate in leukocyte rolling. Very 
Late Antigen-4 (VLA-4) has been shown to be important for monocyte and T cell rolling 
on VCAM-1 expressed by endothelial cells. In addition, the rolling of leukocytes on E-
selectin induces a conformational change in the leukocyte integrin lymphocyte 
function-associated antigen-1 (LFA-1), which allows it to form transient interactions 
with the endothelial adhesion molecule intercellular adhesion molecule 1 (ICAM-1). 
The process of rolling enables the leukocyte to be brought into close contact with the 
endothelium, allowing for activation of the leukocyte and subsequent adhesion to the 
surface of the endothelium. 
The slowing of rolling and subsequent arrest of leukocytes on the endothelium is 
triggered by chemokines and other chemoattractants, as well as binding to EC 
adhesion molecules such as ICAM-1 and also vascular cell adhesion molecule 1 
(VCAM-1). Chemokines can be generated and displayed on the luminal surface of the 
endothelium, transported from their abluminal surface, deposited by activated 
platelets or mast cells, or delivered to ECs by microparticles. Chemokine binding to 
high affinity G-protein coupled receptors (GPCRs) on the leukocytes increases integrin 
avidity by increases both affinity and valency. The engagement of the chemokine 
receptors triggers intracellular signalling within seconds, in a process referred to as 
inside-out signalling. This signalling induces a conformational change in the integrin 
from a bent conformation to an extended high-affinity conformation that opens the 
ligand binding pocket. Different leukocyte subsets require activation of at least one of 
the major leukocyte integrins, such as LFA-1, macrophage antigen-1 (Mac-1) and 
20 
 
VLA-4. Integrin clustering and conformational changes upon arrest contribute to 
outside-in signalling events. The cytosolic tail of LFA-1 changes conformation upon 
binding to ICAM-1 which contributes to rapid leukocyte adhesion and arrest under 
flow conditions. 
In addition to chemokines, other pro-inflammatory mediators such as prostanoids and 
leukotrienes are also important during leukocyte rolling and adhesion. For example, 
leukotriene B4 (LTB4) is known to induce adhesion of neutrophils to endothelial cells  
and this is dependent on the activity of β2 integrins, which is significantly increased by 
LTB4 binding to the BLT-1 receptor on neutrophils (Subramanian et al., 2017). 
Prostaglandins such as PGE1, PGE2 and PGF have long been known to induce leukocyte 
migration (Shibuya et al., 1976). PGE2 significantly increases the chemotactic response 
of monocytes towards the chemokines CCL2 and CCL5 (Panzer and Uguccioni, 2004), 
while PGD2 has been shown to mediate the chemotaxis of leukocytes both in vitro and 
in vivo (Ricciotti and FitzGerald, 2011).  
The final step of leukocyte extravasation is migration through the venular wall, known 
as transendothelial migration (TEM). Before they traverse the endothelium though, 
leukocytes often crawl on the luminal side of the blood vessel seeking preferred sites 
to cross. This is mediated by leukocyte expressed integrin αMβ2 (Macrophage antigen-
1, Mac-1) interaction with ICAM-1 expressed on ECs (Phillipson et al., 2006, Schenkel 
et al., 2004b). Most TEM occurs via the paracellular route, which involves penetrating 
the endothelial barrier through junctions between adjacent ECs. A number of 
molecules present in these junctions actively participate in TEM, such as platelet 
endothelial cell adhesion molecule (PECAM-1) and the junctional adhesion molecule 
(JAM) family of molecules (described later). Clustering of EC integrin ligands at 
junctions provides the platform for leukocytes to engage with the junction (Carman 
and Springer, 2004). Breaching of the endothelium is then regulated by adhesion 
molecules expressed in the junctions between ECs. Transcellular TEM, where 
leukocytes breach the endothelium through the body of ECs, represents only a 
minority of events in most systems. This is not the case in the brain, where paracellular 
TEM events are highly restricted to ensure the maintenance of high endothelial barrier 
integrity (Muller, 2011). Emerging evidence regarding TEM suggest that many of the 
same molecules implicated in paracellular migration also control transcellular TEM 
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(Muller, 2013). Leukocyte migration through the endothelial barrier often occurs in a 
rapid manner, taking anywhere between 2-5 minutes. Following this, leukocytes must 
then migrate through the endothelial basement membrane and pericyte sheath in 
order to reach the affected tissue, a process which takes significantly longer (up to 15 
minutes). 
 
Figure 1.1. The leukocyte adhesion cascade. In response to injury or infection, circulating 
leukocytes are attracted to damaged tissues by pro-inflammatory cytokines and chemokines. 
The initial capture of leukocytes onto the endothelial wall begins with leukocyte rolling, which 
is mediated through interactions of selectins expressed on both the endothelium and 
leukocyte with their cognate ligands. Chemokines expressed and displayed by the endothelium 
activate the leukocytes, slowing the rolling and leading to increased binding of leukocyte 
integrins to endothelial adhesion molecules such as ICAM-1. As these interactions are 
strengthened, the rolling arrests and the leukocytes firmly adhere to the endothelium. 
Leukocytes then crawl along the endothelium until the find a suitable site to transmigrate, 
which they do through either the transcellular or paracellular route. 
 
 
1.2 Endothelial Cells 
1.2.1 Characteristics, development and role in homeostasis 
ECs line the entire vascular and lymphatic system and exhibit many important 
properties, including regulation of thrombosis and of vascular tone, maintenance of 
blood flow, angiogenesis, platelet adherence, and regulation of immune responses 
(Landmesser et al., 2004). The endothelium is an important physical barrier that 
separates the blood (and lymph) from the surrounding tissue and plays an active role 
in relaying signals from the tissue to the blood to help meet the requirements of the 
perfused organs.  
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ECs are characterised by a number of features: (1) In vessels, ECs form very elongated 
and thin shapes, often hexagonal in shape (Adamson, 1993); (2) Formation of cell-cell 
junctions crucial to their wide ranging functions (discussed in section 1.4 onwards); (3) 
Presence of Weibel-Palade bodies, rod shaped organelles specific for ECs that contains 
von Willebrand Factor (vWF) protein, but also other proteins such as P-selectin and 
IL-8. These organelles secrete their vWF stores by exocytosis (Nightingale, 2013); (4) 
Expression of a number of cell surface adhesion molecules, such as PECAM-1, Vascular 
Cell Adhesion Molecule 1 (VCAM-1), E-selectin, and additional cell-cell adhesion 
molecules such as vascular endothelial cadherin (VE-Cadherin) that are enriched at 
junctions between ECs (Nourshargh and Alon, 2014); (5) The overall phenotype of ECs 
can vary greatly, depending on their vascular bed, tissue localisation and vessel type, 
e.g. arterial vs venous and vascular vs lymphatic (Bouis et al., 2001);  
During embryonic development, ECs arise in concert with the hematopoietic lineage. 
In fact, both endothelial and hematopoietic cells are derived from the same progenitor 
cell, the hemangioblast (Choi et al., 1998). The cardiovascular system is the first organ 
to develop in the gastrulating embryo. The organisation of ECs into vessels in the 
absence of any vascular system in known as vasculogenesis. Angiogenesis is the 
continued expansion of the vascular tree in the embryo and continues into maturity, 
where it is important for wound healing and tumour metastasis (Cines et al., 1998)  
ECs are important in inhibiting coagulation through a number of mechanisms, 
including expressing tissue factor inhibitors (Lupu et al., 1997), expression of heparin 
sulphate proteoglycans that inactive thrombin (Mertens et al., 1992), and production 
of endothelial cell protein C receptor (ECPCR) to inhibit the clotting cascade 
(Thiyagarajan et al., 2007). ECs also produce nitric oxide (NO) and prostacyclin to 
inhibit platelet aggregation (Moncada et al., 1976). Resting ECs very rarely interact 
with circulating leukocytes, as they sequester ligands and chemokines intracellularly 
and suppress the transcription of other inflammatory molecules (Deanfield et al., 
2007). For example, P-selectin is found stored within Weibel-Palade bodies and has 
been shown to be recruited to this organelle during its formation at the trans-golgi 
network (Metcalf et al., 2008). This has been shown to be functionally important, 
where mice lacking vWF and therefore Weibel-Palade bodies, cannot store P-selectin 
properly and subsequently show decreased leukocyte adhesion (Denis et al., 2001).  
23 
 
 
1.2.2 Control of EC gene expression 
The E26 transformation specific (ETS) family of transcription factors are essential for 
controlling EC gene expression under basal conditions. Indeed, ETS binding motifs have 
been found in a number of key EC expressed genes, such as VEGFR2, TIE2, ENOS and 
CDH5 (Shah et al., 2016). In particular, the ETS related gene, or Erg, is a crucial 
regulator of EC homeostasis and gene expression. It is key in regulating the 
transcription of a number of EC junctional genes such as VE-Cadherin and Claudin-5, as 
well as in maintaining vessel development and vessel stability (Birdsey et al., 2008, 
Yuan et al., 2012). Particularly important is the anti-inflammatory actions of Erg, where 
it represses the expression of pro-inflammatory genes such as ICAM1, VCAM1 and IL8. 
This repression is brought about through inhibition of nuclear factor kappa-light-chain-
enhancer of activated B cells (NFκB) subunit p65 binding to its target gene promoters 
(Dryden et al., 2012, Sperone et al., 2011). 
A range of other molecules are also key for regulating EC gene expression in vitro and 
in the mature vasculature in vivo. Sirtuin-1 (SIRT1) controls the angiogenic activity of 
ECs through regulation of chromatin remodelling and therefore gene expression 
(Potente et al., 2007). In vivo, where ECs in blood vessels are constantly exposed the 
laminar shear stress, an anti-oxidant and anti-apoptotic gene expression phenotype is 
induced, which is cytoprotective and helps ensure EC homeostasis is maintained 
(Wasserman et al., 2002). 
Angiopoietin-1 controls vascular development through the transcription factor 
Forkhead Box protein O1 (FoxO1), leading to a pro-survival phenotype and maturation 
of blood vessels (Daly et al., 2004). Angiopoietin-1 has also been shown to induce Erg 
phosphorylation through PI3K/Akt signalling, increasing the transcription of Erg-
responsive genes such as Delta-like ligand 4 (Dll4) and so regulating vascular tone and 
stability (Shah et al., 2017). In addition, angiopoietin-1 controls EC proliferation and 
migration through increased expression of IL-8, resulting from elevated MAPK and PI3K 
signalling, inducing increased DNA binding of the transcription factor AP-1 to the IL-8 
promoter (Abdel-Malak et al., 2008). 
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1.3 Endothelial cells in inflammation 
ECs can be activated by a number of stimuli, and this activation can be classed as 
either type I or type II. Type I activation is independent of further gene expression, 
while type II activation is dependent on additional transcription (Pober and Sessa, 
2007). Type I activation involves binding of ligands to G-protein coupled receptors on 
the cell surface, triggering intracellular G-protein signalling and a subsequent increase 
in release of Ca2+ from the endoplasmic reticulum (ER). This increases blood flow, 
blood pressure (Harris et al., 2008) and vascular leakiness, as well as playing a major 
role in leukocyte recruitment. This type of activation is very short lived, only lasting for 
about 10-20 minutes. Longer activation and prolonged inflammatory responses require 
type II activation, mediators of which include tumour necrosis factor α (TNFα) and 
interleukin 1 β (IL-1β). Stimulants such as these lead to activation of transcription 
factors (e.g. nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB) and 
activator protein 1 (AP-1)) that initiate the transcription of pro-inflammatory genes. 
TNFα and IL-1β also cause vascular leakiness through the reorganisation of EC actin 
and tubulin cytoskeletons. Leukocyte recruitment is much more efficient following 
type II activation due to the synthesis and release of chemokines (e.g. CXCL1, IL-8, 
CCL2) and upregulation of adhesion molecule expression (e.g. E-selectin, ICAM-1 and 
VCAM-1) that facilitate efficient emigration of leukocytes into inflamed tissues (Ley 
and Reutershan, 2006). 
 
1.3.1 Generation of chemokines by endothelial cells 
The production of chemokines by ECs is crucial for the efficient recruitment of 
leukocytes to sites of injury or infection. Primarily, chemokines act to induce integrin 
expression, clustering and activation on target leukocytes, such as LFA-1, resulting in 
the arrest of rolling leukocytes and the promotion of TEM (Turner et al., 2014). 
Perhaps the most studied chemokine is IL-8 (CXCL8), and its mouse homologs Cxcl1, 
Cxcl2 and Cxcl5, which are highly chemotactic and crucial for neutrophil recruitment. It 
is also chemotactic for monocytes and some lymphocytes. These chemokines all bind 
with various affinities to the receptor CXCR2 on target leukocytes, activating 
downstream signalling pathways induce the subsequent firm adhesion of leukocytes.  
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Binding of IL-8 to its receptor stimulates the formation of β2 integrin complexes in 
neutrophils (Detmers et al., 1990) and has been shown to induce β2 integrin mediated 
arrest of neutrophils in vivo (Bargatze and Butcher, 1993). Downstream signalling 
events of IL-8 receptor engagement include MAPK and PKC activation, which are both 
needed for IL-8 stimulated adhesion of neutrophils through Mac-1 in vitro (Takami et 
al., 2002) Binding of IL-8 to its receptor CXCR2 on target leukocytes has also been 
shown to induce signalling through the phosphatidylinositol 3-kinase/protein kinase B 
(PI3K/Akt) pathway, resulting in the mobilisation of molecules key for leukocyte TEM 
such as the integrin Mac-1 (Smith et al., 2006). 
The synthesis of chemokines by ECs is well established and this process can be 
upregulated by inflammatory stimuli (Oynebraten et al., 2004). Human lung 
microvascular ECs have been shown to constitutively express CCL2 and IL-8, and their 
increased expression can be induced by interleukin 1-alpha (IL-1α), interferon-gamma 
(IFNγ) and TNFα (Brown et al., 1994). Some chemokines, such as IL-8, are preformed 
and are contained in Weibel-Palade bodies alongside vWF and as a result IL-8 is rapidly 
released within minutes of stimulation by histamine and thrombin (Utgaard et al., 
1998). Furthermore, additional chemokines such as Gro-α (CXCL1) and CCL2 have been 
demonstrated to reside pre-stored in small vesicles, and CCL26 (Eotaxin 3) has been 
shown to be present in Weibel-Palade bodies (Oynebraten et al., 2004). These 
chemokines are stimulated to be secreted rapidly from ECs by secretagogues such as 
histamine, whereas others such as CXCL10 (IP-10) and CCL5 (RANTES) are not. 
 
1.3.2 Endothelial cell adhesion molecules 
As explained in section 1.1.1, EC adhesion molecules are critical for leukocyte TEM. The 
selectins are a family of lectin-like transmembrane glycoproteins that function to 
mediate leukocyte rolling (as described in section 1.1.1). Only P- and E-selectin are 
expressed by ECs. The expression of E-selectin is upregulated in inflammation, while P-
selectin is constitutively expressed by some vascular beds and is stored in Weibel-
Palade bodies enabling it to be rapidly mobilised upon stimulation (Granger and 
Senchenkova, 2010). Ligands for E- and P-selectin on circulating leukocytes, such as 
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PSGL1, enable the efficient capture and rolling of leukocytes on vessel walls, further 
enabling their activation by chemokines displayed by those ECs. 
Another important family of EC adhesion molecules are the Immunoglobulin-like 
adhesion molecules, namely ICAM-1, ICAM-2 and VCAM-1 and PECAM-1. These 
molecules bind cognate integrins expressed by rolling leukocytes to ensure slow 
leukocyte rolling is translated into arrest and firm adhesion. ICAM-1 and VCAM-1 
expression is kept low under basal conditions but its expression can be rapidly induced 
by a number of inflammatory stimuli. By contrast, ICAM-2 expression remains 
significant in most vascular beds under basal conditions (Granger and Senchenkova, 
2010). VCAM-1 is important for monocyte and lymphocyte adherence to ECs, through 
its interaction with the α4β1 integrin VLA-4. β2 integrins, such as Mac-1 and LFA-1, bind 
to ICAM-1 expressed on ECs and mediate adhesion of a number of leukocyte subtypes, 
especially neutrophils, monocytes and lymphocytes. Importantly, ICAM-1 and VCAM-1, 
are known to cluster on the EC at contact sites with the leukocyte, helping to firmly 
adhere the leukocyte to the surface of the endothelium prior to TEM (Tilghman and 
Hoover, 2002, van Buul et al., 2010, Wojciak-Stothard et al., 1999). 
PECAM-1 was the first EC membrane protein shown to mediate neutrophil TEM in vivo 
and in vitro. PECAM-1 expressed on the endothelium interacts homophilically with 
PECAM-1 expressed on leukocytes, an interaction which has been shown to be 
required for leukocyte TEM (Muller et al., 1993). Blockade of PECAM-1 on either ECs or 
leukocytes with blocking antibodies abrogates leukocyte TEM, but has no effect on 
leukocyte adhesion to the endothelium (Muller, 1995). 
In the majority of mouse strains, PECAM knockout blocks leukocyte TEM and arrests 
leukocytes on the apical side of the endothelium. This however, is not the case for all 
strains of mice. The commonly used C57BL/6 mice are unresponsive to either PECAM 
blockade or genetic deletion in terms of leukocyte TEM. Instead, leukocytes in this 
strain are arrest post TEM in the basement membrane. This highlights the complexity 
in the functional role of PECAM depending on the mouse strain used (Schenkel et al., 
2004a, Sullivan and Muller, 2014). 
Further studies into this phenomenon have shown that PECAM also regulates 
leukocyte TEM in a tissue and stimulus specific manner (Woodfin et al., 2007). Here 
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the authors show that PECAM-1 mediates leukocyte TEM responses to stimuli such as 
IL-1β in the mouse cremaster muscle and lungs but not in response to stimuli such as 
TNFα or adenovirus. In addition, cultured ECs only exhibit PECAM-1 dependent 
neutrophil TEM responses after stimulation with IL-1β, but not IL-8 or LTB4. Clearly, 
PECAM-1 is not as essential for leukocyte TEM as originally described and its role in 
TEM is mouse strain, tissue and stimulus specific. 
VE-Cadherin is a major EC surface adhesion molecule usually localised to junctional 
regions, which negatively regulates leukocyte TEM. It has been shown that blocking 
VE-Cadherin in vivo enhances neutrophil TEM (Gotsch et al., 1997) and that it is 
transiently removed from EC junctions during TEM (Allport et al., 2000). Under resting 
conditions, receptor-type tyrosine-protein phosphatase (VE-PTP) associates with VE-
Cadherin and thus maintains it in a state of dephosphorylation. This stabilises VE-
Cadherin at adherens junctions and therefore maintains the barrier function (Muller, 
2014).  
The adhesion of leukocytes to ECs has been shown to trigger the dissociation of this 
VE-Cadherin/VE-PTP complex, enabling VE-Cadherin to be phosphorylated. This occurs 
through a VCAM-1-Rac1-Pyk2 kinase signalling pathway (Nottebaum et al., 2008). The 
phosphorylation of VE-Cadherin inhibits binding of partners B-catenin and p120, 
facilitating its removal from adherens junctions. This process is essential for leukocyte 
TEM to occur, as mutation of either C-terminal tyrosine in the cytoplasmic tail of VE-
Cadherin drastically reduces leukocyte TEM (Allingham et al., 2007). 
These adhesion molecules are also important for other EC functions, such as 
angiogenesis. Endothelial expressed E- and P-selectin has been shown to be important 
in regulating skin wound healing, where deficiency of one or both delays healing 
(Yukami et al., 2007). The same is also true of ICAM-1. E-selectin has also been shown 
to be expressed in proliferating ECs in models of non-inflammatory angiogenesis 
(Kraling et al., 1996). Soluble forms of these adhesion molecules have also been shown 
to regulate angiogenesis. Soluble ICAM-1 (sICAM-1) has been shown to induce EC 
migration, tube formation and tumour growth in vivo (Gho et al., 2001, Gho et al., 
1999), while E-selectin and soluble VCAM-1 (sVCAM-1) were shown to be chemotactic 
for ECs in vitro and angiogenic stimuli in vivo (Bodolay et al., 2002). 
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Numerous other adhesion molecules are expressed by ECs, with their pattern of 
expression and localisation, such as at junctional regions, playing a key role in 
inflammation and leukocyte TEM, as discussed below. 
 
1.4 Endothelial cell junctions 
Key to the function of ECs is their ability to form cell-cell junctions and therefore act as 
gatekeepers for access of blood borne proteins and circulating immune cells to the 
interstitial tissue. ECs adhere to each other through these junctions, the interactions in 
which are mediated by a number of transmembrane proteins. These proteins are 
linked to intracellular partners that help stabilise the junctions through anchoring the 
actin cytoskeleton (Bazzoni, 2004). During the process of leukocyte transmigration, the 
interaction of leukocytes with EC junctional molecules ensures that the barrier 
between the blood and the tissue remains intact. EC junctions, established at the 
contact point between two adjacent ECs (see Figure 1.2), form two principal modes of 
cell-cell adhesion; adherens junctions and tight junctions, each of which is described in 
detail below:  
 
1.4.1 Adherens junctions 
Adherens junctions are found across the mature vasculature, in both blood and 
lymphatic vessels. In ECs, they are characterised by the expression of an EC specific 
cadherin, namely VE-Cadherin. This molecule is expressed during development once 
cells become committed to the EC lineage (Breier et al., 1996). ECs have also been 
shown to express other cadherins such as N-Cadherin and T-Cadherin, albeit at much 
lower levels (Ivanov et al., 2001, Navarro et al., 1998). In stable adherens junctions, VE-
Cadherin is found bound to its partner molecules, the catenins, which anchor the 
junctions into the actin cytoskeleton of the cell. Most well studied of these are β-
catenin and plakoglobin. Binding of these catenins to VE-Cadherin at cell-cell contacts 
stabilises them and sequesters them at the membrane, inhibiting their activity to 
shuttle to the nucleus and regulate gene transcription (Yamada et al., 2005). Thus, 
reduced expression of VE-Cadherin may increase the free cytosolic pool of catenins 
and therefore increase transcriptional activity resulting from their signalling. 
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Figure 1.2. Organisation of endothelial cell junctions. 
Endothelial junctions are split into two distinct types; adherens and tight junctions. Adherens 
junctions, shown here at the top, classically contain transmembrane proteins such as VE-
Cadherin and PECAM-1. These are the first junctions to form during EC junction biogenesis and 
are heavily cross-linked to the actin cytoskeleton through the activity of VE-Cadherin binding 
proteins such as α- and β-catenin. Tight junction proteins were originally characterised by the 
expression of zona occludens proteins, ZO-1 and ZO-2 being the most prominent. These 
intracellular proteins have been shown to bind a number of transmembrane proteins at tight 
junctions, such as the claudins, occludin and members of the JAM family. Hetero- and 
homophilic interactions between members of the JAM family are often found at the edges of 
tight junctions, immediately adjacent to areas of adherens junctions. While adherens junctions 
are primarily important for structural organisation, tight junctions, as the name might suggest, 
form an impervious barrier to blood and tissue fluid. 
 
PECAM-1 is another transmembrane protein that is often found at the edge of 
adherens junctions is ECs but is not restricted to this compartment. It can also be 
found on non-junctional apical membranes, as well as being expressed on both 
leukocytes and platelets. It is important for regulating leukocyte transmigration and 
has been shown in a number of models to regulate vascular permeability. Both 
PECAM-1 knockdown (KD) ECs and PECAM-1 knockout (KO) mice exhibit increased 
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permeability and vascular leakage (Muller, 1995, Privratsky and Newman, 2014). It has 
also been shown to associate with β-catenin, suggesting it uses a similar mechanism to 
signal from EC adherens junctions. 
Adherens junctions are crucial in forming stable cell-cell contacts and supporting the 
formation of a confluent EC monolayer. These molecules also have complex 
interactions with the intracellular cytoskeletal network. As such, adherens junctions 
are crucial for EC functionalities. For example, VE-Cadherin deficient ECs are unable to 
respond to vascular endothelial growth factor (VEGF) stimulation (Carmeliet et al., 
1999). It was also discovered in the same study that VE-Cadherin associates with 
vascular endothelial growth factor receptor 2 (VEGFR2) at adherens junctions to 
induce PI3K activation upon VEGF binding to VEGFR2, thus promoting EC survival. 
 
1.4.2 Tight junctions 
In epithelial cells, tight junctions are mostly found at the apical side of the junction and 
the adherens junctions located below in a more basolateral manner. In ECs, the 
distribution of the two types is much less defined and they are more intermingled 
throughout the whole junction/cleft, forming a zipper-like structure (Dejana, 2004). 
The tight junctions, originally defined as the zona occludens, as the name would 
suggest form tight contacts between adjacent ECs to act primarily as a diffusion barrier 
(Bazzoni, 2004). Tight junctions vary considerably according to their localisation within 
the wider vascular tree. Areas exposed to high laminar flow, such as aortic ECs, have 
very well organised tight junction structures more located to the apical side. By 
contrast post-capillary venules, which are the primary sites of leukocyte 
transmigration, have much less complex tight junction structures. 
A number of molecules classically define the tight junctions of ECs. Occludin was the 
first transmembrane protein of tight junctions to be identified, where it is present at 
high concentrations in brain ECs especially. As such, it is a crucial determinant of brain 
EC permeability, an important function in this tissue bed (Hirase et al., 1997). Of the 
claudin molecules, Claudin-5 is the most prominent in ECs, where it acts to limit 
paracellular permeability across EC monolayers (Kluger et al., 2013). Intriguingly, VE-
Cadherin in adherens junctions has been shown to regulated Claudin-5 expression by 
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preventing the nuclear translocation of β-catenin which represses Claudin-5 
expression. This indicates cross-talk can occur between these two junctional structures 
in ECs (Gavard and Gutkind, 2008). 
Zona occludens-1 (ZO-1) is perhaps the most well studied tight junction protein. Along 
with its closely related family members zona occludens-2 (ZO-2) and zona occludens-3 
(ZO-3), these are cytosolic proteins that associate peripherally with tight junction 
structures to organise and assemble molecular complexes. ZO-1 can bind to a number 
of tight and adherens junctions molecules such as occludin, claudins, JAMs and VE-
Cadherin, and also links into the actin cytoskeleton through proteins such as cortactin 
and cingulin-like 1 (Bazzoni et al., 2000, Tornavaca et al., 2015, Odenwald et al., 2017). 
Recently, it has been identified that ZO-1 is an important regulator of cell-cell tension 
and adherens junctions in ECs, angiogenesis and barrier formation (Tornavaca et al., 
2015). 
 
1.4.3 Formation of EC junctions 
The mechanisms by which EC junctions are established are poorly understood. Its 
widely accepted that significant actin cytoskeleton rearrangements are likely to be 
involved during initial contacts between two adjacent ECs. One recent study has used 
subconfluent human umbilical vein endothelial cells (HUVECs) to determine the initial 
events in formation of EC adherens junctions (Hoelzle and Svitkina, 2012). Here, 
protruding lamellipodia convert into filopodia-like bridge structures in initial cell-cell 
contacts. These bridges are highly enriched with VE-Cadherin and filopodia markers 
such as fascin. The actin network within these filopodia collapses into tight actin 
bundles as the bridges are formed. Non-muscle myosin II invades and incorporates 
into the maturing bridges to ensure stabilisation of these nascent structures. The 
activity of myosin II in these bridges is essential for continued bridge maturation and 
VE-Cadherin accumulation. 
It is not known how formation and stabilisation of adherens junctions in ECs then leads 
to tight junction formation. In epithelial cells, E-Cadherin contacts in adherens 
junctions are important for the organisation of tight junctions (Contreras et al., 2002). 
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Presumably a similar mechanism occurs in ECs, where the establishment of stable VE-
Cadherin contacts would enable the organisation of tight junctions. 
1.5 Junctional adhesion molecules (JAMs) 
One important family of molecules involved in the formation of EC tight junctions are 
the JAMs. These molecules are members of the CTX (Cortical Thymocyte marker for 
Xenopus) family and belong to the wider immunoglobulin superfamily of molecules. 
The family consists of three closely related molecules, Junctional adhesion molecule-A, 
-B and -C (JAM-A, JAM-B and JAM-C), also known as the classical members. The family 
also includes the related proteins junctional adhesion molecule-4 (JAM4), JAM-like 
(JAM-L), Coxsackie and adenovirus receptor (CAR), CAR-like membrane protein (CLMP) 
and endothelial cell-selective adhesion molecule (ESAM). Much of the functions of the 
classical JAMs have been identified through their roles in tight junctions of epithelial 
and ECs (Ebnet et al., 2004). 
 
1.5.1 Expression 
JAM-A has been shown to be expressed on the surface of both epithelial and ECs (Liu 
et al., 2000), together with various blood cells (including platelets, monocytes, and 
lymphocytes) and tissue resident immune cells (macrophages and dendritic cells) 
(Gupta et al., 2000, Malergue et al., 1998, Williams et al., 1999). JAM-B expression by 
contrast is restricted to the endothelium, both vascular and lymphatic (Palmeri et al., 
2000), and no expression has been reported on any circulating cells. Similar to JAM-A, 
JAM-C is expressed on both epithelial and ECs, as well as a number of other cell types 
discussed in section 1.3.4. No expression has yet been found on circulating mouse 
blood cells, however it is expressed on various human leukocyte subsets. 
All of the JAMs localise to the tight junction regions of polarised epithelial and ECs, 
however they differ in their sub-compartmental localisation. JAM-C co-localises with 
ZO-1 at tight junctions, whereas JAM-A only partially co-localises with ZO-1 (Aurrand-
Lions et al., 2001b) and JAM-B is found more diffusely at the lateral membrane. The 
difference in expression is also apparent in different tissue. For example, high 
endothelial venules (HEVs) and lymphatic ECs have high levels of JAM-B and JAM-C, 
but lower levels of JAM-A (Aurrand-Lions et al., 2001b). 
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Table 1.1. Expression and functions of the members of the JAM family. 
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1.5.2 Structure and interactions 
The classical JAM family members have very similar structures, sharing about 35% 
sequence identity in mice (Aurrand-Lions, 2000), and have less identity (about 15%) to 
the more distant family members (e.g. JAM-L). The JAMs are type I transmembrane 
glycoproteins, with a structure composed of two Immunoglobulin (Ig)-like extracellular 
domains, a transmembrane domain and a short cytoplasmic tail containing a type II 
PDZ binding motif and ZO-1 binding domain. The two Ig domains are made up of one 
V-type domain containing a J-like sequence at the N-terminal end and a C2-type 
domain which is proximal to the transmembrane domain. For JAM-C, both the V-type 
and C2-type domain contain one disulphide. In JAM-B and JAM-C, the V-type domain 
has one disulphide bridge as for JAM-A, whereas the C2-type domain contains two 
disulphide bridges (see Figure 1.3). The type II PDZ binding motifs in the classical JAMs 
can interact with a number of intracellular scaffolding proteins which helps form 
polarity complexes (Ebnet, 2003). The non-classical JAMs differ mainly in their C-
terminal sequences, which are longer and contain and type I PDZ binding motifs 
instead of type II motifs.  
JAMs can form homophilic interactions in trans via their extracellular domains, and 
they can also form heterophilic, interactions with other JAM family members or 
integrins, in either cis or trans configurations. For example, JAM-B and JAM-C form a 
heterophilic interaction between adjacent ECs (Lamagna et al., 2005b), while JAM-A is 
able to interact with LFA-1 on leukocytes and αVβ3 integrin on the endothelium 
(Fraemohs et al., 2004, Naik and Naik, 2006). JAM-B can also interact with α4β1 integrin 
on leukocytes (Ludwig et al., 2009). 
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Figure 1.3. Schematic structure of JAM-C and its type II PDZ binding domain. 
(A) Structure of JAM-C. From the N-terminal end, the JAM-C extracellular domain contains two 
Ig-like domains, one V-like and one C2-like, held in conformation by disulphide bridges. This is 
followed by a short single pass transmembrane domain and a short cytoplasmic tail, which 
contains a type II PDZ binding domain at the C-terminus. This domain enables binding of JAM-C 
to PDZ domain containing proteins such as ZO-1. 
(B) Amino acid sequence of the type II PDZ binding domains of JAM-A, -B and –C. Al three of 
the classical JAMs share high sequence similarity in their PDZ-binding domains, reflecting both 
their overall sequence and structural homology and also their ability to similarly bind proteins 
such as ZO-1. The five amino acid sequence of the PDZ binding domain begins at the C-
terminus in the JAMs, here shown as C-term, with each corresponding amino acid referred to 
as C-1, C-2 and so on. 
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1.5.3 Functions of the JAM family in the endothelium and beyond 
The functional roles of EC JAMs have been intensely studied, indicating their important 
roles in inflammation and leukocyte trafficking, vascular permeability and 
angiogenesis. 
JAM-A was the first family member identified to play a role in leukocyte transmigration 
(Martin-Padura et al., 1998). This study showed that blockade of JAM-A inhibited 
monocyte transmigration across endothelial monolayers in vitro and into sites of 
inflammation in a mouse subcutaneous air pouch model(79)(78). Use of JAM-A 
deficient mice subsequently highlighted the importance of JAM-A in leukocyte 
transmigration (Cera et al., 2004). Further analysis of this phenomenon revealed that 
JAM-A controls leukocyte TEM by interacting with LFA-1 on leukocytes (Ostermann et 
al., 2002). Some in vitro studies have indicated that the relocalisation of JAM-A away 
from EC junctions following inflammatory stimulation could be responsible for guiding 
leukocyte TEM (Stamatovic et al., 2012). There are inconsistencies in the literature 
though for the importance of JAM-A in regulating this process. Some have reported 
that inflammatory stimulation of ECs with TNFα and IFNγ under flow conditions, where 
JAM-A is redistributed away from lateral junctions, has no effect on leukocyte TEM 
(Shaw et al., 2001). In vivo studies conducted by our lab identified that sequential 
action of intercellular adhesion molecule 2 (ICAM-2), JAM-A and PECAM-1 modulated 
IL-1β-induced migration of neutrophils through venular walls (Woodfin et al., 2009). 
JAM-A and JAM-B also have a role in angiogenesis, with the majority of work being 
conducted in relation to JAM-A. It was shown that basic fibroblast growth factor 
(bFGF) activation of ECs caused a dissociation of JAM-A:αVβ3 integrin interaction that 
allowed angiogenic signalling to proceed (Naik et al., 2003). Blockade of JAM-A 
signalling reduces bFGF induced angiogenesis, and JAM-A deficient mice have impaired 
bFGF-induced angiogenesis (Cooke et al., 2006). Recent evidence has highlighted a role 
for JAM-A in regulating wound induced inflammation and angiogenesis. Chatterjee et 
al., showed that JAM-A deficient mice have spontaneous corneal wounding associated 
with angiogenesis. This is correlated with increased Vascular endothelial growth factor 
A (VEGF-A) and VEGF receptor 2 (VEGF-R2) signalling, suggesting that JAM-A also 
regulates VEGF-R2 driven angiogenesis (Chatterjee et al., 2013). 
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JAM-B has been less well studied in leukocyte TEM. It is known to interact with α4β1 
integrin, which in turn mediates T-lymphocyte adhesion to ECs via VCAM-1 (Berlin et 
al., 1993). JAM-B has been implicated in leukocyte extravasation into mouse skin 
(Ludwig et al., 2005) and there is evidence for its involvement in supporting T cell 
rolling and adhesion via interactions with α4β1 integrin expressed on the T cells 
(Ludwig et al., 2009). JAM-B has also been shown to maintain hematopoietic stem cells 
in the bone marrow through a JAM-C dependent interaction (Arcangeli et al., 2011), 
and in regulating VEGF/VEGFR2 signalling during angiogenesis (Meguenani et al., 
2015). However most of the interest in JAM-B has been in relation to its interaction 
with JAM-C in the endothelium (see section 0). 
JAML has been shown to be expressed on both neutrophils and monocytes. In 
neutrophils, it regulates transepithelial migration (TEpM) (Zen et al., 2005), while in 
monocytes it binds to CD49d/CD29 integrin expressed on ECs and ensures increased 
adhesion to ECs (Luissint et al., 2008). ESAM expression is restricted to platelets and EC 
tight junctions, where it plays a role in neutrophil TEM. ESAM KO mice display much 
reduced leukocyte transmigration, while adhesion and rolling where unaffected. In 
addition, these mice exhibited reduced vascular permeability as stimulated by VEGF, 
due to reduced Rho activation at EC junctions (Wegmann et al., 2006). CAR has been 
shown to be crucial for spermatogenesis in mice through its interactions with JAM-C in 
spermatozoa, postulating a role for both molecules in spermatogenesis and male 
fertility (Mirza et al., 2006). JAM4 was originally identified as an adhesion molecule 
that regulates epithelial permeability. No roles have yet been found for this molecule 
in leukocyte migration. Studies on JAM4 KO mice have revealed no clear phenotype 
and so the physiological role of this molecule is unclear (Nagamatsu et al., 2006). 
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1.6 JAM-C 
1.6.1 Expression 
JAM-C was originally identified in 2000 as a novel immunoglobulin superfamily 
member similar in sequence to JAM-A and expressed in both vascular and lymphatic 
ECs (Aurrand-Lions et al., 2001a). Following this, it was demonstrated that this 
expression of JAM-C localised to the tight junctions of ECs (Aurrand-Lions et al., 
2001b). The literature suggests that JAM-C exhibits different expression patterns 
between various types of ECs. Orlova et al., 2006 showed that in human dermal 
microvascular ECs (HDMECs), JAM-C is redistributed to the junctions of ECs from an 
intracellular pool upon stimulation with vasoactive factors such as VEGF or histamine 
(Orlova et al., 2006). In HUVECs JAM-C is constitutively expressed at EC junctions and 
this is reportedly increased following cell stimulation by VEGF or histamine (Orlova et 
al., 2006). However this contrasts with other reports which showed that surface JAM-C 
expression is low In HUVECs, but that there is a significant intracellular pool of JAM-C 
(Sircar et al., 2007). Application of inflammatory stimuli such as lipopolysaccharide 
(LPS) and IL-1β did not increase the junctional expression of JAM-C in this model. Data 
acquired as part of the present work in our lab has shown that JAM-C is expressed at 
the cell surface of HUVECs where it is most abundant at the cell-cell junctions. 
Unsurprisingly, JAM-C is also expressed in epithelial cells, where like JAM-A, it localises 
to tight junctions, see Figure 1.4 (Ebnet, 2003, Zen et al., 2004). In particular, it has 
been shown to be important in the formation of tight junctions in the human retinal 
pigment epithelium (Economopoulou et al., 2009). Expression of JAM-C has also been 
found in a number of other tissues, including nerves, fibroblasts, platelets and 
leukocytes. Our laboratory discovered JAM-C expression in peripheral nerves, where 
the expression was found to be localised to Schwann cells at junctions (see Figure 1.4) 
between myelin end loops (Scheiermann, 2007). Further investigations revealed that 
Schwann cell JAM-C KO mice exhibited several neural and behavioural defects (Colom 
et al., 2012), postulating a role for JAM-C in modulating neuronal responses. 
Fibroblasts from a number of tissue sources, such as cornea, lung and skin, express 
JAM-C in adherens-like junctions and colocalise with ZO-1 expression. More recently 
JAM-C expression has also been shown in lymph node fibroblast reticular cells where it 
is important for regulating T cell emigration from lymph nodes (Frontera et al., 2011). 
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Platelets also express JAM-C, where it was identified as a receptor for Mac-1 integrin 
expressed on leukocytes (Santoso et al., 2002). In atherosclerotic lesions, JAM-C is 
highly expressed in both endothelial and smooth muscle cells (Keiper et al., 2005). 
Human leukocytes but not mouse leukocytes express JAM-C, therefore highlighting a 
potential species difference in roles of JAM-C. JAM-C expression has been found on 
both naïve and activated T cells (Immenschuh et al., 2009) as well as B lymphocytes 
where it is postulated it might present a marker for distinguishing germinal center B 
cells (Ody et al., 2007). 
 
 
Figure 1.4. Expression of JAM-C in mouse tissue. 
(A) ECs from cremaster venules co-stained for EC markers VE-Cadherin and PECAM-1; (B) 
epithelial cell layer of cremaster muscle; (C) Sciatic nerves stained for adherens junction 
marker E-Cadherin, Schwann cell basement membrane marker laminin α2, and JAM-C. Figure 
adapted from Colom et al., 2012 
 
 
1.6.2 JAM-C ligands 
A number of ligands for JAM-C have been identified. At EC tight junctions, JAM-C forms 
homodimers in trans with JAM-C, as well as heterodimers with JAM-B on adjacent ECs 
(Arrate et al., 2001, Lamagna et al., 2005b). It has also been shown to interact with the 
β2-integrin Mac-1 that is present on a number of leukocytes and therefore a Mac-1-
JAM-C interaction is likely involved in supporting leukocyte adhesion and 
transmigration (Chavakis et al., 2004, Santoso et al., 2002). The PDZ binding motif of 
JAM-C has been shown to interact with the cell polarity protein protease activated 
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receptor 3 (PAR-3), thereby proposing a role for JAM-C in regulating cellular polarity 
(Ebnet, 2003, Ebnet et al., 2017). Through the type II PDZ binding domain, JAM-C is 
able to bind to the tight junction protein ZO-1 in epithelial cells (Ebnet, 2003). Co-
localisation of ZO-1 and JAM-C has been demonstrated in ECs (Orlova et al., 2006), but 
a direct interaction has not yet been identified. JAM-C has also been shown to 
colocalise with the JAM family member CAR in mouse testis, where JAM-C is crucial for 
the differentiation of spermatids into spermatozoa (Gliki et al., 2004). 
 
1.6.3 Role of JAM-C in vascular processes 
Important endothelial functions such as angiogenesis and vascular permeability are 
regulated by JAM-C. Soluble JAM-C (sJAM-C) is a potent mediator of angiogenesis, 
where it stimulates EC migration in vitro and also in vivo across Matrigel membranes 
(Rabquer et al., 2010). Antibody-mediated blockade of JAM-C significantly reduces 
tumour growth and angiogenesis in mice injected with carcinoma cells (Lamagna et al., 
2005a). Vascular permeability is increased by the presence of JAM-C at EC junctions. 
Silencing of JAM-C in cultured ECs increases VE-Cadherin cell-cell contacts in a Ras 
related protein 1 (Rap1) dependent manner, resulting in decreased permeability 
(Orlova et al., 2006). Overexpression of JAM-C increases permeability, as do 
permeability inducing stimuli such as thrombin, which increases junctional JAM-C 
expression in ECs (Li et al., 2009). 
JAM-C expressed on human platelets mediates the adhesion of dendritic cells (DCs) to 
those platelets through interaction with Mac-1. It has been shown that under 
conditions of flow, the initial interaction between DCs and platelets is mediated 
through a Mac-1/JAM-C interaction. This interaction induces differentiation of the DCs 
and subsequently enables them to induce lymphocyte proliferation. Prolonged DC-
platelet interactions through Mac1/JAM-C result in platelet phagocytosis and also in 
DC apoptosis, which is dependent on that JAM-C/Mac-1 interaction. Indeed, the pre-
treatment of DCs with sJAM-C decreases DC apoptosis (Langer et al., 2007). DCs are 
implicated in the progression of atherosclerosis, where they are found in the intima of 
atherosclerosis-prove vessels. As such, it is speculated by the authors here that high 
platelet concentrations in atherosclerosis lesions may recruit DCs through JAM-C/Mac-
1 and so perpetuate the inflammation. However, it is important to note here that 
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platelet expressed JAM-C has only been demonstrated in humans and not mice and as 
such, demonstrating this mechanism in mice in vivo would be rather difficult. 
Platelet expressed JAM-C is also important for facilitating the binding of CD34+ 
hematopoietic progenitor cells, presenting a potential role for JAM-C in directing 
homing of these cells to bone marrow niches (Stellos et al., 2012). Indeed, in this study 
it was shown that platelets activated with thrombin in vitro had increased JAM-C 
expression and also correlated with increased P-selectin expression on platelets from 
coronary artery patients. Adherence of CD34+ progenitor cells to platelets was block in 
this in vitro model by the addition of antibodies against JAM-C or its counter-receptor 
MAC-1 reduced this adhesion and this occurred under conditions of flow. 
 
1.6.4 JAM-C and leukocyte migration 
Two studies in 2004 dictated a role for JAM-C in regulating neutrophil TEM and also 
trans-epithelial migration. In both studies it was found this migration occurs in a Mac-1 
dependent manner, relying on the previously established interaction of EC JAM-C with 
Mac-1 integrin expressed on leukocytes (Zen et al., 2004). In ECs, JAM-C does not 
participate in adhesion of leukocytes, but rather diapedesis through the endothelial 
barrier (Chavakis et al., 2004). Further studies identified that the accumulation of 
leukocytes to inflammatory sites is reduced when treated with JAM-C functional 
blocking antibodies. Conversely, transgenic mice overexpressing JAM-C recruited 
significantly more leukocytes to the lungs of mice challenged with LPS (Aurrand-Lions 
et al., 2005). 
JAM-C has also been shown to regulate monocyte TEM, using both in vitro and in vivo 
models. Treatment with anti-JAM-C blocking antibodies suppresses TNF-stimulated 
monocyte recruitment in mouse cremaster muscles (Bradfield et al., 2007). Monocyte 
TEM across HUVEC monolayers was reduced by blocking the JAM-C/JAM-B interaction 
in the same study, which also resulted in an increase in monocyte reverse TEM (rTEM) 
from the abluminal compartment. 
Work conducted by our laboratory has determined that JAM-C is key in mediating 
leukocyte infiltration in response to inflammatory stimuli such as ischemia/reperfusion 
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(I/R) injury. Treatment of mice with soluble JAM-C reduced leukocyte infiltration in 
both kidney and cremaster muscle I/R models (Scheiermann et al., 2009). JAM-C KO 
mice exhibited markedly reduced leukocyte adhesion and TEM across venules in the 
same cremaster I/R model. This is in contrast to the findings of Chavakis et al., 
discussed previously, which postulated no role for JAM-C in leukocyte adhesion to 
HUVECs stimulated with Phorbol 12-myristate 13-acetate (PMA) (Chavakis et al., 
2004), where JAM-C localises mainly to the cell-cell junctions. This can be consolidated 
by further findings from Scheiermann et al., which showed that the expression pattern 
of EC JAM-C was changed by I/R injury, with reduced expression at EC junctions and 
increased expression at non-junctional membranes that can support adhesion 
(Scheiermann et al., 2009). Further confirming this role of JAM-C in directing leukocyte 
TEM in I/R injury, transgenic mice overexpressing JAM-C had increased leukocyte 
adhesion and TEM in this model.  
While JAM-C is important for directing leukocyte TEM in inflammation, disrupted 
expression of JAM-C has been shown to support aberrant modes of neutrophil TEM. 
Indeed, where I/R induces reduced expression of junctional JAM-C, increased 
frequency of hesitant and neutrophil rTEM is observed. This frequency is further 
increased in conditional EC JAM-C KO mice and by using JAM-C blocking antibodies. 
Furthermore, EC JAM-C KO mice exhibit neutrophil rTEM following inflammatory 
stimuli that don’t normally support such modes of migration, such as IL-1β (Woodfin et 
al., 2011). Further investigations into the mechanisms behind this have revealed that 
I/R injury drives release of LTB4 by the injured tissue, which acts to recruit neutrophils 
and induce release of neutrophil elastase (NE), which in turn is a potent protease that 
cleaves EC JAM-C as neutrophils transmigrate the endothelium (Colom et al., 2015). 
 
1.6.5 Additional roles for JAM-C in inflammation and cancer 
Aside from its crucial role in leukocyte trafficking, JAM-C also has a number of 
additional roles in inflammation, inflammatory diseases and cancer. For example, 
JAM-C expressed on fibroblast reticular cells in lymph nodes is crucial for regulating 
chemokine secretion. Indeed, it was found that blocking JAM-C in vivo significantly 
reduced the amount of secreted CCL21 and CXCL12 from these cells, resulting in 
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reduced T cell egress and increased retention within lymph nodes (Frontera et al., 
2011). 
In human synovial tissue from rheumatoid arthritis, JAM-C expression was elevated 
and similarly this was the case in antigen-induced arthritic mice. In the latter, 
treatment with anti-JAM-C antibodies reduced the disease severity, with reduced 
levels of circulating arthritis markers such as amyloid A. This also correlated with 
reduced neutrophil infiltration (Palmer et al., 2007). In a separate study, myeloid cell 
adhesion to arthritic synovial tissue was also dependent on JAM-C expression (Rabquer 
et al., 2008). 
JAM-C has also been studied within a variety of atherosclerosis models. Typically, 
atherosclerosis is seen as a primarily monocyte driven process, where monocyte 
interactions with the inflamed and activated endothelium induces monocyte 
extravasation and subsequent differentiation into macrophages that produce reactive 
oxygen species, pro-inflammatory cytokines and that ingest vast quantities of oxidised 
low-density lipoprotein (oxLDL) (Prame Kumar et al., 2018). Monocytes are recruited 
to the subendothelial intima through the tightly regulated leukocyte adhesion cascade, 
where activation of endothelial cells upregulates adhesion molecules (E-selectin, 
ICAM-1, VCAM-1) and chemokines (CCL2, CCL5, CXCL1) that are necessary for 
monocyte migration (Pamukcu et al., 2010). Early on in the progression of the disease, 
the atherosclerotic monocytes differentiate into foam cells due to their large 
quantities of ingested oxLDL to form the early plaque, or fatty streaks, within the 
intima of inflamed vessels. Over time, these fatty streaks develop into mature 
atherosclerotic plaques due to the accumulation of inflammatory leukocytes and lipid, 
which is surrounded by a cap of smooth muscle cells and extra cellular matrix. Thinning 
and subsequent rupture of the plaque releases plaque debris and causes thrombosis, 
coagulation and eventually artery stenosis (Woollard and Geissmann, 2010). 
More evidence is emerging for the role of neutrophils within the pathogenesis of 
atherosclerosis, where they have been identified in both human and murine 
atherosclerotic lesions (Drechsler et al., 2010, van Leeuwen et al., 2008). Indeed, 
mouse neutrophils have been detected in both early lesions in the subendothelial 
intima, and also within rupture prone lesions (Rotzius et al., 2009). Data from human 
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studies have identified that neutrophils are present in the culprit lesions of myocardial 
infarction patients. Further study of human plaque samples has revealed that intra-
plaque haemorrhage may release further neutrophils into the lesion, thus enriching 
neutrophils released proteases and increasing plaque fragility. Recent data from 
mouse atherosclerosis studies suggests neutrophils accumulate in large arteries very 
soon after high-fat diet feeding starts, where the lesion size is directly correlated with 
neutrophil size (van Leeuwen et al., 2008). The importance of neutrophils recruitment 
in the onset of atherosclerosis is highlighted by mouse studies using LTB4 deficient 
mice. Here, where neutrophil recruitment is significantly impaired due to deficiency in 
LTB4, the lesion size is significantly reduced and the levels of lesion leukocytes 
(macrophages and T cells) are also lower. 
The study of JAM-C expression in atherosclerosis models has revealed that oxLDL 
induces a redistribution of JAM-C away from EC junctions, mediating leukocyte 
adhesion and TEM into atherosclerotic plaques and as such contributing to increased 
disease pathogenesis (Keiper et al., 2005). Efforts to interfere with JAM-C in 
atherosclerosis lead to increased monocyte rTEM out of inflamed lesions in vivo, thus 
decreasing the size of the atherosclerotic plaques. This makes targeting JAM-C an 
attractive target in this disease (Bradfield et al., 2016). However, one must consider 
the impact on neutrophil migration when targeting JAM-C in this model, where there 
would presumably also be an increase in neutrophil rTEM from these inflammatory 
sites, thus increasing the circulating population of activated neutrophils that may be 
detrimental to secondary organs such as the lungs and kidneys. 
In type 1 diabetes (T1D), JAM-C was expression is upregulated around pancreatic islets 
of Langerhans in a virus induced T1D model. Treatment with JAM-C blocking 
antibodies in these mice reduced T1D incidence. Overexpression of JAM-C in ECs did 
not accelerate T1D disease progression. This highlights a likely role for JAM-C in 
regulating the trafficking of autoreactive T cells to β-cells in the pancreas (Christen et 
al., 2013). 
Due to its significant role in regulating leukocyte TEM, much interest has also focussed 
on how JAM-C might be involved in regulating tumour cell migration and therefore 
metastasis. Indeed, it was found that adhesion of the cancer cell line NHI-H522 to ECs 
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was blocked by sJAM-C, postulating a role for JAM-C in tumour cell-EC interactions 
(Santoso et al., 2005). Recent work has found JAM-C to be expressed in tumours with a 
high metastatic potential (Fuse et al., 2007). In a model of metastatic melanoma, JAM-
C KO mice showed reduced B16 melanoma cell metastasis to the lungs of challenged 
mice (Langer et al., 2011). Studies in ovarian cancer models established that EC JAM-C 
KO mice have increased survival, whereas JAM-C overexpressing transgenic mice have 
conversely reduced survival. Tumour growth was reduced in EC JAM-C KO mice, where 
vessels had reduced pericyte coverage and increased vascular leakage, indicating a role 
for JAM-C in organising functional tumour vessels (Leinster et al., 2013). 
 
1.7 Autophagy 
It is clear that JAM-C is key for regulating a number of EC functions, both under 
homeostatic and inflammatory conditions. This is highlighted by the disruption of 
processes such as leukocyte trafficking and angiogenesis when JAM-C expression is 
disrupted, targeted or re-distributed. It could be said that disruption of EC JAM-C, and 
perhaps more widely junctional integrity, impacts upon the homeostatic state of ECs 
and so resulting in the various phenotypes detailed above. A key process in the 
maintaining cellular homeostasis is autophagy, which is triggered by numerous cellular 
stressors and insults, as discussed in more detail below. As part of the work in this 
thesis, it was hypothesised that disruption of EC JAM-C expression would represent 
such a cellular insult and could therefore impact on EC autophagy.  
Autophagy itself is an evolutionary conserved cellular process important in protein 
degradation. It is classically determined as a process of self-eating, where it functions 
to degrade long-lived proteins and dysfunctional organelles such as mitochondria and 
ribosomes. This enables the recycling of cellular nutrients to enable cell survival during 
times of cellular hardship, such as during starvation. Increasingly, autophagy is 
becoming recognised as a selective process, where proteins are deliberately targeted 
for degradation (Kaur and Debnath, 2015). 
The molecular pathway of autophagy is a complex one, with a number of dedicated 
autophagy proteins (ATG proteins) and non-ATG signalling proteins involved. Initial 
stages of autophagy begin with formation of an isolation membrane, or phagophore, 
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which most likely derives from the endoplasmic reticulum or the trans-golgi, though 
this is yet to be fully defined. This membrane expands to engulf the target 
cargo/proteins/organelle, thus sequestering them in a double membrane 
autophagosome. These autophagosomes are matured by fusion with lysosomes, 
forming autophagolysosomes which promotes the degradation of the autophagosome 
content. Amino acids and other nutrients are then transported back into the cytosol 
(Glick et al., 2010). 
More connections are being made between the autophagy pathway and protein 
secretion through unconventional routes. The ATG proteins have been implicated in 
secretion of Acb1 protein in yeast (Duran et al., 2010). They have also been found to 
be important for autophagy-mediated secretion of pro-inflammatory mediators such 
as IL-1β and high mobility group box 1 (HMGB1) (Dupont et al., 2011), which is 
discussed in more detail below. 
 
1.7.1 Autophagy in infection and inflammation 
Multiple studies have highlighted the important role of autophagy in conferring 
resistance to various pathogens that infect mammalian organisms. It functions to 
control infection with such microbes by helping in their degradation, as well as helping 
to coordinate an effective immune response. This importance is highlighted by the fact 
that loss of the key autophagy related protein 5 (ATG5) in neutrophils and 
macrophages leads to increased susceptibility to infections with L. monocytogenes and 
T. gondii (Zhao et al., 2008). Typically, cells of the innate immune system are the first 
line of defence to such pathogens, where engagement of pattern recognition 
receptors (PRRs) leads to their activation. Activation of PRRs by pathogens has also 
been shown to result in upregulation of autophagy in immune cells (Oh and Lee, 2014). 
In a related manner, autophagy also plays an important role in the cross-presentation 
of intracellular antigens to MHC class II antigens (Crotzer and Blum, 2009). This helps in 
the activation of CD4+ T helper cells, and as such leads to the coordination of an 
effective immune response. 
The relationship between inflammation and autophagy during sterile conditions and 
non-pathogen induced inflammation is complex. Essentially autophagy is 
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characteristically an anti-inflammatory process, acting to suppress inflammasome 
activation under basal conditions (Deretic et al., 2013). This is highlighted by the fact 
the mice deficient in the autophagy related protein 16 (ATG16L) have increased 
production of IL-1β and IL-18 (Saitoh et al., 2008). Under sterile conditions, autophagy 
acts to rid cells of any cellular debris and defunct organelles that could act as 
endogenous inflammatory stimuli. Confirming this, blockade of autophagy by 
pharmacological or genetic means results in an accumulation of defective 
mitochondria and therefore and increase in endogenous inflammasome agonists. 
Autophagy also acts to suppress inflammatory signalling pathways, such as the NFκB 
pathway, so as to prevent aberrant inflammation under basal conditions. Here, IκB 
kinase (IKK) proteins are targeted for degradation by autophagy, through a pathway 
involving the chaperone protein Hsp90 (Trocoli and Djavaheri-Mergny, 2011). 
As mentioned briefly earlier, a number of ATG proteins are known to function in 
unconventional secretion of pro-inflammatory mediators such as IL-1β and HMGB1. 
Indeed, it is thought that this autophagy-dependent secretion of IL-1β is important in 
the early acute phase of inflammasome activation. Investigations into the mechanisms 
behind this unconventional secretion have found that it is dependent on ATG5, as IL-
1β secretion is completely ablated in ATG5-/- macrophages (Dupont et al., 2011). In 
addition, it seems the autophagy machinery cooperates with the golgi reassembly-
stacking protein 55 (GRASP55) and the exocytosis regulator protein Ras related protein 
Rab8a (Rab8a) to achieve this unconventional secretion. In the same study, it was 
found that HMGB1 is a substrate for the same secretion model, raising the possibility 
that a number of other inflammatory mediators such as chemokines could be 
regulated in a similar manner. The latter is an issue addressed as part of the present 
work. 
 
1.7.2 Autophagy in endothelial cells 
The role of autophagy in EC physiology is becoming increasingly recognised. In normal 
quiescent cultures of ECs, there is a low level of basal autophagic flux, highlighted by 
the accumulation of autophagosomes in the presence of the late stage autophagy 
inhibitor chloroquine (Jiang, 2016). Stimuli such as oxLDL and LPS can trigger 
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autophagy in cultured ECs. In vivo, shear stress also induces autophagy, which acts in a 
cytoprotective manner to reduce oxidative stress, oxidative insults and inflammation. 
In the same manner, an increase in EC autophagy is associated with an increase in 
endothelial nitric oxide synthase (eNOS) expression under shear flow conditions (Guo 
et al., 2014). 
More recent work has highlighted emerging roles for EC autophagy in regulating the 
haemostatic and angiogenic functions of ECs. Autophagy has been shown to be 
important for the secretion of vWF from Weibel-Palade Bodies in vitro and mice 
deficient in Autophagy related protein 7 (ATG7) show defective vWF release in vivo 
(Torisu et al., 2013). Another cytoprotective role of autophagy in ECs is highlighted by 
its role in regulating angiogenesis. Angiogenesis is crucial in recovery from ischemic 
events where hypoxic environments place extreme stress on the cells of the affected 
tissue. Pharmacological or genetic inhibition of autophagy results in decreased 
angiogenesis in ischemia models. Autophagy isn’t necessary for production of 
angiogenic factors such as VEGF, but rather is important for reactive oxygen species 
(ROS) production and Akt signalling that direct effective angiogenesis (Du et al., 2012). 
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1.8 Aims 
Studying JAM-C function in vivo has been somewhat limited by the severe phenotype 
that full JAM-C KO mice exhibit, with developmental, hematopoietic, neural and 
cardiovascular defects and male sterility (Imhof et al., 2007). As such, researchers have 
moved to using cell lineage-specific JAM-C knockouts, such as the Schwann cell specific 
JAM-C KO used to study the neural role of JAM-C (Colom et al., 2012). Our lab has 
acquired an endothelial specific JAM-C KO mouse line, where JAM3 is selectively 
deleted in ECs by a Cre-recombinase expressed under the control of an endothelial 
expressed Tie2 promoter (Langer et al., 2011, Pellegrini et al., 2011, Woodfin et al., 
2011). Using this tool as well as RNA interference (RNAi) approaches for knocking 
down JAM-C in ECs in vitro, the present project aims to further investigate the role of 
JAM-C in EC biology. The principal aims addressed in this project are as follows: 
 
1) To investigate the impact of JAM-C deficiency on EC junctions and EC 
morphology, proliferation and survival in vitro 
Cultured HUVECs were used to assess the role of JAM-C in EC biology in vitro. For 
this purpose, small interfering (siRNA) was employed to target JAM-C expression in 
cultured ECs, upon which they were assessed for junctional molecule expression 
and basic cellular characteristics such as proliferation and apoptosis. 
 
2) To investigate the impact of EC JAM-C deficiency on EC autophagy 
The role of EC junctional molecules in regulating autophagy is poorly understood. 
We hypothesised that loss of EC JAM-C impacts the homeostatic status of ECs, such 
that autophagy is upregulated. The in vitro model of JAM-C KD HUVECs was thus 
used to assess this hypothesis, while classical pharmacological inhibition of 
autophagy was used to confirm a role for autophagy in this model. 
 
3) To investigate the impact of loss of JAM-C on global EC gene expression profiles. 
Due to its critical role in ECs, we hypothesised that loss of EC JAM-C could impact 
gene expression profile of cultured ECs. To address this, a gene expression 
microarray study was be performed on cultured JAM-C deficient ECs, both under 
basal and IL-1β stimulated conditions. Differential gene expression analysis and 
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pathway analysis was used to investigate gene expression changes in JAM-C KD 
HUVECs, analysis that provided insight into potential pathways through which JAM-
C regulates EC functions in vitro. 
 
4) To investigate the impact of JAM-C deficiency on chemokine generation and 
secretion by ECs. 
The generation of chemokines by ECs is essential for directing effective leukocyte 
recruitment to sites of inflammation. Furthermore, disrupted EC JAM-C expression 
leads to aberrant modes of neutrophil TEM in in vivo models of inflammation. As 
such, we hypothesised that JAM-C deficient ECs could have disrupted generation of 
chemokines that may provide mechanistic insight into the phenomenon of 
neutrophil rTEM. This possibility was primarily investigated in an in vivo setting, 
using local inflammatory stimulation of EC JAM-C KO mice. 
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2 Materials and Methods 
2.1 Animals 
All mice were housed in individually ventilated cages under conditions of controlled 
12-hour light/dark cycles in a constant temperature (21 ± 2oC). Male and female mice 
were used for experiments between the ages of 4 and 15 weeks. All animal procedures 
were subject to Queen Mary, University of London ethical approval and carried out in 
accordance with the United Kingdom Home Office Animals Scientific Procedures Act 
1986. Mice were humanely culled by cervical dislocation in agreement with Home 
Office regulations. 
 
2.1.1 Mouse Strains 
C57BL/6 Wild Type (WT) mice 
Male WT C57BL/6 mice were purchased from Charles River Laboratories (Margate, 
Kent, UK). 
Endothelial JAM-C KO mice (Tie2Cre;JAM-Cflox/flox) 
An in vivo model of endothelial specific JAM-C deficiency was obtained by Cre-
recombinase directed removal of a portion of exon 1 of the Jam3 gene containing a 
region of the promoter sequence and the start of the protein coding sequence. This 
region of exon 1 is flanked by loxP sites (JAM-Cflox/flox) which enabled deletion of the 
region using Cre-Lox recombination. JAM-Cflox/flox mutants were crossed with mice 
transgenic for Cre recombinase under the endothelial specific Tie2-promoter/enhancer 
(Tie2Cre;JAM-Cflox/flox). Due to variable expression of Tie2 in ECs, with this strategy a 
full endothelial JAM-C KO mouse was not generated, but there was significant JAM-C 
KO (EC JAM-C KO). The extent of this KD has previously been reported to be in the 
region of 40-60%, depending on mouse variability (Woodfin et al., 2011). For 
simplification of nomenclature, Tie2Cre;JAM-Cflox/flox mice and JAM-Cflox/flox mice will be 
henceforth referred to as EC JAM-C KO and littermate control mice respectively. The 
mice were generated as described previously (Langer et al., 2011, Pellegrini et al., 
2011, Woodfin et al., 2011). All genotyping was performed by Matthew Golding. 
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2.1.2 Anaesthetics 
 
Ketamine 
Narketan®-10 solution, 100 mg/ml (Vetoquinol 
UK, Buckingham, UK) 
 
Xylazine 
Rompun® 2% w/v, 20 mg/ml (Bayer HealthCare, 
Berkshire, UK)  
 
2.2 Reagents 
2.2.1 Antibodies 
Primary antibodies 
Target Antibody 
β-actin Mouse anti-mouse β-actin, clone AC-15 (Sigma, St Louis, MO, USA) 
β-tubulin Mouse anti-rat β-tubulin, clone TUB 2.1 (Sigma) 
B220 PE/Cyanine7 rat anti-mouse/human CD45R/B220, clone RA3-6B2 
(eBioscience, Santa Clara, CA, USA) 
CD3 PerCP/Cy5.5 hamster anti-mouse CD3, clone 17A2 (eBioscience) 
CD16/CD32 Rat anti-mouse CD16/CD32, clone 2.4G2 (BD Biosciences, Franklin 
Lakes, NJ, USA) 
CD31 
(PECAM-1) 
1. Goat anti-human CD31, clone M-20 (Santa Cruz, Dallas, TX, USA) 
2. Mouse anti-human CD31, clone WM-59 (eBioscience) 
3. Rat anti-mouse CD31, clone MEC13.3 (BD Biosciences) 
4. Rat anti-mouse CD31, clone C390 (eBioscience) 
CD45 Pacific BlueTM rat anti-mouse CD45, clone 30-F11 (Biolegend, 
London, UK) 
CD115 Anti-mouse CD115 (c-fms) Alexa Fluor®488, clone AF598 
(eBioscience) 
ICAM-1 1. Rabbit anti-human ICAM-1, clone H-108 (Santa Cruz) 
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2. Mouse anti-human ICAM-1, clone BBIG-I1 (R&D systems, 
Minneapolis, MN, USA) 
ICAM-2 Rat anti-mouse CD102, clone mIC2/4 (AbD Serotec, Oxford, 
Oxfordshire, UK) 
JAM-A 1) Mouse anti-human JAM-A, clone J10.4 (Gift, C.A. Parkos, Atlanta, 
USA) 
2) Mouse anti-human JAM-A, clone 1H2A9 (Gift, C.A. Parkos) 
JAM-C 1. Rabbit anti-human JAM-C, clone J85 (Gift, B.A. Imhof, Geneva, 
Switzerland) 
2. Rabbit anti-mouse JAM-C clone J74 (Gift, B.A. Imhof) 
LC3 1. Rabbit anti-human LC3B, (Cell Signalling, Hitchin, Hertfordshire, 
UK) 
2. Mouse anti-human LC3, clone 5F10 (Nanotools, Teningen, 
Germany) 
NF-κB p65 1. Mouse anti-NF-κB  p65, clone L8F6, (Cell Signalling) 
2. Rabbit anti-phospho-NF-κB p65, clone 93H1, (Cell Signalling) 
VE-Cadherin 1. Goat anti-human VE-Cadherin, clone C-19 (Santa Cruz) 
2. Mouse anti-human Cadherin-5, clone 75/Cadherin-5 (BD 
Biosciences) 
3. Rat anti-mouse VE-Cadherin, clone BV14 (eBioscience) 
 
Secondary antibodies 
 
Antibody Conjugate Source 
Goat anti-rabbit IgG Horseradish Peroxidase Dako (Glostrup, Denmark) 
Goat anti-mouse IgG Horseradish Peroxidase Dako (Glostrup, Denmark) 
Rabbit anti-mouse IgG Horseradish Peroxidase Dako (Glostrup, Denmark) 
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Mouse anti-rabbit IgG Horseradish Peroxidase Dako (Glostrup, Denmark) 
Rabbit anti-goat IgG Horseradish Peroxidase Dako (Glostrup, Denmark) 
Donkey anti-rabbit 
IgG 
Alexa Fluor 488 Invitrogen (Carlsbad, CA, USA) 
Donkey anti-rabbit 
IgG 
Alexa Fluor 555 Invitrogen (Carlsbad, CA, USA) 
Goat anti-rabbit IgG Alexa Fluor 488 Invitrogen (Carlsbad, CA, USA) 
Chicken anti-mouse 
IgG 
Alexa Fluor 488 Invitrogen (Carlsbad, CA, USA) 
Chicken anti-goat IgG Alexa Fluor 647 Invitrogen (Carlsbad, CA, USA) 
Donkey anti-mouse 
IgG 
Alexa Fluor 647 Invitrogen (Carlsbad, CA, USA) 
Donkey anti-goat IgG Alexa Fluor 488 Invitrogen (Carlsbad, CA, USA) 
 
 
2.2.2 Fluorescent Dyes 
Mouse IgG1  
Rabbit IgG Purified normal rabbit IgG isotype 
control (Peprotech, Rocky Hill, NJ, USA) 
Rat IgG2a Purified rat IgG2a κ isotype control, 
clone RTK2758 (Biolegend) 
 
2.2.3 Inflammatory Stimuli 
Mouse interleukin-1β Recombinant mouse IL-1β/IL-1F2, Cat # 401-
ML/CF (R&D systems) 
Human interleukin-1β Recombinant human IL-1β/IL-1F2, Cat # 201-LB 
(R&D systems) 
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Lipopolysaccharide (LPS) LPS from Escherichia coli 0111:B4, Cat # L4391 
(Sigma) 
2.2.4 Kits 
Human CXCL1/Gro-α DuoSet ELISA Cat # DY275 (R&D systems) 
Human IL-8 ELISA Ready-SET-Go!® Cat # 88-8086 (eBioscience) 
Human TNFα ELISA Ready-SET-Go!® Cat # 88-7346 (eBioscience) 
Mouse CCL2/JE/MCP-1 DuoSet ELISA Cat # DY479 (R&D systems) 
Mouse/Rat CCL5/RANTES Quantikine 
ELISA 
Cat # MMR00 (R&D systems) 
Mouse CXCL1/KC DuoSet ELISA Cat # DY453 (R&D systems) 
Mouse LIX/CXCL5 DuoSet ELISA Cat # DY443 (R&D systems) 
Mouse LIX/CXCL5 Quantikine ELISA Cat # MMX00 (R&D systems) 
Mouse TNFα ELISA Ready-SET-Go!® Cat # 88-7490 (eBioscience) 
Proteome ProfilerTM Human XL Cytokine 
Array Kit 
Cat # ARY022B (R&D systems) 
Human Cytokine Array Kit Cat # ARY005 (R&D systems) 
Proteome ProfilerTM Mouse XL Cytokine 
Array 
Cat # ARY028 (R&D systems) 
 
2.2.5 Cell/tissue lysis buffers 
 
ACK lysis buffer 
150 mM NH4Cl, 10 mM KHCO3, 0.1 mM EDTA, 
pH 7.3 in H2O 
 
Cremaster lysis buffer 
PBS with 1% Triton X-100 and 1% protease and 
phosphatase inhibitor cocktail 
 
RIPA buffer 
150 mM NaCl, 1% IGEPAL®CA-630, 0.5% 
sodium deoxycholate, 0.1% SDS, 50 mM Tris, 
pH 8.0 (Sigma) 
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2.2.6 Other Reagents 
Bovine Serum Albumin (BSA) Standard Grade Powder, Fraction V, Cat # BP9701 
(Fisher Scientific, Loughborough, UK) 
Magnetic Dynabeads Dynabeads® Sheep Anti-Rat IgG, Cat # 11035 
(ThermoFisher) 
EDTA Ethylenediaminetetraacetic acid disodium salt 
dehydrate, Cat # E5134 (Sigma) 
Fetal Bovine Serum (FBS) FBS, qualified, heat inactivated, Cat # 10500064 
(ThermoFisher) 
FBS, non-heat inactivated, Cat # FB-1001 (LabTech, 
Uckfield, UK) 
Protease inhibitor cocktail HaltTM Protease and Phosphatase Inhibitor Cocktail 
(100X), Cat # 78440 (ThermoFisher) 
Normal Goat Serum (NGS) Goat serum donor herd, Cat # G6767 (Sigma) 
TritonTM X-100 Laboratory grade, Cat # T8787 (Sigma) 
 
 
 
2.3 Cell culture 
2.3.1 HUVECs 
Human umbilical vein ECs (HUVECs), isolated and pooled from 2-3 different umbilical 
cords, were obtained from PromoCell (Heidelberg, Germany). HUVECs were 
maintained in HUVEC Growth Medium (HGM, M199 + Glutamax; Gibco, Paisley, UK) 
supplemented with 20% fetal bovine serum (FBS, LabTech, Uckfield, UK), 10 U/ml 
Heparin (Sigma) and 100 μg/ml endothelial growth supplement (ECGS) (Sigma)). Cells 
were kept in 5% CO2 humidified atmosphere at 37oC. Once they had reached 70-80% 
confluency HUVECs were split and used for experiments between passages 3-6. For 
57 
 
passaging, cells were washed once with phosphate buffered saline (PBS) containing 
calcium and magnesium salts (Gibco) and detached using 0.025% Trypsin/0.01% EDTA 
(Gibco) or 1X TrypLETM Express reagent (Life Technologies, Paisley, UK), and then 
subcultured. 
 
HUVECs were sourced from Promocell at passage 0 and were expanded to passage 2 in 
EC basal medium (EBM, Promocell) at which point aliquots were frozen down for 
storage. Aliquots of ≈ 1 x 106 cells were suspended in 1 ml FBS supplemented with 10% 
dimethyl sulphoxide (DMSO, Sigma) and frozen at -80oC overnight, then transferred to 
a liquid nitrogen tank. For usage, aliquots were thawed at 37oC, resuspended in 1 
volume of M199 media and plated between three 145 cm2 tissue culture plates (Nunc, 
ThermoFisher, Waltham, MA, USA), previously coated with 1% w/v pig skin  
 
2.3.2 siRNA transfection 
siRNA oligonucleotides are listed in Table 1. HUVECs were transiently transfected with 
siRNA using the Amaxa NucleofectorTM system (Lonza, Basel, Switzerland). Passage 
three HUVECs were dissociated with TrypLETM Express, centrifuged at 288xg for 5 min, 
and resuspended at 2 x 106 cells per 100 μl nucleofection buffer containing 140 pmoles 
of siRNA. The suspension was then transferred to a 0.1 cm cuvette (GeneFlow, 
Lichfield, Staffs, UK), placed in the nucleofector and pulsed using the HUVEC-old 
programme (U-001). Cells were rescued immediately in 0.5 ml of HGM and seeded at 
300,000 or 500,000 cells per well of a six well plate for protein/RNA extraction or 
immunofluorescence (IF) staining, respectively. Plates were coated in gelatin (1% w/v), 
and coverslips coated in gelatin (1% w/v), fibronectin (10 µg/ml) and rat collagen-I 
(0.03 µg/ml), as described above. Transfected HUVECs were used for experiments 48-
72 hours post transfection, allowing cells to reach confluency and for the siRNA KD to 
reach optimal efficiency. Level of protein KD was assessed by Western Blot, qPCR and 
by IF staining. 
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siRNA oligo Sequence 
Human JAM-C siRNA 1 5’-AUGUAGUUAACUCCAUCUGGUUUCC-3’ 
Human JAM-C siRNA 2 5’-AUUGCUGGAUUUGAGAUUUACAGCC-3’ 
Control siRNA (Luciferase) 5’-CGUACGCGGAAUACUUCGA-3’ 
 
Table 2.1. List of human siRNA oligonucleotide primers 
 
2.3.3 Cell stimulation 
48-72h after siRNA transfection the response of ECs to different stimuli were 
investigated. Unless otherwise indicated, confluent HUVECs were cultured for 2 hours 
in M199 supplemented with FBS (5%) and then stimulated with Interleukin-1 beta (IL-
1β 1 ng/ml, R&D systems) or lipopolysaccharide (LPS 100 ng/ml, R&D systems) for 4 
hours. Following 4h stimulation, conditioned medium was collected, aliquoted and 
frozen at -80oC for subsequent analysis of secreted proteins. Cells were then lysed 
appropriately depending on the experimental needs (see below). For stimulating 
autophagy, cells were cultured in a specific EC starvation medium (Tebu-Bio, 
Rambouillet, France) for 2 hours. In addition, Bafilomycin A1 (100 nM) and 3-
Methyladenine (5 mM) (both from Sigma) were used to inhibit different stages of the 
autophagic pathway. 
 
2.3.4 Proliferation Assay 
Differences in cell proliferation were measured using an MTT cell proliferation assay 
purchased from ATCC (Manassas, VA, USA), according to manufacturer’s instructions. 
 
2.3.5 Cell viability and apoptosis assays 
Cell viability of HUVECs was measured using a lactate dehydrogenase (LDH) 
cytotoxicity assay kit (ThermoFisher). Briefly, cells were analysed for LDH release by 
colourimetric absorbance at 490nm and compared to a positive control of lysed cells. 
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Apoptosis of HUVECs was measured using a mitochondrial membrane potential 
apoptosis kit (Life Technologies). Cells were stained for Alexa Fluor 488 annexin V and 
MitoTracker® Red and analysed by Flow Cytometry. Percentage of apoptotic cells in 
HUVEC samples were compared to a positive control of HUVECs given heat shock 
treatment (95oC for 10 minutes) to induce high levels of apoptosis. 
 
2.4 In vivo inflammation models 
2.4.1 Neutrophil depletion 
In some experiments, mice were depleted of their circulating neutrophils by 
intraperitoneal (i.p.) injection of anti-granulocyte-differentiation antigen 1 (GR1) 
antibody at 25 μg/day for three consecutive days (Voisin et al., 2009). Blood samples 
were then taken from the tail vein the day after antibody treatment and the levels of 
neutrophils and monocytes determined by flow cytometry. 
 
2.4.2 Cremaster inflammation model 
Male mice were anaesthetised by intramuscular (i.m.) injection of 1 ml/kg ketamine 
(40 mg) and xylazine (2 mg) and then administered an intrascrotal (i.s.) injection of 
inflammatory stimulus or pharmacological agent prepared in a 400 μl sterile PBS bolas. 
Control mice were injected with PBS only. In some experiments mice were pre-treated 
with the JAM-C blocking antibody H33 or isotype control (10 mg/kg), which was 
administered by intravenous (i.v.) injection. After a 4-hour in vivo test period, mice 
were culled by cervical dislocation and cremaster muscles collected for subsequent 
analysis. 
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2.5 Characterisation of neutrophil depletion 
2.5.1 Immunofluorescence labelling of leukocytes 
Blood from tail vein samples was collected into 50 μl 5 mM EDTA and erythrocytes 
were removed by incubation with ACK lysis buffer (see section 1.2.5) at room 
temperature for 5 mins. Samples were then washed twice by centrifugation in PBS 
(300g, 5 mins, 4oC). Cells were then incubated with fluorescently labelled primary 
antibody cocktail containing Ly6G, CD115 and CD45 to label neutrophils, monocytes 
and the whole leukocyte population. Samples were incubated for 1-2 hours at 4oC in 
the dark. 
 
2.5.2 Flow cytometry 
Labelled cells were washed with PBS by centrifugation at 300g for 5 mins at 4oC, 
before resuspension in 200 μl cold PBS to achieve a single cell suspension. Samples 
were run on a LSRFortessa flow cytometer (BD Biosciences) using FACSDiva software, 
with at least 5,000 events per sample acquired. Data was then analysed using FlowJo 
version 7.6 software (Treestar). 
 
2.6 Gene expression analysis 
2.6.1 RNA extraction from cell culture 
RNA was extracted from cultured ECs using the AllPrep RNA/Protein kit (Qiagen), 
according to manufacturer’s instructions. Briefly, cells were washed in PBS and lysed 
with Buffer APL before being bound to and spun through an AllPrep spin column. RNA 
bound to the column while protein washed through, and protein was extracted using 
protein cleanup spin columns. RNA was eluted from the AllPrep spin columns in Buffer 
RLT, mixed 1:1 with 70% ethanol and purified using RNeasy spin columns. 
 
2.6.2 Analysis of RNA quality 
The quality of extracted RNA from both tissue and cell culture samples was analysed 
using the Agilent 2100 Bioanalyser system (Agilent, Santa Clara, CA, USA). This 
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analysed RNA integrity and displayed the quality as a RIN score, ranging from 1.0 (fully 
degraded RNA) to 10.0 (fully intact RNA), as well as giving the ratio of 28S to 18S rRNA 
in the sample. A RIN score of 7.0 and above was considered to be of appropriate 
quality for subsequent use in microarray analysis, as advised by Dr Charles Mein (Barts 
and the London Genome Centre). 
 
2.6.3 Gene expression microarray 
HUVECs were transfected with control or JAM-C specific siRNA as previously specified 
and left unstimulated or subjected to IL-1β treatment for 4 hours. Three independent 
experiments were performed to give biological triplicates to be used for the gene 
expression microarray analysis. RNA was isolated and analysed for quality as previously 
described in section 2.6.2. 
RNA was subjected to gene expression microarray analysis using HumanHT-12 v4 
Expression BeadChip technology (Illumina, San Diego, CA, USA)). Briefly, the protocol 
involved a two-step reverse transcription process to create cDNA, followed by a single 
in vitro transcription amplification step that creates biotin labelled cRNA. Gene specific 
probes are attached to beads and assembled into array chips. The cRNA is hybridised 
to the probes and then stained with streptavidin-Cy3 for fluorescence emission 
detection of the probes. 
 
2.6.4 Gene expression data analysis 
Data was extracted using Genome Studio software (Illumina) and then analysed using 
Bioconductor and Limma. Pathway analysis was performed using Ingenuity Pathway 
Analysis software (Qiagen). Heatmaps were generated using Cluster 3.0 and Java 
TreeView software. Genes were clustered using Kendall’s tau rank correlation 
coefficient, in collaboration with Dr Michael Barnes and Dr Claudia Cabrera of the 
Department of Bioinformatics, WHRI. 
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2.6.5 Quantitative real-time polymerase chain reaction (qPCR) 
Isolated RNA (500 ng) was reverse transcribed to complementary (cDNA) in 20 μl 
reaction volume using iScriptTM cDNA synthesis kit (Bio-Rad) according to the 
manufacturer’s protocol. The cDNA was then diluted to 2.5 μg/ml prior to use in qPCR 
reactions. Primers were designed and obtained from Integrated DNA Technologies 
(IDT, Coralville, IA, USA). qPCR reactions were conducted using the 7900HT Fast Real-
Time PCR system (Applied Biosystems, Forster City, CA, USA) in 384-well microplates. 
For each reaction, cDNA was added at 125 ng/ml and primer mix at 100 nM, with the 
reaction mix completed by the addition of iQ SYBR® Green Supermix (Bio-Rad). 
Reaction conditions were as follows: One step of 50oC for 2 mins, one at 95oC for 10 
mins, then 40 cycles of 95oC for 15 seconds (denaturation step) and 60oC for 1 minute 
(annealing and elongation step). Data was analysed using the ΔΔCt method (Livak and 
Schmittgen, 2001). A list of primers is detailed in Tables 2a and 2b. 
 
 
Gene 
 
Sense/Antisense 
 
Sequence 
Product 
size 
ACTB Sense 5’-GCGAGAAGATGACCCAGAT-3’ 261 bp 
 Antisense 5’-TGGTGGTGAAGCTGTAGCC  
CXCL1 Sense 5’-AACCGAAGTCATAGCCACAC-3’ 124 bp 
 Antisense 5’-CCTCCCTTCTGGTCAGTTG-3’  
CCL2 Sense 5’-CAGAAGTGGGTTCAGGATTCC-3’ 87 bp 
 Antisense 5’-ATTCTTGGGTTGTGGAGTGAG-3’  
HIF1A Sense 5’- AGTGTACCCTAACTAGCCGAG-3’ 181 bp 
 Antisense 5’- TTTGATGGGTGAGGAATGGG-3’  
HMGB1 Sense 5’- GGAGAGTAATGTTACAGAGCGG-3’ 145 bp 
 Antisense 5’- GATCTCCTTTGCCCATGTTTAG-3’  
ICAM1 Sense 5’-CGGAAGGTGTATGAACTGAGC-3’ 179 bp 
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 Antisense 5’-CAGCGTAGGGTAAGGTTCTTG-3’  
CXCL8 Sense 5’-ACTGAGAGTGATTGAGAGTGGAC-3’ 112 bp 
 Antisense 5’-AACCCTCTGCACCCAGTTTTC-3’  
JAM-C Sense 5’-CAAGGACGACTCTGGGCAGT-3’ 112 bp 
 Antisense 5’-CCCAATAATTCCGCCAATGTTC-3’  
PPIA  Sense 5’-CCCACCGTGTTCTTCGACATT-3’ 275 bp 
 Antisense 5’-GGACCCGTATGCTTTAGGATC-3’  
SEMA3E Sense 5’- ACCCCACGATCTTTACAAGCG-3’ 148 bp 
 Antisense 5’- AGGTCCCAGCATCTGATTTGT-3’  
SEMA3G Sense 5’- CTCAAAGTCATCGCTCTCCAG-3’ 142 bp 
 Antisense 5’- GAGAGCCCACGTATAGCATTTG-3’  
SEMA4C Sense 5’- TCAACTTCATCCGCTTCCTGC-3’ 139 bp 
 Antisense 5’- CCCTTCCCATCTTCAAACTCTC-3’  
SEMA4F Sense 5’- GAAATGTCCTTTTGAGCCAGC-3’ 148 bp 
 Antisense 5’- GGTATCTGTCCGAATCCAGTC-3’  
SEMA6B Sense 5’- GTGTCGGATGAAGGGCAAAC-3’ 136 bp 
 Antisense 5’- GGGTGTCTATGCTGTAGTTGG-3’  
VCAM1 Sense 5’-CAGTAAGGCAGGCTGTAAAGA-3’ 137 bp 
 Antisense 5’-TGGAGCTGGTAGACCCTCG-3’  
 
Table 2.2. List of qPCR human oligonucleotide primers 
 
 
64 
 
2.7 Inflammatory Mediator analysis 
2.7.1 Preparation of cremaster lysate samples 
Stimulation of the cremaster was carried out as previously described in section 1.4.2. 
Cremaster muscles were isolated following cervical dislocation culling of the mice. 
Both cremaster muscles were isolated, snap frozen in liquid nitrogen and kept at -80oC 
prior to homogenisation. To prepare the lysates, cremasters were mixed with 
cremaster lysis buffer (see section 1.2.5) in 2ml homogenisation tubes containing 2.8 
mm ceramic beads (Stretton Scientific, Stretton, Derbyshire, UK). Homogenisation 
used a Precellys®24 homogeniser (Stretton Scientific) at 6500 rpm for 3x20s, which 
was then repeated to ensure full homogenisation. Samples were then frozen for 1 
hour at -80oC, then thawed and centrifuged at 10,000g for 5 mins. Supernatants were 
collected and stored at -80oC until further analysis. 
 
2.7.2 Preparation of plasma samples 
Blood was obtained by either cardiac puncture using a 27-gauge needle, or from the 
descending vena cava using a 21-gauge needle, and a 1 ml syringe filled with 50 μl 
5 mM EDTA. 0.5-1 ml blood was collected per mouse. Plasma was obtained by 
centrifugation of the blood at 10,000g for 10 mins, upon which the supernatant 
containing the plasma was collected, snap frozen in liquid nitrogen and stored at -
80oC. 
 
2.7.3 Proteome ProfilerTM and cytokine arrays 
Mouse cremaster tissue samples were analysed using the Proteome ProfilerTM Mouse 
XL Cytokine Array. Cremaster samples were pooled from three individual mice per 
group, before addition to the array panel. The procedure was followed according to 
the manufacturer’s instructions. However, instead of using streptavidin-HRP 
conjugate, streptavidin conjugated to IRDye® 800CW (LI-COR, Lincoln, NE, USA) was 
used to detect the presence of mediators. Array panels were imaged using the 
Odyssey® Classic Infrared Imaging System (LI-COR). Images were analysed using 
65 
 
ImageStudio Lite software (LI-COR) to determine the pixel intensity of each cytokine 
spot. 
To analyse release of inflammatory mediators in vitro, conditioned media from 
HUVECs stimulated for 4 hours were added to a Proteome ProfilerTM Human XL 
Cytokine Array or to a standard Human Cytokine Array kit. The procedure was followed 
as described previously for the mouse array. An example image of the array 
membranes can be seen in Figure 2.1. 
 
 
Figure 2.1. Human Cytokine Array Panel 
Conditioned cell culture medium from untreated (A) and IL-1β stimulated (B) HUVECs were 
incubated with the cytokine array panel membranes overnight at 4oC. Bound cytokines were 
detected by IRDye® 800CW Streptavidin and read using an Odyssey® CLx imaging system. 
Increases in highlighted cytokines were visible following IL-1β stimulation. 1CXCL1/GRO α, 2IL-
1β, 3IL-8, 4CCL2/MCP-1. 
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2.7.4 Enzyme-linked Immunosorbent Assay (ELISA) 
Mouse tissue and plasma samples were assayed for CXCL1, CCL2, CCL5, CXCL5 and 
Granulocyte colony-stimulating factor (G-CSF) using the kits detailed in section 1.2.4, 
according to manufacturer’s instructions. 
Levels of human TNFα, CXCL1 and IL-8 in cell culture supernatants and cell lysates of 
HUVECs were measured by ELISA kits purchased from eBioscience, according to 
manufacturer’s protocols. 
 
2.8 Immunofluorescence Confocal Microscopy 
2.8.1 Immunofluorescent labelling of cells 
HUVECs were cultured on 10 mm diameter glass coverslips for immunofluorescence 
staining, as previously described (Section 2.2.3). Following stimulation, cells were fixed 
in either 4% paraformaldehyde (PFA, Sigma) for 15 minutes at room temperature, or in 
100% ice-cold methanol for 5 minutes at -20oC. Following fixation in 4% PFA, cells were 
then permeabilised with 0.1% Triton X-100 for 10 minutes at room temperature. Any 
auto-fluorescence was quenched by the use of 0.1 M ammonium chloride in PBS for 5 
minutes at room temperature. Coverslips were blocked in 2% bovine serum albumin 
(BSA, ThermoFisher) in PBS for 30 minutes at room temperature to minimise any non-
specific binding of antibodies. Primary antibodies or cellular dyes were then incubated 
with the samples for 1 hour at room temperature or overnight at 4oC. Cells were then 
washed 3 times in PBS before incubation with fluorescently labelled secondary 
antibodies for 1 hour at room temperature. After further washing, samples were 
mounted on slides (VWR, Lutterworth, Leicestershire, UK) using ProLong Gold Antifade 
Mountant media with 4',6-Diamidino-2-phenylindole (DAPI) (ThermoFisher). Figure 2.2 
shows a representative image of confluent HUVECs immuno-stained in this way to 
show that the handling of the cells enabled formation of confluent monolayers with 
intact junctions (VE-Cadherin, green) and caused minimal stress to the cells as shown 
by the absence of any stress fibres (F-actin, stained with phalloidin, red). 
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Figure 2.2. Immunoﬂuorescence staining of conﬂuent HUVECs. 
Human Umbilical Endothelial Cells (HUVECs) were ﬁxed and immunoﬂuorescently stained for 
VE-Cadherin (Top left panel, green), F-actin (Top right panel, red) and DAPI (Bottom left panel, 
blue). Scale bars represent 20 μm. 
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2.8.2 Immunofluorescent labelling of tissue 
Mice were culled by cervical dislocation and cremaster muscles were exteriorised and 
surgically removed. A midline incision was made in the scrotum and the testicles 
drawn out, the cremaster separated from the connective tissue and then fully 
dissected from the testis. The cremasters were then pinned out on dental wax and 
fixed in 4% PFA for 10-20 minutes at 4oC. Blocking and permeabilisation was carried 
out in PBS containing 12.5% fetal calf serum (FCS), 12.5% normal goat serum (NGS) and 
0.5% Triton X-100 for 2 hours at room temperature. Primary antibodies (JAM-C, CD31, 
VE-Cadherin) were incubated in PBS containing 5% FCS and 5% NGS at 4oC overnight 
(Colom et al., 2015, Woodfin et al., 2011). After washing for 30 minutes in PBS three 
times, tissues were incubated with secondary antibodies in PBS again containing 5% 
FCS and 5% NGS for 3 hours at 4oC. Finally, tissues were washed extensively in PBS 
before proceeding to analysis by confocal microscopy. 
 
2.8.3 Confocal Microscopy 
Both immunofluorescently labelled HUVECs and cremaster muscles were analysed 
using a Zeiss LSM-5 Pascal or Zeiss LSM 800 laser-scanning confocal microscope (Carl 
Zeiss AG Ltd, Jena, Germany). Z-stack images were taken using a 63X oil-dipping 
objective (1.4 numerical aperture) and single-track scanning mode. Images were then 
analysed using ImageJ and Imaris (Bitplane, Zurich, Switzerland) software. 
 
2.9 Western Blotting 
HUVECs or MLECs were lysed using RIPA buffer (Sigma) containing protease inhibitor 
cocktail (Life Technologies). If necessary, protein concentrations of cell lysates were 
then determined by BCA assay (Life Technologies). 2X SDS-PAGE loading buffer (100 
mM Tris-HCl (pH 6.8), 4% (w/v) SDS, 0.2% bromophenol blue, 20% glycerol, 10% β-
mercaptoethanol) was added to cell lysates in a 1:1 ratio and samples were then 
boiled at 95oC for 5 minutes to denature proteins. Samples were electrophoresed and 
separated on precast 16% RunBlue gels (Expedeon) using Tris-Glycine Buffer 
(Expedeon) for 45 minutes to 1 hour at 150V. Separated protein was then transferred 
onto PVDF membrane using the wet transfer method. Gel and membrane were 
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sandwiched together and submerged in transfer buffer (20% methanol, 25mM Tris 
190mM Glycine) for 1 hour at 100V. 
 
Next, membranes were stained with Ponceau Red solution (Sigma) for 5 mins at room 
temperature to check for efficiency of transfer and protein integrity. Membranes were 
then destained with deionised water and blocked for 1 hour in PBS containing 5% 
BSA/0.05% Tween 20. Primary antibodies against proteins of interest were diluted in 
5% BSA PBS/0.05% Tween and incubated with the membrane overnight at 4oC. Primary 
antibody was washed off with PBS/0.05% Tween for 10 minutes three times, and 
membranes were incubated with HRP-conjugated secondary antibodies diluted in PBS 
containing 5% milk/0.05% Tween for 1 hour at room temperature. Finally, membranes 
were washed extensively with PBS/0.05% Tween and bands visualised using 
SuperSignalTM West Pico Chemiluminescent Substrate (ThermoFisher) and developed 
on an SRX-101A Medical Film Processor (Konica-Minolta, Ramsey, NJ, USA). 
 
2.10 Statistics 
All data were expressed as mean ± standard error of the mean (SEM). Data analysis 
was carried out using GraphPad Prism software (GraphPad, San Diego, CA, USA), with 
data being classed as significant when p values were below 0.05. Statistical significance 
was evaluated by unpaired two-tailed Student’s t-test or by one-way ANOVA. 
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3 Investigating the impact of JAM-C deficiency on endothelial 
cell junctions, survival and proliferation in vitro 
3.1. Introduction 
As described in detail in Chapter 1, JAM-C is a tight junction protein expressed by a 
number of cell types including ECs and epithelial cells. Investigating the functional role 
of JAM-C, numerous studies have identified roles for this adhesion molecule within 
processes such as angiogenesis, permeability, neural functions and leukocyte 
migration (Bradfield et al., 2007, Li et al., 2009, Orlova et al., 2006, Rabquer et al., 
2010, Scheiermann et al., 2009, Woodfin et al., 2011, Leinster et al., 2013). Despite 
such studies, the role of EC JAM-C in ECs under basal conditions remains unclear. The 
aim of this project was to address this issue and gain better insights into how EC JAM-C 
regulates EC functions. As highlighted in Chapter 1, the full JAM-C KO mouse is 
severely sick that limits its use experimentally, notably severe hydrocephaly, 
cardiovascular problems and male sterility among others (Pellegrini et al., 2011, Wyss 
et al., 2012). In addition to this, JAM-C is deleted in every cell type and tissue in this 
model. Whilst the use of an endothelial specific JAM-C KO mouse was employed in 
Chapter 6, initial studies were aimed at establishing an in vitro model of JAM-C 
deficiency in cultured ECs. It was considered that such a model would provide a simple 
system for biochemical assays and would also be amenable to high resolution imaging.  
There are a number of methods that can be used to KD expression of a desired 
molecule in cells in culture in vitro, and the most widely employed method is to utilise 
the RNAi system (Wilson and Doudna, 2013). Endogenously within the cell, small non-
coding RNAs, known as microRNAs (miRNA), regulate gene expression by driving 
messenger RNA (mRNA) degradation or by repressing transcription. These are 
transcribed in the nucleus and then exported into the cytoplasm, upon which they are 
cleaved to short double stranded RNAs by the endonuclease enzyme Dicer. These 
short RNAs are loaded into the RNA-induced silencing complex (RISC), where the 
dsRNA is unwound to form single stranded RNA, which guides the RISC to mRNA that 
has a complementary sequence. Subsequently, the target mRNA is cleaved by the RISC 
complex and then degraded, resulting in no translation of the gene of interest (Martin 
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and Caplen, 2007). Biomedical research has taken advantage of this in-built system 
through the design of small RNA sequences to target specific genes for silencing. Two 
of the most widely used methods in this respect are transient transfection with siRNA 
or short hairpin RNA (shRNA). These custom synthesised siRNAs can be used to target 
genes of interest, where upon transfection into cells it engages the RNA-induced 
silencing complex (RISC) and silences gene expression in the same manner as for 
endogenous miRNAs. shRNA works in a similar manner to siRNA, where a custom 
siRNA is designed incorporating a short loop between the two strands. The shRNA 
requires a transfection vector for delivery into cells, such as a plasmid or viral vector. 
Once transfected into the cell and transcribed by host polymerases, the shRNA is 
exported and then cleaved by Dicer to form siRNA and the process proceeds as 
previously described. 
There are some caveats to using either method. Transfection with siRNA is only 
transient leading to a short lived KD of the gene of interest. shRNA transfection on the 
other hand provides a long lasting KD that can be passed on to subsequent generations 
of cells, especially when a viral vector that integrates into the host genome is used. 
However, use of shRNA does have inherent disadvantages. For example, the shRNA 
could be incorporated into a region of the genome which is silenced or has low 
transcriptional activity and as such the shRNA would be ineffective. In addition, the use 
of viral vectors (especially retroviruses) may impact on the transfected cell itself and 
cause immune or inflammatory responses that would be associated with viral 
infection. As such, the aims of each individual project must be carefully considered 
before deciding on a chosen KD system (Moore et al., 2010, Rao et al., 2009). 
 
3.2. Aims 
To enable studies into the effect of JAM-C deficiency on EC biology and functions, a 
robust protocol was established for creating JAM-C KD ECs in vitro. Following this, the 
basic properties of JAM-C KD ECs was assessed, before investigating the JAM-C KD ECs 
in more complex functional studies. Collectively the following objectives were 
addressed in this chapter. 
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• To establish a reliable experimental protocol for KD of JAM-C in human ECs in 
vitro. 
• To analyse the expression of other EC junctional molecules in conditions of 
JAM-C KD. 
• To verify that JAM-C KD had no adverse effect on basic EC functions, such as 
morphology, proliferation and viability. 
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3.3. Results 
3.3.1. Cellular localisation of JAM-C in endothelial cells in vitro 
Before attempting to knock-down JAM-C in ECs in vitro, the cellular localisation of 
JAM-C in cultured ECs was first investigated. In quiescent macrovascular ECs (HUVECs, 
Figure 3.1) JAM-C localised to the inter-endothelial cell junctions and was also present 
intracellularly, although the precise location of the latter was not investigated here. 
Interestingly, JAM-C also showed expression in the nucleus of quiescent HUVECs, as 
shown by co-localisation with DAPI staining. Staining of HUVECs with isotype control 
antibody can be found in Appendix 1, where isotype control shows no junctional or 
intracellular JAM-C staining as compared to that observed when using the JAM-C 
specific antibody. 
In resting microvascular ECs (HDMECs, Figure 3.2) JAM-C showed a similar pattern of 
immuno-staining to that observed in HUVECs. Here, JAM-C was localised to both the 
junctional and intracellular compartment, with expression also being detected in the 
nucleus in a similar manner to that seen in HUVECs. In HDMECs, the morphology of the 
junctions was however different to that noted in HUVECs, with the profile being less 
serrated and more continuous. VE-Cadherin and JAM-C largely localised to the same 
regions in the junctional compartment under basal conditions.  
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Figure 3.1. JAM-C is largely expressed at cell-cell junctions in unstimulated HUVECs. 
Untransfected HUVECs were cultured for 48-72 h to reach confluence and then fixed for 15 
mins in 4% PFA at room temperature. Cells were then immuno-stained for VE-Cadherin 
(top-left), JAM-C (top-right) and DAPI (bottom-left). Images were taken using a Zeiss LSM800 
confocal microscope; scale bars represent 15 μm. 
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Figure 3.2. JAM-C is present at the junctions of HDMECs under resting conditions. 
Untransfected HDMECs were cultured for 48-72 h to reach confluence and then fixed for 15 
mins in 4% PFA at room temperature. Cells were then immuno-stained for VE-Cadherin 
(top-left), JAM-C (top-right) and DAPI (bottom-left). Images were taken using a Zeiss LSM800 
confocal microscope; scale bars represent 15 μm. 
 
 
3.3.2. siRNA mediated KD of JAM-C expression in HUVECs 
To KD JAM-C in ECs, transfection of primary HUVECs with siRNA targeted to JAM-C was 
chosen as the preferred method. Two different approaches were used to achieve this 
knock-down. Initially, transfection using JetPEI® reagent was employed, which is a 
polyethylenimine based low-toxicity transfection reagent. This method packages the 
siRNA into positively charged vesicles that are taken up by endocytosis. Using this 
76 
 
approach, HUVECs were transfected with either JAM-C siRNA or control siRNA.  The 
siRNA sequences targeting JAM-C was taken from a publication where the authors 
used the sequences to effectively KD JAM-C in cultured HUVECs (Li et al., 2009). The 
siRNA consisted of two pooled sequences. Using this tool, a visible KD of JAM-C was 
observed in JAM-C siRNA transfected cells compared to control siRNA transfected cells, 
as assessed by Western Blot (Figure 3.3A, lanes 1&2). However, the level of KD was 
variable in repeat experiments (Figure 3.3A, lanes 3&4) and on average only achieved a 
modest 46% KD compared to control cells when analysed 48-72h post-transfection 
(Figure 3.3C). 
Following these results, a different method of transfection was utilised, namely 
electroporation using the AmaxaTM NucleofectorTM system (Liu et al., 2011). In this 
method, electrical pulses are used to create pores in the cell membrane, allowing the 
siRNA to be transferred directly into the cytoplasm and nucleus of the cell. Using this 
approach, a much more robust and reproducible KD of JAM-C protein was achieved in 
JAM-C siRNA transfected HUVECs (Figure 3.3B). Specifically, the KD of JAM-C achieved 
was on average greater than 90% and remained highly significant 48-72 post-
transfection (Figure 3.3D). 
To further verify this KD, HUVECs transfected with either control or JAM-C siRNA and 
then grown on 10 mm glass coverslips were fixed and immuno-stained for JAM-C. The 
confocal microscopy images shown in Figure 3.4 highlight the near complete loss of 
JAM-C expression in HUVECs transfected with JAM-C siRNA (right panel) compared to 
control siRNA transfected HUVECs (left panel). The images demonstrate the loss of 
both junctional JAM-C and the intracellular pool of JAM-C that was observed in Figure 
3.1. Interestingly, unlike previous works (Figure 3.1 and Figure 3.2), a nuclear pool of 
JAM-C was not detected in control HUVECs in this instance. This perhaps suggests a 
methodological anomaly of the JAM-C immuno-staining rather than real expression. 
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Figure 3.3. Comparison of different methods used for siRNA mediated KD of JAM-C in 
HUVECs. 
(A) After 24 h of growth, HUVECs were transfected with control or JAM-C siRNA using JetPEI® 
transfection reagent and cultured for a further 48 h. Cells were lysed and analysed for level of 
JAM-C protein by Western Blot. 
(B) HUVECs were transfected with control or JAM-C siRNA using the AmaxaTM Nucleofection 
system. Cells were cultured for 48-72 h then lysed and analysed for JAM-C protein by Western 
Blot. 
(C&D) Quantification of JAM-C protein in (A) and (B) respectively, where JAM-C protein levels 
were normalised to loading control (β-tubulin or β-actin). Error bars represent SEM from n=4 
(C) and n=5 (D) experiments. Statistical significance determined by Mann-Whitney test, 
**=p<0.01. 
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Figure 3.4. Immunofluorescence confocal microscopy validation of KD of JAM-C using the 
nucleofection method. 
HUVECs were transfected with either control siRNA (left panel) or JAM-C siRNA (right panel) 
and then cultured for 72 h to reach confluence and then fixed for 15 mins in 4% PFA at room 
temperature. Cells were then immuno-stained for JAM-C and DAPI. Images were taken using a 
Zeiss LSM800 confocal microscope; scale bars represent 15 μm. 
79 
 
 
Figure 3.5 JAM-C KD in HUVECs does not impact VE-Cadherin expression. 
(A) HUVECs were transfected with either control siRNA (lanes 1 & 3) or JAM-C siRNA (lanes 2 & 
4) and then cultured for 48-72 h to reach confluence. Cells were then lysed and analysed for 
JAM-C and VE-Cadherin protein by Western Blot. 
(B) Quantification of (A), where VE-Cadherin protein levels were normalised to β-actin loading 
control. Error bars represent SEM from and n=5 experiments. 
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(C) Immunofluorescence confocal microscopy of control and JAM-C KD HUVECs, cultured for 
72h post-transfection then fixed for 15 mins in 4% PFA at room temperature. Fixed cells were 
then immuno-stained for VE-Cadherin (left-panels) and JAM-C (middle-panels). Images were 
taken using a Zeiss LSM-5 Pascal confocal microscope; scale bars represent 15 μm. 
 
 
3.3.3. JAM-C KD does not affect expression of key EC junctional molecules 
Prior to investigating the functional effects of JAM-C KD on ECs, it was first necessary 
to analyse the effect of the KD on general EC characteristics to ensure no adverse 
effects existed that could compromise further studies. Firstly, the expression level of 
additional EC junctional molecules was investigated under conditions of JAM-C KD. 
The expression of the adherens junctional protein VE-Cadherin was analysed in JAM-C 
siRNA transfected HUVECs (hereafter referred to as JAM-C KD HUVECs). Western Blot 
analysis of these KD HUVECs under basal conditions indicated no change in VE-
Cadherin protein expression between control and JAM-C KD HUVECs (Figure 3.5A&B). 
Additionally, immunofluorescence confocal microscopy of JAM-C KD HUVECs (Figure 
3.5C, bottom panel) also showed no discernible change in VE-Cadherin expression 
when compared to control HUVECs (Figure 3.5C, top panel). Indeed, the localisation of 
VE-Cadherin was also unaffected, where it seemed to remain highly localised to the 
junctional compartment in the same manner to that observed under control 
conditions. However, without quantification of the micrographs in this figure these 
observations remain solely qualitative without such measurements. 
The expression of the junctional protein JAM-A was also assessed in this model, as it is 
a close family member of JAM-C and an important component of EC tight junctions. 
Figure 3.6 shows immunofluorescence confocal microscopy images of control and 
JAM-C KD HUVECs immuno-stained for VE-Cadherin, JAM-C and JAM-A. As was 
observed with VE-Cadherin, no discernible change in JAM-A expression or localisation 
was observed under conditions of JAM-C KD. Quantification of total JAM-A levels by 
Western Blot and junctional JAM-A from the micrographs are needed confirm these 
observations   
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Figure 3.6. JAM-C KD does not impact JAM-A expression. 
HUVECs were transfected with either control siRNA (left panel) or JAM-C siRNA (right panel), 
then cultured for 72 h to reach confluence and fixed for 15 mins in 4% PFA at room 
temperature. Cells were then immuno-stained for JAM-A (top-panels), JAM-C (middle-panels) 
and VE-Cadherin (bottom-panels). Images were taken using a Zeiss LSM-5 Pascal confocal 
microscope; scale bars represent 20 μm. 
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3.3.4. JAM-C KD does not affect EC morphology or proliferation 
It was also necessary to assess the cellular morphology of the ECs that had been 
transfected with JAM-C siRNA. To achieve this, HUVECs were immuno-stained with VE-
Cadherin to mark cell borders and assess cell shape, phalloidin to identify the F-actin 
cytoskeleton and DAPI to identify nuclear morphology.  VE-Cadherin staining revealed 
no distinct changes in cellular size and shape 
Figure 3.7 top panel) in JAM-C KD HUVECs compared to control HUVECs, although 
these parameters were not quantified from the micrographs. Finally, nuclear 
morphology also remained unaffected by JAM-C KD as assessed by DAPI staining. 
F-actin stress fibers are necessary for ECs to maintain cell-cell contact and also for their 
interaction with the extracellular matrix (ECM) (Tojkander et al., 2012). HUVECs often 
display more actin stress fibers than microvascular ECs such as HDMECs, due to 
reduced stability of their adherens junctions and in particular discontinuous expression 
of VE-Cadherin (Millan et al., 2010). F-actin immuno-staining revealed stress fiber 
formation in both control and JAM-C KD HUVECs, with no discernible differences 
between them. In order to confirm and quantify these observations, protein extracts 
from control and JAM-C siRNA transfected cells would be analysed by Western Blot for 
the G- and F-actin pools and the F/G actin ratio calculated. 
Another key feature of ECs is their proliferative capacity, which is crucial for their 
functionality in angiogenesis (Adair and Montani, 2010). As such, the proliferative 
capacity of JAM-C KD ECs was assessed using an MTS-based proliferation assay, where 
the MTS substrate is hydrolysed to a formazan product by dehydrogenase enzymes in 
metabolically active cells. The amount of formazan product measured at 490 nm is 
directly proportional to the number of living cells in culture. Using this method, control 
and JAM-C KD HUVECs were compared alongside untransfected HUVECs over 24-72 h 
of culture. After 72 h of culture, untransfected HUVECs showed significant 
proliferation when compared to the 24 h time-point (Figure 3.8B). The transfection 
procedure itself slightly reduced the proliferative capacity of HUVECs, though this was 
not significant. No differences were observed between control and JAM-C KD HUVECs 
over 72 h of culture, a period during which both cell types showed significant 
proliferation. 
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Figure 3.7. JAM-C KD does not impact EC morphology. 
HUVECs were transfected with either control siRNA (left panel) or JAM-C siRNA (right panel), 
then cultured for 72 h to reach confluence and fixed for 15 mins in 4% PFA at room 
temperature. Cells were then immuno-stained for VE-Cadherin, JAM-C, F-actin and DAPI. 
Images were taken using a Zeiss LSM800 confocal microscope; scale bars represent 15 μm. 
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Figure 3.8. JAM-C KD does not affect proliferative potential of HUVECs. 
(A) HUVECs were transfected with either control siRNA (top panels) or JAM-C siRNA (bottom 
panels) and then cultured for 48 h. Bright-field images of confluent cells were taken using an 
inverted Olympus IX81 microscope. 
(B) HUVECs transfected with control or JAM-C siRNA were analysed for proliferation using an 
MTS based proliferation assay. Briefly, transfected cells were seeded at 5,000 cells per well in 
96 well plates, then analysed for proliferation over 24-72 h. MTS compound was added to the 
cells to enable the detection of formazan product through absorbance at 570 nm. Transfected 
cells were compared alongside untransfected HUVECs. Error bars represent SEM from 3 
independent experiments. Statistical significance determined by two-way ANOVA, **=p<0.01 
compared to control siRNA 24 h, #=p<0.05 compared to JAM-C siRNA 24 h, ††=p<0.01 
compared to no siRNA 24 h. 
 
 
3.3.5. JAM-C KD does not impact EC viability 
Finally, it was necessary to examine whether KD of JAM-C in HUVECs resulted in 
decreased cell viability due to increased levels of cell death. It was important to verify 
the viability state of the ECs before embarking on further studies, such as those into 
gene expression and responses to inflammation that are documented in Chapters 5 & 
6. As such, two mechanisms of cell death were investigated in this model of in vitro EC 
JAM-C KD, those being apoptotic and necrotic cell death. 
In normal, healthy cells, phosphatidylserine (PS) residues are found in the inner leaflet 
of the plasma membrane. Upon induction of apoptosis, these PS residues are 
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translocated to the outer leaflet and therefore externalised, providing a marker for 
apoptosis. The protein Annexin-V is a specific binding protein of PS and so can 
therefore be used to detect apoptosis (Bossy-Wetzel and Green, 2000). As such, 
control and JAM-C KD HUVECs were immuno-stained for Annexin-V and DAPI and then 
analysed by FACS. Double negative cells were determined as live viable cells, while 
Annexin-V positive cells were determined as apoptotic (Figure 3.9A). The majority of 
both control and JAM-C KD HUVECs were found to be viable and there was no 
difference in apoptotic cells found between the two conditions (Figure 3.9B). 
Control and JAM-C KD HUVECs were also assessed for release of lactate 
dehydrogenase (LDH), a commonly used measure of necrotic cell death. LDH is 
released by cells when the cell membrane is compromised, as happens during 
necrosis. The level of LDH released into the supernatant of cultured cells can then be 
calculated by absorbance. As seen for apoptosis, no difference between control and 
JAM-C KD HUVECs was observed for LDH release (Figure 3.9C). 
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Figure 3.9. JAM-C KD does not impact EC viability. 
(A) HUVECs were transfected with either control siRNA (top panels) or JAM-C siRNA (bottom 
panels) and then cultured for 48-72 h to reach confluence. Cells were then detached and 
stained with Annexin-V and DAPI. Samples were run on an LSRFortessa flow cytometer and 
analysed using FACSDiva software. 
(B) Quantification of data in (A). Viable cells were determined as Annexin-V-/DAPI-. Apoptotic 
cells were determined as those Annexin-V+/DAPI- or Annexin-V+/DAPI-. Transfected HUVECs 
were compared to cells treated with 95oC heat-shock for 10 mins as a positive control. Error 
bars represent SEM from three independent experiments. 
(C) Control and JAM-C KD HUVECs were analysed for cellular cytotoxicity by LDH release assay. 
Sample medium from transfected HUVECs was tested for production of formazan product 
following addition of kit reagents. The absorbance of each sample was analysed and compared 
to a positive control sample. Error bars represent SEM from three independent experiments. 
This part of the work was done in collaboration with Dr Natalia Reglero. 
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3.4. Discussion 
While a great deal is known about the role of JAM-C in biological processes such as 
angiogenesis, permeability and leukocyte migration, little is known about how JAM-C 
functions within the ECs themselves and more importantly, what the effect of JAM-C 
deficiency is on ECs. As such, this chapter sought to establish a robust protocol for in 
vitro KD of JAM-C in cultured ECs. 
Initially, attempts were undertaken to investigate the localisation of JAM-C in cultured 
ECs in vitro by immunofluorescence confocal microscopy. Using both HUVECs and 
HDMECs, JAM-C localised to the inter-endothelial junctions and also to intracellular 
stores. Intriguingly JAM-C also showed expression in the nucleus on some occasions, 
perhaps suggesting a potential role for JAM-C in the nucleus that is yet to be identified. 
It must be stressed that this localisation was not observed in every case, highlighting 
either heterogeneity in JAM-C expression across batches of cultured HUVECs, or 
perhaps some non-specific binding of the antibody to the nucleus. This nuclear 
localisation is somewhat controversial, as JAM-C is a transmembrane junctional 
protein and so many argue against it having a role in the nucleus. However, a number 
of junctional and junctional associated molecules such as ZO-2 and ZONAB have been 
shown to localise to the nucleus (Balda et al., 2003, Islas et al., 2002, Traweger et al., 
2003), so it is not inconceivable for JAM-C to localise there and have a nuclear 
function. This potential expression is interesting in the context of the results that will 
be discussed in Chapter 5 on gene expression and as such this expression requires 
further investigation. 
To date, there have been a number of studies investigating the localisation of JAM-C in 
a similar manner. The majority of reports suggest that in HUVECs, JAM-C localises to EC 
junctions under resting conditions in agreement with the data presented in the first 
part of this chapter (Chavakis et al., 2004, Li et al., 2009, Orlova et al., 2006, Sircar et 
al., 2007). In addition, Orlova et al., showed that this expression at EC junctions is not 
affected by stimuli such as histamine and VEGF. In contrast, another study in HUVECs 
suggested that JAM-C was only present at EC junctions following VEGF stimulation 
(Lamagna et al., 2005b). While the data in this chapter indicate that JAM-C is present 
at junctions of HDMECs under resting conditions, conflicting data has previously been 
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reported in the same cell type where it was shown JAM-C is only expressed at the 
junctions following stimulation with VEGF or histamine. 
In order to investigate the effects of loss of JAM-C on EC function, it was necessary to 
establish a protocol of targeted KD of JAM-C in ECs in vitro. For this purpose, 
transfection of HUVECs with siRNA targeted to JAM-C was chosen as the preferred 
method. siRNA was chosen over shRNA to attain the JAM-C KD for a number of 
reasons. Firstly, as HUVECs can only be passaged a limited number of times until they 
lose their endothelial characteristics (Liao et al., 2014, Prasad Chennazhy and Krishnan, 
2005), the use of shRNA to produce a stably transfected cell line was not deemed 
necessary. Secondly, a number of studies have used siRNA to KD JAM-C in various cell 
types to good effect (Bradfield et al., 2007, Economopoulou et al., 2009, Li et al., 2009, 
Orlova et al., 2006), indicating that this was a good method to replicate. Indeed, the 
siRNA sequences from one such study (Li et al., 2009) were used in this study to KD 
JAM-C in HUVECs. Transfection of HUVECs with this siRNA targeted to JAM-C yielded a 
reproducible and highly significant KD of JAM-C, in excess of 90%. Thus, a reliable 
protocol was established for KD of JAM-C in ECs in vitro which would allow for 
investigations into the functions of EC JAM-C. 
It must be stressed that the use of siRNA to KD expression of any molecule is not 
without limitations, the most notable of which is the off-target effects of the siRNA. It 
could be possible that any subsequent effects observed when analysing JAM-C KD 
HUVECs are due to siRNA impacting the expression of one or more additional genes in 
the cell rather than just JAM-C. Indeed, it has been established that siRNA can exert 
effects of mRNA silencing when there are as many as five mismatches in the siRNA 
sequence. As such, it is important to recognise this potential caveat during the 
experimental design and to design methods to reduce the off-target effects. Reducing 
the concentration of individual siRNA sequences is an effective way to reduce the 
possibility of off-target effects, or even combining a pool of two or more siRNAs 
targeted to the same molecule in much reduced concentrations (Jackson and Linsley, 
2010). Given that the two siRNA sequences used to KD JAM-C in this model are taken 
from published research and were also used in combination at lower concentrations 
(70 nM per siRNA) to achieve effective KD than would be required for one siRNA alone, 
we were confident that any subsequent functional effects of JAM-C KD were in fact 
89 
 
due to an impact on JAM-C expression. To conclusively ensure the effects of the siRNA 
are target specific, a rescue experiment can be performed. This would involve the 
overexpression of a JAM-C construct on a JAM-C KD background and then analysing 
the subsequent functionality of those cells, specifically addressing whether the over-
expression ameliorates the phenotype seen under conditions of JAM-C KD. While this 
was not performed in the current project, ongoing works are evaluating this as a 
possible validation of the EC JAM-C KD phenotypes that are discussed in the 
subsequent chapters. 
Prior to embarking on functional studies into the effects of JAM-C KD in ECs, this 
chapter also assessed the expression level and localisation of additional junctional 
molecules following JAM-C KD. Using both total protein analysis by Western Blot and 
immunofluorescence confocal microscopy it was confirmed that JAM-C KD had no 
impact on VE-Cadherin expression or localisation in HUVECs, corroborating previous 
findings (Li et al., 2009, Orlova et al., 2006). While it was not investigated in this 
setting, Li et al also demonstrated that PECAM-1 expression is also unaffected. The 
present study also confirmed that both expression and localisation of the tight junction 
molecule JAM-A, a close family member of JAM-C, remained unperturbed by JAM-C 
KD. Studies on JAM-C KD in epithelial cells have repeated the same findings 
(Economopoulou et al., 2009), where the authors suggested that loss of JAM-C does 
not lead to a compensatory change in the expression of other JAM family members. As 
such, results suggest that much like epithelial cells, ECs do not compensate for loss of 
JAM-C by upregulating JAM-A expression. The findings from this section were crucial to 
the subsequent studies reported in this thesis. If JAM-C KD had caused disrupted 
expression of additional junctional molecules, it could be argued that any phenotype 
seen in JAM-C ECs would be attributed to the secondary disrupted expression rather 
than the loss of JAM-C expression itself. As this was not the case, any cellular 
phenotypes reported in JAM-C KD ECs could therefore be directly linked to JAM-C 
deficiency. 
Finally, it was necessary to check the morphology and viability of JAM-C KD ECs to 
confirm they were suitable for functional analysis. Nuclear morphology was 
unaffected, as was the actin cytoskeleton as identified by no changes in F-actin 
structures between control and JAM-C KD HUVECs (Figure 3.7). HUVECs form loose 
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and discontinuous adherens junctions, resulting in the formation of actin stress fibers 
and therefore increased cell tension (Millan et al., 2010). VE-Cadherin binds to β-
catenin at the adherens junctions and β-catenin can in turn bind to α-catenin. It is 
suggested that α-catenin can either bind to F-actin or β-catenin, but not both, so in 
stable adherens junctions α-catenin is recruited to the VE-Cadherin/β-catenin complex 
and stress fiber formation is reduced (Drees et al., 2005, Yamada et al., 2005). 
However, disruption of adherens junctions specifically would enable α-catenin to bind 
to F-actin and regulate stress fiber formation. Such a mechanism could account for the 
presence of some stress fibers in both control and JAM-C KD HUVECs in this model 
where some disruption of the adherens junctions is observed. This was interesting 
given the previous findings of Orlova et al., that reported a reduction in F-actin stress 
fibers in JAM-C KD HDMECs, a response that contributes to reduced EC contractility 
(Orlova et al., 2006). The differences between the findings of the present study and 
published works could be due to heterogeneity in EC type and source. There are no 
direct reports published on EC morphology, confluency or proliferation in JAM-C KD 
ECs and hence the data generated as part of this thesis provides a valuable resource. 
The present work also showed that JAM-C KD had no impact on cell viability in ECs due 
to apoptosis or necrosis. Increased cell death could impact greatly on EC functional 
studies, particularly into EC inflammatory responses. Taken together, these findings 
allowed for the current model of in vitro EC JAM-C KD to be extended to novel 
functional studies. 
 
Summary of key findings 
• Targeted siRNA to JAM-C effectively depletes expression in HUVECs as 
indicated by both immunoblot and immunofluorescence. 
• Loss of JAM-C from HUVECs does not affect expression of junctional markers 
JAM-A or VE-Cadherin. 
• Loss of JAM-C does not significantly impact basic cellular properties such as 
proliferation or apoptosis. 
91 
 
4 Loss of endothelial cell JAM-C triggers autophagy in vitro 
4.1 Introduction 
4.1.1 Autophagy and cellular homeostasis 
The cellular process of autophagy is intrinsically linked to the homeostatic status of the 
cell itself. Many cellular insults or stressors that can affect the status of the cell and 
therefore impact upon homeostasis can also result in the upregulation of autophagy. 
Such stressors can include nutrient deprivation, hypoxia, damaged organelles, protein 
aggregates and infection by pathogens, among many others (Ryter et al., 2013). In 
essence, autophagy can be thought of as a process that is upregulated during times of 
cell stress that serves to maintain homeostasis and ultimately cell survival (Kroemer et 
al., 2010, Levine et al., 2011, Awan and Deng, 2014). 
Recently, upregulation of autophagy has been associated with the disruption of tight 
junction integrity (Nighot et al., 2015). Here it was demonstrated that increased 
autophagy reduces intestinal epithelial permeability to small molecules and ions by 
targeting claudin-2 for endo-lysosomal degradation. However, to date there have been 
no publications reporting a direct role of EC junctional molecules as regulators of 
autophagy. In this context, unpublished works from our laboratory have indicated that 
mice with conditional KD of JAM-C in ECs exhibited increased autophagy. To build on 
these novel findings using a well-controlled and established in vitro model, the present 
works aimed to elucidate the potential impact of JAM-C deficiency on EC autophagy. 
In a related manner, it has been shown that the main components of plasma 
membrane gap junctions in epithelial cells, the connexins, control autophagy through 
interactions with proteins involved in autophagosome formation (Bejarano et al., 
2014). While a multitude of different cells types have gap junctions, ECs are known to 
only contain adherens and tight junctions (Bazzoni, 2004). Junction stability through 
regular junctional molecule expression is undoubtedly crucial for maintaining normal 
EC function, as highlighted by the embryonic lethality of junctional molecule KO mice, 
such as VE-Cadherin (Carmeliet et al., 1999) and ZO-1 (Katsuno et al., 2008). As such, 
disrupted expression of junctional molecules might represent a potential cellular insult 
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that could impact upon EC homeostasis and thus stimulate autophagy. This concept 
was investigated here in the context of JAM-C. 
 
4.1.2 Methods for analysing autophagy 
The level of the lipidated form of the protein Microtubule-associated protein 1A/1B-
light chain 3 (LC3) is a commonly used method of measuring autophagy both in vitro 
and in vivo. LC3-I is the cytosolic form of LC3, which upon autophagic stimuli is cleaved 
and conjugated to phosphatidylethanolamine (PE) to form LC3-II and recruited to the 
autophagosome membrane (Tanida et al., 2008) (See Figure 4.1). Hence, increased 
levels of LC3-II protein can be used as a method to measure autophagy in cultured 
HUVECs. In addition to this, pharmacological inhibitors of autophagy, such as 
Bafilomycin A1 and 3-methyladenine (3-MA), are also useful tools for studying 
autophagy (Figure 4.1). Bafilomycin A1, a V-ATPase inhibitor, inhibits the acidification 
of lysosomes and as such is used to inhibit the fusion of autophagosomes and 
lysosomes, which would normally lead to autophagosome content degradation (Yang 
et al., 2013). Bafilomycin A1 treatment therefore creates an accumulation of LC3-II 
positive autophagosomes under any given condition and serves as a reliable readout 
for rates of autophagic flux (Barth et al., 2010). Class III PI3Ks have been shown to be 
crucial in the early steps of autophagosome biosynthesis in mammalian cells. These 
PI3Ks form a core initiation complex with Beclin-1 and the p150 PI3K adaptor protein 
to enable autophagosome isolation membrane nucleation, the critical first step in the 
formation of the autophagosome (Pyo et al., 2012, Miller et al., 2010). As such, 
inhibition of class III PI3Ks is a commonly used mechanism to prevent autophagosome 
formation, the most widely used of which is 3-MA. To stimulate autophagy, a number 
of different approaches may be taken. One of the most widely used methods is 
nutrient deprivation, or starvation, which induces autophagy to recycle cellular 
constituents for energy consumption and to maintain cell survival (Shang et al., 2011, 
Xiong et al., 2014). The other commonly used method is to treat with the mammalian 
target of rapamycin (mTOR) inhibitor rapamycin, which has been shown to be a potent 
inducer of autophagy in many cell lines (Sarkar et al., 2009, Wu et al., 2013). mTOR is a 
negative regulator of autophagy and so inhibition of its kinase activity releases the 
negative checkpoint, allowing autophagy to proceed (He and Klionsky, 2009). 
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Figure 4.1. Overview of the molecules involved in autophagosome formation and the various 
sites of pharmacological inhibition. Taken from (Yang et al., 2011). 
 
4.2 Aims 
The results in the previous chapter demonstrated that KD of JAM-C in HUVECs had no 
effect on cell viability nor did it result in increased EC apoptosis. With that in mind and 
given the previous findings that loss of JAM-C from EC tight junctions results in a 
number of phenomena (such as increased neutrophil rTEM and decreased EC 
permeability), we hypothesised that loss of JAM-C impacts upon the cellular status of 
the ECs, which could result in the upregulation of autophagy as a counteractive 
measure to maintain homeostasis. This hypothesis is supported by preliminary in vivo 
works stemming from our laboratory and to extend to an in vitro setting, objectives of 
the present work included: 
94 
 
• To establish reliable methods for the detection of autophagy in cultured ECs in 
our laboratory. 
• To determine whether the loss of JAM-C from ECs triggers autophagy in vitro. 
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4.3 Results 
4.3.1 Starvation induces autophagy in HUVECs 
Prior to investigating the role of JAM-C in EC autophagy, the response of ECs to 
established autophagic stimuli and inhibitors was characterised. Thus, HUVECs were 
subjected to nutrient starvation for 2 h and compared to HUVECs cultured in complete 
growth media. Figure 4.2 shows the response of HUVECs to starvation, where a 
significant increase in LC3-II protein is seen by Western Blot following 2 h of starvation 
(lanes 1 & 2, p<0.05). Treatment of HUVECs with 100 nM Bafilomycin A1 to inhibit 
autophagosome and lysosome fusion resulted in a significant increase in LC3-II levels 
under both basal and starved conditions (Figure 4.2, lanes 3 & 4, p<0.0001). More 
significantly, HUVECs subjected to both starvation and Bafilomycin treatment showed 
a significantly greater level of LC3-II protein compared to cells treated with Bafilomycin 
alone (p<0.01). These results indicate that starvation induces a bona fide increase in 
autophagic flux in cultured ECs. 
To corroborate these findings, HUVECs subjected to starvation were immuno-stained 
for detection of LC3 puncta representing autophagosomes. Immunofluorescence 
confocal microscopy of control and starved HUVECs (Figure 4.3) highlighted increased 
numbers of LC3 puncta in starved HUVECs compared to their non-starved control 
counterparts. Under basal conditions LC3 immunostaining was much more diffusely 
distributed in the perinuclear region, indicative of more cytosolic LC3-I protein in non-
starved control cells. By contrast, starved HUVECs exhibited a more vesicular 
immunostaining for LC3, which was less diffusely distributed. Treatment of HUVECs 
with both starvation and Bafilomycin A1 induced a drastic increased in LC3 positive 
puncta, correlating well with the Western Blot data indicated in Figure 4.2. Starvation 
induces autophagy in HUVECs. 
Immunostaining with isotype control to demonstrate specificity to LC3 can be found in 
Appendix 2. Here, in HUVECs treated with both starvation and Bafilomycin A1, isotype 
control staining identified no puncta that are observed compared to that seen when 
the LC3 specific antibody is used. 
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Figure 4.2. Starvation induces autophagy in HUVECs. 
(A) Confluent HUVECs were treated with complete growth or starvation medium for 2 h, in the 
presence of Bafilomycin A1 (100 nM) or vehicle control. Cells were lysed and then analysed for 
changes in LC3-II protein levels by Western Blot.  
(B) LC3-II protein levels were quantified and normalised to β-tubulin loading control using 
ImageJ software. Each experiment was expressed as fold increase in LC3-II protein levels 
compared to untreated control cells. Error bars represent SEM from n= 6-9 experiments. 
Statistical significance calculated by one-way ANOVA, * = p<0.05 ** = p<0.01 **** = p<0.0001 
all compared to non-starved cells, ## = p<0.01 compared to Bafilomycin treated cells, ### = 
p<0.001 compared to starved cells. 
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Figure 4.3. Starvation induces LC3 puncta formation in HUVECs. 
Untransfected HUVECs were cultured for 48-72 h to reach confluence, then cultured with 
either starvation medium or complete growth medium for 2h. Bafilomycin A1 inhibitor or 
vehicle control was added for the same time period as indicated. Cells were fixed in 100% 
methanol for 3-5 mins at -20oC, then immuno-stained for and LC3 (green), JAM-C (red) and VE-
Cadherin (blue). Images were taken using a Zeiss LSM800 confocal microscope, scale bars 
represent 15μm. 
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4.3.2 Pharmacological inhibition of starvation induced autophagy by 3-MA 
The formation of autophagosomes through the canonical route is dependent on the 
activity of PI3Ks. This can be either through the regulation of mTOR activity by PI3Ks or 
by PI3K recruitment to the Beclin1 complex at the initiation of autophagosome 
formation. As such, inhibition of PI3Ks enables identification of canonical autophagic 
responses to stimuli. Thus, treatment of HUVECs with the PI3K inhibitor 3-MA for 2 h 
slightly reduced the LC3-II levels compared to vehicle control treated HUVECs (Figure 
4.4, lanes 1 & 3), though this was not significant. Treatment of HUVECs with 3-MA 
when cultured under starved conditions for 2 h resulted in significantly reduced LC3-II 
protein (p<0.05) to levels similar to that observed under basal growth conditions 
(Figure 4.4, lanes 2 & 4). These results demonstrated that starvation-induced 
autophagy, and to a certain extent basal autophagy, in HUVECs is dependent on PI3K 
activity. 
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Figure 4.4. The PI3K inhibitor 3-MA inhibits starvation induced autophagy in HUVECs. 
(A) Confluent HUVECs were cultured in complete growth or starvation medium for 2 h in the 
presence of 3-MA (5 mM) or vehicle control. Cells were lysed and then analysed by Western 
Blot for levels of LC3-II protein. 
(B) LC3-II protein levels were quantified and normalised to β-actin loading control using ImageJ 
software. Each experiment was expressed as fold increase in LC3-II protein levels compared to 
untreated control cells Error bars represent SEM from n=3 experiments. Statistical significance 
calculated by unpaired t-test, *,# = p<0.05. 
  
4.3.3 JAM-C KD induces autophagy in HUVECs 
To investigate the potential role of JAM-C in regulating EC autophagy, the established 
method of siRNA mediated JAM-C KD in HUVECs was employed (See Chapter 3). KD of 
JAM-C in HUVECs resulted in a statistically significant increase in LC3-II protein levels 
(p<0.01) under basal growth conditions nearly three-fold over that in control HUVECs 
(Figure 4.5, lanes 1 & 2). When control and JAM-C KD HUVECs were treated with 
Bafilomycin A1 for 4 h, a significant increase (p<0.05) in LC3-II levels was still observed 
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in JAM-C KD HUVECs (Figure 4.5, lanes 3 & 4). These results demonstrated that loss of 
JAM-C resulted in an increase in autophagic flux, in a similar manner to that observed 
for starvation-induced autophagy (Section 4.3.1). 
 
Figure 4.5. Autophagy is increased in JAM-C KD HUVECs under basal conditions. 
(A) HUVECs were transfected with control or JAM-C siRNA, then cultured for 72 h for maximum 
efficiency of KD. Bafilomycin or vehicle control was added at 100 nM for 4 h and cells then 
lysed and assessed for LC3-II protein levels. 
(B) LC3-II protein levels were quantified and normalised to β-actin using ImageJ and GraphPad 
Prism software. Error bars represent SEM from n=7-8 experiments. * = p<0.05 paired t-test. 
This work was conducted in collaboration with Dr Natalia Reglero. 
(C) LC3-II protein levels from bafilomycin treated cells shown in (B) were normalised to control 
for each experiment and plotted. Error bars represent SEM from n=7 independent 
experiments. ** = p<0.01 paired t-test 
 
These findings were confirmed by immuno-staining of control and JAM-C KD HUVECs 
for LC3 puncta. Thus, control and JAM-C KD HUVECs were cultured on 10 mm diameter 
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glass coverslips, fixed and immuno-stained for VE-Cadherin to identify confluent ECs, 
JAM-C to assess the level of JAM-C KD and LC3 to identify autophagosomes. LC3 
positive puncta could be identified in about 50% of control HUVECs (Figure 4.6, left 
panel). By contrast JAM-C KD HUVECs (Figure 4.6, right panel) exhibited LC3 puncta in 
the majority of cells and which were increased in prevalence per cell. The LC3 immuno-
staining was perinuclear in localisation, in a similar manner to that seen under 
starvation conditions (Section 4.3.1). 
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Figure 4.6. JAM-C KD HUVECs exhibit increased LC3 puncta formation. 
HUVECs were transfected with control or JAM-C siRNA, then cultured for 72 h to achieve 
maximum efficiency of KD. Cells were then fixed in 100% methanol at -20oC for 3-5 min. Cells 
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were immuno-stained for VE-Cadherin (blue), JAM-C (red) and LC3 (green) and imaged using a 
Zeiss LSM 800 confocal microscope. Scale bars represent 20 µm. 
 
 
Figure 4.7. JAM-C mediated autophagy in HUVECs is dependent on PI3K activity. 
(A) HUVECs were transfected with control or JAM-C siRNA, then left for 72 h for maximum 
efficiency of KD. Cells were then subjected to treatment with 5 mM 3-MA or vehicle control for 
4 h (in the presence of 100 nM Bafilomycin A1) prior to lysis and then immunoblotted for LC3-
II and β-actin. 
(B) LC3-II protein levels were quantified and normalised to β-actin using ImageJ and using 
GraphPad Prism software. Error bars represent SEM from n=6 experiments. * = p<0.05, ## = 
p<0.01, student’s t-test. This work was conducted in collaboration with Dr Natalia Reglero. 
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4.3.4 JAM-C KD induced autophagy in HUVECs is inhibited by 3-MA 
Next, we addressed whether increased autophagy in JAM-C KD HUVECs was 
dependent on PI3K activity. For this purpose, control and JAM-C KD HUVECs were 
treated with 5 mM 3-MA or vehicle control for 4 h, then analysed for LC3-II protein 
levels. Concordant with previous data, JAM-C KD significantly increased LC3-II protein 
levels (p<0.05) under basal conditions (Figure 4.7, lanes 1 & 2). Addition of 3-MA for 
4 h significantly reduced LC3-II protein in JAM-C KD HUVECs (p<0.01) to similar levels 
of those observed in control HUVECs under basal conditions (Figure 4.7). 
 
4.3.5 IL-1β-mediated increase in LC3-II is not inhibited by 3-MA. 
Next, we tested the effect of IL-1β stimulation on the autophagy in cultured HUVECs to 
observe whether a similar response was observed as for that with starvation. Indeed, 
pro-inflammatory cytokines such as TNFα have been shown to induce autophagy in a 
range of different cell types, although the effects of IL-1β stimulation on autophagy in 
endothelial cells is less clear (Chu et al., 2017). 
Therefore, HUVECs were stimulated with IL-1β (1 ng/ml) for 4 hours and then analysed 
for LC3-II protein levels. A two-fold increase in LC3-II levels was seen in IL-1β 
stimulated HUVECs as compared to unstimulated, although this was not quite 
significant at this stage (Figure 4.8 p=0.068, n=4). Interestingly, treatment with the 
autophagy inhibitor 3-MA had no diminishing effect on the levels of LC3-II protein in IL-
1β stimulated HUVECs, unlike that observed for starvation induced autophagy. This 
indicates that IL-1β induced increases in LC3-II protein are not induced through PI3K 
signalling and as such, are likely formed through a non-canonical autophagic pathway. 
This response is currently being tested in JAM-C KD HUVECs to analyse any potential 
differences in the response. 
 
105 
 
 
Figure 4.8. IL-1β stimulation of HUVECs increases LC3-II protein levels in HUVECs. 
(A) HUVECs were stimulated with IL-1β (1 ng/ml) for 4 hours in the presence of either 5 mM 
3MA inhibitor or vehicle control. Cells were then lysed and immunoblotted for LC3-II and 
β-actin. 
(B) LC3-II protein levels were quantified relative to β-actin loading control using ImageJ and 
GraphPad Prism software. Error bars represent SEM from n=4 experiments. Statistics 
conducted using student’s t-test. 
 
4.4 Discussion 
This chapter sought to investigate EC autophagy, and more specifically whether 
disrupted expression of JAM-C impacted upon this cellular process. First, it was 
essential to establish a reliable method for detection of autophagy in cultured ECs. To 
achieve this, HUVECs were subjected to starvation, which is the classical inducer of 
autophagy in many different cell types (Mizushima, 2007). In agreement with this 
dogma and the well-established literature (Liu et al., 2015, Xiong et al., 2014), 
starvation did indeed induce autophagy in HUVECs in the present model, as measured 
by both increased LC3-II protein levels and increased LC3 puncta formation. Nutrient 
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starvation (specifically amino acid deprivation) induces autophagy through the 
canonical mechanism, which involves the inhibition of mTOR and subsequent 
downstream activation of class III PI3Ks (Jaber and Zong, 2013, Pyo et al., 2012). 
Inhibition of class III PI3Ks using 3-MA in the starvation model in the present study 
abrogated this induction of autophagy, confirming that HUVEC autophagy induced by 
starvation is dependent on PI3K activity and therefore follows the canonical pathway. 
These results demonstrated a reliable method for analysis of autophagy in cultured 
HUVECs in our laboratory and enabled further novel studies to be conducted. 
This model was extended to analyse the effects of IL-1β on autophagy in cultured 
endothelial cells. Stimulation with IL-1β induced LC3-II protein increases, which are 
consistent with recent work detailing that pro-inflammatory stimuli TNFα and IL-1β 
also induce autophagy in cultured HUVECs (Chu et al., 2017). The work in this project 
also determines that the IL-1β induced increases in LC3-II protein are not inhibited by 
3-MA, suggesting a non-canonical autophagic pathway by which this is achieved. 
Interestingly, it has been reported that a non-canonical autophagy based pathway is 
important for secretion of IL-1β (Dupont et al., 2011) and as such, our findings that IL-
1β may induce a non-canonical autophagic pathway could suggest that exogenous IL-
1β might feed into this pathway. 
The results in the second part of this chapter focused on the hypothesis that loss of 
JAM-C might impact EC autophagy. This work built upon the findings in the previous 
chapter that loss of EC JAM-C did not result in increased apoptosis nor increased cell 
cytotoxicity due to necrotic cell death. Autophagy and cell death, in particular 
apoptotic cell death, can be thought of as two sides of a balancing scale. Broadly 
speaking, autophagy functions to maintain cell survival and blocks the induction of 
apoptosis by selectively reducing the amount of pro-apoptotic proteins. Apoptosis 
functions to limit the impact of cell stress and damage on the collateral tissue and as 
such, induction of caspase activity during the initial stages of apoptotic cell death acts 
to switch off autophagy (Marino et al., 2014). With this in mind and considering that 
JAM-C KD HUVECs do not exhibit increased apoptosis (Chapter 3), we hypothesised 
that they might instead upregulate autophagy to counterbalance the effects of JAM-C 
deficiency. Thus, the established model of siRNA mediated JAM-C KD in HUVECs was 
used to investigate the loss of EC JAM-C on autophagy. 
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The findings from this part of the work demonstrated that loss of JAM-C from ECs 
induces autophagy under basal conditions, a completely novel finding. Even more 
striking is that this induction of autophagy occurs in the absence of any other stimulus. 
Autophagy in JAM-C KD HUVECs was completely abrogated by inhibiting class III PI3Ks 
with 3-MA, suggesting that JAM-C KD induced autophagy in ECs requires the activity of 
PI3Ks, in a similar manner to that of starvation induced autophagy. These findings are 
supported by previous work in the lab (conducted by Catherine Pickworth) which 
demonstrated that mutant mice conditionally null for EC JAM-C exhibit increased 
autophagy in vivo under basal conditions (unpublished data). 
Little is known about the relationship between tight junction molecules and 
autophagy. In one of the few studies investigating this link, autophagy was shown to 
regulate tight junction dynamics by targeting epithelial cell claudin-2 for degradation, 
thereby decreasing epithelial permeability and enhancing cell barrier functions, and as 
such providing a protective effect (Nighot et al., 2015). Recently a component of 
epithelial cell gap junctions, Connexin 43 (Cx43), has been shown to downregulate 
autophagy through direct interactions with proteins involved in autophagosome 
biosynthesis (Bejarano et al., 2014). The authors demonstrated here that Cx43 
sequestered molecules such as ATG16L and Beclin-1 at the gap junctions and thereby 
preventing their involvement in the initiation of autophagy. This is the first and only 
evidence of a cell junctional molecule of any sort regulating autophagy. However, ECs 
do not contain gap junctions, highlighting the novel findings presented in this chapter 
in relation to a role for a tight junction protein in regulating EC autophagy. 
Taking a broader view of these findings leads us to speculate on how loss of EC JAM-C 
might induce autophagy and more specifically whether this might be direct or indirect 
effect of the expression level of JAM-C. The relatively scarce literature on the impact of 
junctional molecule expression on autophagy makes it hard to draw any comparisons. 
However, using the Connexin 43 study as an example (Bejarano et al., 2014), it could 
be conceivable that JAM-C might directly sequester molecules critical for the initiation 
of autophagy at the tight junctions of ECs. The cytoplasmic tail of JAM-C contains a 
type-II PDZ binding motif that enables binding of the partner molecules ZO-1 and PAR-
3 (Mandicourt et al., 2007). As such, this motif or other portion of the C-terminus 
might represent a docking site for a number of proteins necessary for autophagosome 
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biosynthesis, although such an interaction has yet to be identified. Alternatively, and 
perhaps more likely, JAM-C may provide the basis for a protein scaffold structure that 
could facilitate the binding of key autophagy proteins through distant protein 
interactors within the scaffold. Thus, disrupted expression of JAM-C would remove this 
protein scaffold and therefore any potential pro-autophagic proteins that are 
necessary for the initiation of autophagy. 
It is indeed intriguing that loss of an endothelial junctional molecule results in 
upregulation of autophagy, which is essentially a process designed to supply the cell 
with more energy. This begs the question why do ECs need more energy following 
junctional disruption? In this context, it is important to take into account the 
functional roles for JAM-C that have been described, such as during leukocyte 
transmigration (Bradfield et al., 2007, Scheiermann et al., 2009). During migration of 
leukocytes through the endothelial barrier, adherens and tight junctions, as well as the 
cytoskeleton, undergo extensive remodelling that involves the cleavage of molecules 
such as JAM-C (Colom et al., 2015). This process by which functional JAM-C is lost 
could represent a trigger that results in the upregulation of autophagy to cope with 
the increased energy demand subsequently placed upon the ECs. 
An alternative view as to why ECs upregulate autophagy following loss of JAM-C lies 
within the fact that cells are always trying to maintain homeostasis. Autophagy can be 
stimulated by numerous physical, chemical and environmental stressors that impact 
upon the cell and ultimately it serves to help maintain that state of homeostasis. Loss 
of or dysfunctional JAM-C may serve as one such physical stressor that in turn results 
in the upregulation of autophagy in these cells. This would then help protect the cell 
from adverse effects of loss of JAM-C and maintain homeostasis and cell survival, as 
has been described for multiple other inducers of cell stress (Kroemer et al., 2010, 
Murrow and Debnath, 2013). This theory is supported by the results from this chapter 
and those from our groups in vivo works showing that JAM-C deficient ECs exhibit 
increased autophagy under resting conditions, where little or no leukocytes are 
present. As such, it is more likely that autophagy is upregulated as a mechanism to 
maintain homeostasis in these cells, and perhaps also to provide energy to the cell to 
deal with any potential subtle changes in tight junction morphology and the 
subsequent impact on the cell that might occur during the loss of JAM-C. Moreover, 
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the results described in Chapter 3 that loss of EC JAM-C does not result in increased EC 
apoptosis are further supportive of this reasoning. Increased autophagy induced by 
loss of JAM-C would serve to protect the cells from apoptotic or other forms of cell 
death and maintain the homeostatic state. 
Current ongoing projects in the lab are aimed at identifying the specificity of this 
phenomena to JAM-C by looking at the impact of loss of other related junctional 
molecules, such as the close family member JAM-A, on EC autophagy, as well as the 
impact of inflammatory stimuli on autophagy in JAM-C deficient ECs. 
 
Summary of key findings 
• Starvation induces autophagy in cultured ECs. 
• EC autophagy induced by starvation is dependent on PI3K activity. 
• Loss of EC JAM-C induces autophagy more than 2-fold under basal growth 
conditions. This increase is dependent on PI3K activity. 
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5 Investigating the effects of JAM-C KD on EC gene expression 
5.1 Introduction 
5.1.1 Control of EC gene expression 
ECs tightly control gene expression in order to maintain quiescence and ultimately 
homeostasis. This is particularly important in vivo in the mature vasculature, where 
maintenance of endothelial homeostasis is crucial to avoid unwanted inflammation, 
stress and subsequent tissue damage (Shah et al., 2016). Key to the regulation of 
endothelial functions is the transcription factor ETS related gene, or Erg. This 
transcription factor has been described as the “master regulator” of EC functions, 
acting to maintain endothelial homeostasis (Shah et al., 2016). Amongst other 
functions, Erg has been shown to negatively regulate the activity of the NFκB subunit 
p65 by preventing it from binding to target promoters of pro-inflammatory genes, thus 
controlling and protecting against inappropriate EC inflammation and maintaining EC 
homeostasis (Dryden et al., 2012). 
Whilst maintenance of EC quiescence is undoubtedly important, ECs must also respond 
rapidly to the ever-changing tissue environment, including to environmental stressors 
(hypoxia and shear stress), inflammatory insults (pathogens, cytokines) and growth 
factors (FGF, VEGF), all of which influence EC gene expression. In particular, type II 
activation of ECs by pro-inflammatory mediators such as IL-1β and TNFα results in the 
rapid upregulation of the expression of many inflammatory genes, such as ICAM1, IL-6 
and IL-8 (Minami and Aird, 2005). Much of these effects are mediated through the 
well-studied NFκB and mitogen activated protein kinase (MAPK) signalling pathways 
(Baud and Karin, 2001, Grethe et al., 2004, Mako et al., 2010). 
 
5.1.2 Junctional molecules and gene expression 
Integrity of EC junctions and the molecules that compose them is crucial for both 
homeostasis and EC functions. As such, some progress has been made in 
understanding how junctional molecules might regulate EC gene expression in order to 
ultimately control EC functionality. Perhaps the most well studied of the junctional 
molecules in this regard is VE-Cadherin. VE-Cadherin is known to bind to β-catenin at 
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adherens junctions and regulate the transcriptional activity of β-catenin by 
sequestering it away from the nucleus (Gavard 2014, Dejana and Kuhl 2010). More 
recently it has also been shown that VE-Cadherin controls YAP transcriptional activity 
in stable adherens junctions by associating with it and preventing its nuclear 
translocation (Giampietro et al., 2015). VE-Cadherin has also been shown to regulate 
expression of tight junctional molecules, i.e. induce the expression of claudin-5 in ECs 
through the PI3K/Akt signalling pathway under basal conditions (Taddei et al., 2008). In 
addition, pharmacological disruption of adherens junctions through disruption of VE-
Cadherin was shown to increase VEGF expression in ECs (Castilla et al., 1999). 
Other EC junctional molecules have also been shown to regulate gene expression. The 
scaffolding tight junctional molecule ZO-1 is known to associate with the transcription 
factor ZO-1 associated nucleic acid binding protein (ZONAB), sequestering it at the 
membrane and thus regulating gene expression and subsequently promoting epithelial 
cell proliferation. This transcription factor has been shown to be important for 
regulating epithelial cell proliferation (Balda et al., 2003). 
Despite these advances, how the JAM family of junctional molecules are involved in 
regulating EC gene expression is poorly understood. In fact, the only finding to date 
reports that JAM-A KO mice show increased claudin-10 and claudin-15 expression in 
the intestinal epithelium (Laukoetter et al., 2007). Whether JAM-C regulates EC gene 
expression and, more importantly, how disrupted expression of JAM-C may impact 
upon this phenomenon is completely unknown. 
 
5.2 Aims 
Due to its importance in many EC functions (angiogenesis, permeability and leukocyte 
trafficking), it was hypothesised that loss of EC JAM-C would impact the homeostatic 
state of ECs and result in an altered gene expression profile. Consequently, this 
chapter aimed to address this hypothesis under the following key objectives: 
• To investigate the silencing of JAM-C protein expression on the gene expression 
profile of resting ECs. 
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• To determine whether EC JAM-C KD impacts EC gene expression responses to 
inflammatory stimuli. 
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5.3 Results 
5.3.1 Quality control assessment of EC RNA and gene expression PCA 
For the purposes of this study, it was decided to use gene expression microarray 
technology from Illumina to investigate the global gene expression profile of control 
and JAM-C deficient ECs. To be effective, gene expression analysis using this 
technology requires RNA of high purity and integrity. Therefore, RNA was isolated from 
control and JAM-C KD HUVECs and tested for purity using the Agilent 2100 Bioanalyser 
system. Sample RNA was run alongside purified synthetic RNA control to check for 
presence of degradation peaks (Figure 5.1A). The sample RNA extracted from HUVECs 
showed very high purity and virtually no degradation, with all samples attaining an 
RNA integrity score (RIN score) of at least 9. This allowed the RNA to be submitted for 
microarray analysis. 
In addition to analysing RNA quality, the samples were also analysed for level of JAM-C 
KD. Using the Qiagen AllPrep system, both RNA and protein were isolated from the 
same sample. Protein lysates were analysed for JAM-C protein and also ICAM-1 to 
confirm the IL-1β induced inflammation had worked appropriately. Indeed, JAM-C was 
effectively reduced (Figure 5.1B, lanes 2&4) in a similar manner to that previously 
described (Chapter 3). In addition, ICAM-1 protein was upregulated in cells treated 
with IL-1β (lanes 3&4) as compared to untreated control cells. 
Principle component analysis (PCA) on the gene expression microarray samples 
revealed interesting correlations. Overall two of the replicates clustered closely when 
compared to the other, perhaps indicating biological diversity in the gene expression 
profile of the cultured HUVECs (Figure 5.2). Post IL-1β stimulation, both control and 
JAM-C KD HUVECs showed the same response in the PCA, as indicated by the location 
of those stimulated samples at the top of the PCA plot. When comparing control and 
JAM-C KD samples under unstimulated conditions, all samples exhibited a shift to the 
right in the PCA plot. The same phenotype was evident for control and JAM-C KD 
HUVECs post IL-1β stimulation. This indicates that despite the overall variance 
between replicates, there is a clear shift in expression profile in the PCA plot between 
control and JAM-C KD HUVECs. 
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Figure 5.1. Dual purification of HUVEC protein and RNA for microarray analysis. 
(A) Analysis of RNA quality for gene expression microarray analysis. RNA was extracted from 
control and JAM-C KD HUVECs using the Qiagen RNA/Protein AllPrep system and then 
subjected to analysis of degradation by Bioanalyser (Agilent). Samples were run alongside 
synthetic purified RNA control. The data is plotted as fluorescence intensity (y-axis) versus size 
of the oligonucleotide (x-axis), where two main peaks for 28S and 18S ribosomal RNA can be 
clearly seen. 
(B) Protein was purified from the same control and JAM-C KD HUVECs in (A), which were 
stimulated with IL-1β for 4 hours or left unstimulated. Protein lysates were analysed for 
ICAM-1 protein to confirm response to IL-1β and also JAM-C to confirm level of protein KD. 
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Figure 5.2. Principle component analysis of replicate samples in gene expression microarray. 
The three biological replicate samples from the gene expression microarray were subjected to 
principle component analysis (PCA) post normalisation. The three independent replicates were 
grouped as shown by the outlines in blue, red or green. 
 
5.3.2 JAM-C KD in HUVECs triggers gene expression changes under basal conditions 
In order to analyse differences in gene expression between control and JAM-C KD 
HUVECs, differential gene expression analysis under basal conditions was performed 
using the Limma package for R (see Chapter 2 for full details). Initial analysis using pre-
determined thresholds based on a nominal P.Value of < 0.05 and a logFC of at least ± 
0.5. Any genes within this category were considered significant and so used for further 
analysis. 
Differential expression analysis of control and JAM-C KD HUVECs using those 
thresholds determined above revealed that 549 genes were significantly regulated by 
JAM-C KD under basal conditions. Of these 549 genes, the top 100 were chosen to be 
displayed graphically as a heatmap (Figure 5.3) and clustered based on their pattern of 
expression. For this representation format, all three of the replicate experiments were 
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plotted, despite the variance that was observed in the PCA. That variance can be quite 
clearly seen from the heatmap in Figure 5.3, where the first replicate has a different 
colour profile as compared to the other two replicates. That being said, it can be 
clearly observed that the 100 differentially expressed genes were clustered into two 
distinct groups; those that exhibit decreased expression (blue) and those that had 
increased expression (yellow) in JAM-C KD HUVECs as compared to their control 
counterparts. Overall, 65% of the genes present in the comparison were upregulated 
in conditions of JAM-C KD, which clustered together in the heatmap analysis. Analysis 
of the downregulated genes revealed a distinct cluster at the top of the heatmap 
where a clear reduction in expression (blue) was observed in all three samples of 
JAM-C HUVECs under unstimulated conditions when compared to control. 
Interestingly, about 25% of the 549 genes were either uncharacterised regions of the 
genome or genes encoding for proteins with no reported function. Perhaps most 
reassuringly, the gene for JAM-C, JAM3, was the most significantly downregulated hit 
within the JAM-C KD HUVECs. 
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Figure 5.3. Top 100 differentially expressed genes between control and JAM-C KD HUVECs 
under basal conditions. 
RNA from Control and JAM-C KD HUVECs (from three independent experiments) was subjected 
to gene expression microarray analysis using Illumina HT-12v4.0 BeadChip technology. Data 
were extracted and analysed using the Limma package for Bioconductor software. Significant 
differentially expressed genes were selected based on a threshold of a log fold change (logFC) 
of greater than +/- 0.5 and p < 0.05. The top 100 genes in this threshold are displayed in the 
heatmap, where blue bars represent lower expression and yellow represents higher 
expression than their counterparts. These data were generated using Cluster 3.0 and Java 
TreeView software. This work was done in collaboration with Drs Michael Barnes and Claudia 
Cabrera in the Department for Bioinformatics, William Harvey Research Institute, QMUL. 
 
5.3.3 Pathway analysis of JAM-C KD EC gene expression 
In order to determine the potential biological effects of the differential gene 
expression pattern observed in ECs following JAM-C KD, the 549 significantly 
differentially expressed genes were subjected to pathway analysis using Ingenuity 
Pathway Analysis (Qiagen) software. Using this method, biological processes that 
might be up- or downregulated in conditions of JAM-C KD due to the differential gene 
expression pattern observed could be identified. As such, the biological processes that 
were upregulated in conditions of JAM-C KD are displayed in Table 5.1. A number of 
immune processes were predicted to be upregulated in this analysis, in particular 
those involved in immune cell trafficking, such as “binding of leukocytes”, “migration 
of neutrophils” and “emigration of leukocytes”. In addition, processes such as cellular 
homeostasis and cell viability were also predicted by pathway analysis to be 
significantly upregulated in conditions of JAM-C KD. 
Following the observation that identification of a number of genes associated with 
immune and cellular homeostasis pathways are upregulated following JAM-C KD, it 
was noticed that many of these biological processes fall into one of three broad 
categories; 1) Immune Response, 2) Immune Cell Trafficking and 3) Cellular 
Homeostasis. To investigate the genes involved in each category and the overlap of 
common genes between these categories, a network map of all candidate genes was 
created. Differentially expressed genes associated with cellular processes that 
displayed an activation score of at least 1.5 and that could be encompassed into one of 
the three broad categories were used for this analysis (Figure 5.4A). The majority of 
the genes in this network were upregulated in response to JAM-C KD (red), many of 
which are pro-inflammatory genes, such as ICAM-1 and CXCL1. In addition, most of the 
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genes in this network belonged to at least two of the categories used to create the 
network, indicating overlapping functions For simplicity, this data set is displayed in a 
Venn diagram format as shown in Figure 5.4B. This representation format shows that 
14 genes are common to all three categories, and another 19 are common to at least 
two categories. 
 
 
Table 5.1. List of biological processes upregulated in JAM-C KD HUVECs. 
The significant differentially expressed genes in JAM-C KD HUVECs under unstimulated 
conditions were subjected to pathway analysis using Ingenuity pathway analysis (IPA) software 
(Qiagen). The categories are ordered by their activation z-score, a prediction of the activation 
state of that process based on the predicted p value for enrichment of the pathway and the 
log fold change of the relevant pathway. 
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Figure 5.4. Network pathway analysis of differentially expressed genes following JAM-C KD 
in HUVECs. 
(A) Network of genes involved in the categories “immune response”, “immune cell trafficking” 
and “cellular homeostasis”, detailing their inter-connections between each of the categories. 
Red and green gene symbols indicate genes upregulated and downregulated respectively 
under conditions of JAM-C KD. 
(B) Venn diagram summarising the overlap of the indicated pathway associated genes that are 
differentially regulated in response to JAM-C KD. 
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5.3.4 Validation of differentially expressed genes by qPCR 
Using this network analysis, a list of candidate genes of interest was compiled, as 
shown in Table 5.2. Using the normalised relative intensities from the microarray data, 
Figure 5.5A highlights the increase in expression shown by some of these genes under 
conditions of JAM-C KD, exhibiting in all cases at least 2-fold or more increased 
expression over control cells. 
 
Table 5.2. List of selected candidate genes to be validated by qPCR that are significantly 
differentially expressed following JAM-C KD. 
 
The expression of a number of these genes was subsequently validated by qPCR, 
including JAM3 (JAM-C), VCAM1, ICAM1, CXCL1, IL8, CCL2, HMGB1 and HIF1A (Figure 
5.5B). Reassuringly, JAM3 was the gene most significantly reduced in expression 
following JAM-C KD while VCAM1 was upregulated about four-fold in JAM-C KD 
HUVECs and this was statistically significant. Another adhesion molecule gene ICAM1 
was also upregulated significantly in conditions of JAM-C KD. The chemokines IL8, 
CXCL1 and CCL2 all showed significantly increased expression at the mRNA level in 
JAM-C KD conditions, in all cases at least two-fold or more above control conditions 
(Figure 5.5B). The genes HMGB1 and HIF1A were also significantly increased in 
expression in JAM-C KD HUVECs, both of which have been extensively implicated in 
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inflammatory reactions and hence were identified as candidate genes from the 
network pathway analysis (Figure 5.4) (Hellwig-Burgel et al., 2005, Palazon et al., 2014, 
Huebener et al., 2015), (Klune et al., 2008), Palazon et al., 2014, (Schiraldi et al., 2012).  
The classical pro-inflammatory genes investigated here (ICAM1, CXCL1, CCL2) showed 
generally low expression in control HUVECs, in agreement with the dogma that Erg 
controls EC homeostasis by restricting pro-inflammatory gene expression. The 
expression of HIF1A and HMGB1 by contrast showed higher expression in control 
HUVECs under basal conditions, so even the smaller changes in the expression of these 
genes observed in JAM-C KD HUVECs could have a potentially large impact on protein 
expression. 
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Figure 5.5. qPCR validation of candidate genes selected from the microarray and pathway 
analysis. 
(A) Normalised intensities for individual genes were extracted from the microarray analysis 
and plotted in histograms to indicate the differential expression of candidate genes in JAM-C 
KD HUVECs compared to control HUVECs under basal conditions. 
(B) RNA was isolated from control and JAM-C KD HUVECs and reverse transcribed to cDNA. 
Primers specific for JAM-C, VCAM1, IL8, CXCL1, CCL2, HMGB1, and HIF1A (detailed in section 
2.4.5) were used to specifically amplify those transcripts. Data was plotted as fold change over 
control cells using the ΔΔCt method, where primers for ACTB and PPIA were used as 
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housekeeping controls. Data is representative of at least four independent experiments. Error 
bars represent mean ± SEM. * = p<0.05, **=p<0.01 paired t-test. 
 
5.3.5 JAM-C KD increases the basal activation of the NFκB pathway in HUVECs 
Many of the genes present in the differential expression analysis of JAM-C KD HUVECs, 
including those validated by qPCR in Figure 5.5B, are hallmarks of increased NFκB 
pathway activation. NFκB is a rapid-response family of transcription factors important 
in regulating a number of key cellular processes, including proliferation, cell death and 
response to inflammation among others (Baeuerle and Henkel, 1994, Joyce et al., 
2001). This family of transcription factors can homo and hetero-dimerise to direct the 
transcription of target genes. The most studied of these is the p65 subunit which is 
activated by phosphorylation on two serine residues, S276 and S536 (Christian et al., 
2016). To investigate whether the NFκB pathway was activated in JAM-C KD HUVECs, 
the S536 phosphorylation status of p65 was investigated in this model. 
Using Western Blot analysis, phosphorylated p65 levels were found to be elevated in 
JAM-C KD HUVECs when compared to control HUVECs (Figure 5.6A, lanes 1&2). Of 
importance, total levels of p65 were similar in control and JAM-C KD HUVECs under 
basal conditions, indicating that the increased p65 phosphorylation is not due to an 
increase in overall protein levels of p65 but rather a bona fide increase in 
phosphorylation status. Quantification of this revealed a significant increase in 
phosphorylated p65 levels (Figure 5.6B, left panel), suggesting a significant activation 
of the NFκB pathway in JAM-C KD HUVECs as compared to control HUVECs under basal 
conditions. 
Cell signalling pathways are notoriously complex and each individual pathway has been 
shown to crosstalk with one or more other signalling pathways. This is particularly 
evident during inflammation, where one or more signalling pathways can be activated 
by the same stimulus, or even where one signalling pathway can activate others (Korus 
et al., 2002). As such, the activation status of two components of the MAPK signalling 
pathway, Extracellular signal-regulated kinases 1 and 2 (ERK1 and ERK2) were also 
investigated. Indeed, the MAPK pathway has been well studied in the context of 
regulating gene expression responses to inflammatory cues, including where ERK1/2 
and p38 MAPK mediate the upregulation in gene expression of pro-inflammatory 
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molecules such as IL-6 and IL-8 (Yang et al., 2008). In the present study, 
phosphorylated levels of both ERK1 and ERK2 were low under basal conditions in 
control cells (Figure 5.6A, lanes 1&2), with no visible increase observed following JAM-
C KD. This was reflected in the quantification shown in Figure 5.6B, lower right panel. 
Subsequent immunofluorescence studies were carried out to analyse nuclear 
translocation and phosphorylation of NFκB p65 in JAM-C KD HUVECs (Figure 5.7). 
Phospho-p65 was clearly upregulated in control cells stimulated with IL-1β for 30 
minutes as compared to control unstimulated cells. In addition, total-p65 was clearly 
translocated to the nucleus in these IL-1β stimulated cells. In unstimulated JAM-C KD 
HUVECs, there was a clear increase in phospho-p65 levels in the cytoplasm of the cells, 
correlating with the total protein data observed in Figure 5.6. However, very little 
nuclear translocation was observed in either control or JAM-C KD unstimulated 
HUVECs, where the staining was predominantly cytoplasmic. 
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Figure 5.6. NFκB pathway is upregulated in JAM-C KD HUVECs. 
(A) HUVECs were transfected with control or JAM-C siRNA and cultured for 72 h to reach 
confluence and then lysed for protein analysis. Lysates were analysed by Western blot for total 
and phosphorylated NFκB, total and phosphorylated ERK1/2 and β-actin loading control. 
Representative blot of four independent experiments. 
(B) Quantification of Western Blots in (A). Phosphorylated NFκB was normalised to total NFκB 
for each sample and the same process repeated for ERK1 and ERK2. Data is representative of 
n=4 independent experiments, error bars represent mean ± SEM. *=p<0.05, unpaired t-test. 
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Figure 5.7. Immunofluorescence staining of total and phospho-p65 in JAM-C KD HUVECs. 
HUVECs were transfected with control or JAM-C siRNA, then cultured for 72 h to achieve 
maximum efficiency of KD. Control cells were also stimulated with IL-1β for 30 mins as a 
positive control for NFκB activation and nuclear translocation. Cells were then fixed in 4% PFA 
at room temperature 15 min. Cells were immuno-stained for total-p65 (red), phospho-p65 
(green) and DAPI (blue) and imaged using a Zeiss LSM 800 confocal microscope. Data is 
representative of two independent experiments. 
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5.3.6 JAM-C KD HUVECs show increased protein expression of IL-8 and ICAM-1 
Following the finding of increased inflammatory gene expression in JAM-C KD HUVECs 
under basal conditions, it was decided to investigate whether this increase was 
translated into increased protein expression. For this purpose, levels of the chemokine 
IL-8 and the adhesion molecule ICAM-1 were investigated by ELISA and Western Blot 
techniques, respectively. Under basal conditions, ICAM-1 protein was found to be 
elevated in JAM-C KD HUVECs when compared to control HUVECs (Figure 5.8A). This 
increase was above two-fold and statistically significant, corresponding with the 
increase in ICAM1 gene expression observed in Figure 5.5B. 
The levels of IL-8 were measured in both the cell associated (lysate) and secreted 
(conditioned medium) fractions of control and JAM-C KD HUVECs under basal 
conditions. JAM-C KD HUVECs showed an increase (1.9 fold) in IL-8 protein in cell 
lysates as compared to control HUVECs (Figure 5.8B, left panel), though this increase 
did not reach statistical significance (p=0.13, n=7). In a similar manner, secreted IL-8 
was also slightly increased (1.55 fold) in JAM-C KD HUVECs but again this was not 
statistically significant (p=0.10, n=8). 
The results described in this part of the chapter indicate that silencing of JAM-C 
expression in ECs results in a pro-inflammatory primed state of the ECs. This is 
illustrated in the form of increased pro-inflammatory gene expression, potentially due 
to increased NFκB pathway activation, that translates to increased protein levels in the 
case of ICAM-1 and the chemokine IL-8. 
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Figure 5.8. IL-8 and ICAM-1 proteins are elevated in JAM-C KD HUVECs. 
(A) HUVECs were transfected with control or JAM-C siRNA and cultured for a further 72 h to 
reach confluence. Cells were lysed and then analysed for ICAM-1 protein levels by Western 
Blot. Data is represented as the ratio of ICAM-1 to β-actin and then normalised to control 
conditions. Error bars represent mean ± SEM from n=4 independent experiments. * = p<0.05, 
paired t-test. 
(B) HUVECs were transfected with control or JAM-C siRNA and cultured for a further 72 h to 
reach confluence. Conditioned cell culture medium was collected and cells lysed for the 
collection of protein lysate. Both lysate and medium were analysed for IL-8 protein levels by 
ELISA. Lysate IL-8 levels were normalised to total protein content of the lysates. Error bars 
represent mean ± SEM from n=7 independent experiments for lysate and n=8 for conditioned 
medium. Data not significant at p=0.05 from unpaired t-test. 
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5.3.7 Differential gene expression analysis of IL-1β stimulated HUVECs 
Using the pre-determined thresholds set out in section 0, comparison of IL-1β 
stimulated control HUVECs (1 ng/ml for 4 h) with unstimulated conditions revealed 
1951 genes that were differentially regulated by IL-1β. In this large gene-set, the split 
between up- and down-regulation by IL-1β was 55% to 45% respectively. Table 5.3 and 
Table 5.4 display the top 25 upregulated and downregulated differentially expressed 
genes following IL-1β stimulation of HUVECs. Of the top upregulated genes, many 
correspond to classical EC inflammatory response genes, notably adhesion molecules 
such as E-selectin (SELE) and ICAM-1 and also chemokines such as CXCL2, CXCL1 and 
CCL2. 
Analysis of the most highly downregulated genes post IL-1β stimulation highlighted 
some interesting findings, most notable of which is that nearly one third of the top 
downregulated genes appeared to be unidentified loci or open reading frames of the 
genome. In addition, while many of the most highly upregulated genes are similar in 
function (adhesion molecules or chemokines), the most highly downregulated genes 
show a variety of functions, such as transcription factors, receptors and ion channels. 
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Table 5.3. Top 25 significantly upregulated differentially expressed genes induced by IL-1β in 
HUVECs. 
The top differentially expressed genes in control cells stimulated with IL-1β compared to 
unstimulated cells were determined by displaying a logFC > 0.5 and P.Value < 0.05. 
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Table 5.4. Top 25 significantly downregulated differentially expressed genes following IL-1β 
stimulation of HUVECs. 
The top differentially expressed genes in control cells stimulated with IL-1β compared to 
unstimulated cells were determined by displaying a logFC < 0.5 and P.Value < 0.05. 
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5.3.8 Impact of IL-1β on differential gene expression in JAM-C KD HUVECs 
Following the findings of increased pro-inflammatory gene expression in JAM-C KD 
HUVECs under basal conditions, the analysis was extended to investigate the impact of 
JAM-C KD on EC gene expression in stimulated ECs. Initially, control and JAM-C KD 
HUVECs stimulated with IL-1β for 4 hours were compared directly using the differential 
expression analysis model applied previously. Using this method, 987 genes were 
found to be differentially expressed in JAM-C KD HUVECs compared to control HUVECs 
following IL-1β stimulation. Out of these genes, there was an even 50% split of up- and 
down-regulation in expression in JAM-C KD HUVECs. Figure 5.9 shows the top 100 of 
those genes displayed graphically in heatmap form, indicating the clustering of 
upregulated (yellow) and downregulated (blue) genes in JAM-C KD HUVECs. In a similar 
manner to that observed under basal conditions, many of the differentially expressed 
genes in this comparison were found to be unidentified loci, transcripts with only 
putative protein reported or open reading frame regions of the genome. 
While nearly 1000 genes were found using this differentially expressed model, it was 
interesting to observe that not one those genes there were previously identified in the 
unstimulated differential gene expression analysis were present in this cohort. Indeed, 
as shown in Table 5.5, many of these genes showed no significant difference in 
expression between control and JAM-C KD HUVECs post IL-1β stimulation. It was 
previously detailed in Table 5.3 that these prototypical inflammation induced genes 
are highly upregulated in control cells following IL-1β stimulation and that is also the 
case in IL-1β stimulated JAM-C KD HUVECs. Taken together, these findings suggest that 
IL-1β-induced expression of proto-typical endothelial pro-inflammatory genes such as 
ICAM1, VCAM1, IL8 and CXCL1 are unaffected by depletion of JAM-C in ECs. 
 
134 
 
 
135 
 
Figure 5.9. The top 100 differentially expressed genes between control and JAM-C KD 
HUVECs following IL-1β stimulation. 
RNA from Control and JAM-C KD HUVECs stimulated with 1 ng/ml IL-1β for 4 h (from three 
independent experiments) was subjected to gene expression microarray analysis using 
Illumina HT-12v4.0 BeadChip technology. Data were extracted and analysed using the Limma 
package for Bioconductor software. Significant differentially expressed genes were selected 
based on a threshold of a log fold change (logFC) of greater than +/- 0.5 and p < 0.05. The top 
100 genes in this threshold are displayed in the heatmap, where blue bars represent lower 
expression and yellow represents higher expression than their counterparts. These data were 
generated using Cluster 3.0 and Java TreeView software. This work was done in collaboration 
with Drs Michael Barnes and Claudia Cabrera in the Department for Bioinformatics, William 
Harvey Research Institute, QMUL. 
 
 
 
Table 5.5. Candidate genes from unstimulated comparison subjected to differential 
expression analysis following IL-1β stimulation. 
The candidate genes that showed upregulation under basal conditions in JAM-C KD HUVECs in 
Table 5.2 were analysed for differential expression in JAM-C KD HUVECs following IL-1β 
stimulation as compared to control HUVECs. They are displayed here with the logFC of 
expression and P.value. 
 
Building on these analyses, an additional approach was taken to analyse the effects of 
JAM-C KD on IL-1β-mediated gene expression in ECs. Using the differential expression 
analysis of the response of control cells to IL-1β (see section 0), the 1951 detected 
regulated genes were plotted in a normalised differential expression heatmap (Figure 
5.10 A&C) to indicate the EC response to IL-1β in control cells. Differential expression 
analysis of these genes was then performed on IL-1β stimulated HUVECs, but this time 
using unstimulated control cells as the comparison. The resulting analysis was plotted 
on the same heatmap (Figure 5.10 A&C, right column). This analysis allowed for 
detection of areas which show no up-regulation (Figure 5.10A) or down-regulation 
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(Figure 5.10C) in gene expression in JAM-C KD HUVECs following IL-1β stimulation  
(green boxes). These genes were extracted and analysed for patterns of expression. 
Here, 147 genes failed to show upregulation (the top 20 of which are detailed in Figure 
5.10B) and instead were downregulated in JAM-C KD HUVECs. Interestingly, a number 
of the unidentified loci of the genome are again present, even in this smaller cohort. 
Analysing the genes that failed to show downregulation in response to IL-1β in JAM-C 
KD HUVECs revealed 154 candidates. The top 20 of these are displayed in Figure 5.10D, 
again indicating a number of those unidentified loci. 
From this analysis, the 301 candidate genes identified were subjected to gene ontology 
enrichment analysis (GO) to identify potential biological pathways that might be 
impacted by JAM-C KD in IL-1β stimulated HUVECs. The top 10 biological processes are 
listed in Table 5.6. Amongst these, processes such as “intracellular signal transduction” 
and “immune system processes” were of interest to the theme of this project and as 
such warrant further investigation. This analysis highlighted a number of inflammatory 
genes which are dysregulated in JAM-C KD HUVECs following IL-1β stimulation, genes 
that are detailed in Table 5.7. Collectively, the present novel studies indicate that 
JAM-C deficient ECs respond abberantly to inflammatory stimululation in the form of 
disrupted gene expression. 
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Figure 5.10. Normalised differential expression heatmap of IL-1β stimulated HUVECs. 
(A&C) IL-1β stimulated control HUVECs were subjected to differential expression analysis 
compared to unstimulated control HUVECs. Using the pre-determined thresholds of logFC > ± 
0.5 and P.value < 0.05, significant genes were plotted in heatmap form. Those same genes 
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were analysed in JAM-C KD HUVECs stimulated with IL-1β again using control unstimulated 
HUVECs as the comparison and plotted in the same heatmap. Regions of dysregulated 
expression are highlighted by the green boxes. 
(B) Genes that were not upregulated in JAM-C KD HUVECs were isolated from the heatmap 
in (A). The top 20 were displayed in table negatively ordered by logFC level in JAM-C KD 
HUVECs. 
(D) Genes that were not downregulated in JAM-C KD HUVECs were isolated from the heatmap 
in (A). The top 20 were displayed in table positively ordered by logFC level in JAM-C KD 
HUVECs. 
 
 
 
Table 5.6. Gene ontology enrichment analysis (GO) of dysregulated genes in IL-1β stimulated 
JAM-C KD HUVECs. 
The candidate genes identified from the heatmap in Figure 5.10 were subjected to gene 
enrichment analysis using gene ontology software (Broad Institute, Cambridge, MA, USA).  
 
 
 
Table 5.7. Candidate genes isolated from GO analysis. 
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5.3.9 Differential expression of semaphorins by JAM-C KD HUVECs 
One of the main aims of this chapter and the project as a whole was to identify 
molecules and novel mechanisms by which loss of EC JAM-C leads to disrupted modes 
of neutrophil migration. In this context, a potential avenue is the possibility that EC 
JAM-C deficiency promotes the generation of chemorepulsive molecules. As such, a list 
of chemorepulsive molecules was compiled (see Appendix 3) and the differential gene 
expression analysis of control and JAM-C KD HUVECs under IL-1β stimulation overlayed 
onto the list to isolate candidate molecules. This process indicated that a number of 
the semaphorin family of molecules were differentially expressed in IL-1β stimulated 
JAM-C KD HUVECs, particularly SEMA3E, SEMA3G and SEMA4F (Figure 5.11A&B). Upon 
further examination, it was also found that some of the semaphorin receptors, the 
plexins and neuropilins, as well as the functionally related molecule RMA, also showed 
differential expression in JAM-C KD HUVECs. The semaphorin molecules and their 
receptors were originally identified due to their role as axonal cone guidance 
molecules (Kruger et al., 2006, Worzfield et al., 2014). More recently, however, they 
have been found to have a role in a number of other biological processes, particularly 
in immune responses (Potiron et al., 2007, Takamatsu et al., 2010) and the regulation 
of leukocyte migration (Movassagh et al., 2016, Morote-Garcia et al., 2012, van Rijn et 
al., 2016). 
To verify the differences observed, the expression of a number of these genes was 
validated by qPCR (Figure 5.12). The findings indicate that there is an increase in gene 
expression of several members of the semaphorin family in JAM-C KD HUVECs 
following IL-1β stimulation, particularly SEMA4F and SEMA3G. With respect to 
SEMA4F, expression is equal in control and JAM-C KD HUVECs under basal conditions 
and slightly reduced in IL-1β stimulated control HUVECs when compared to -
unstimulated control ECs. However, IL-1β stimulated JAM-C KD HUVECs exhibited a 
statistically significant increase in SEMA4F gene expression as compared to control 
stimulated HUVECs. SEMA3G expression was also increased in JAM-C KD HUVECs 
compared to control HUVECs following IL-1β stimulation, though this was a smaller 
two-fold increase and was not statistically significant. In a similar manner, SEMA6B 
expression was increased in JAM-C KD HUVECs under both basal and IL-1β stimulated 
conditions, though again these changes were not statistically significant. Together, the 
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present results identify a novel role for EC JAM-C as a regulator of gene expression of 
chemorepulsive molecules, most notably members of the semaphorin family. Further 
work is currently being conducted to confirm the findings for SEMA3E and SEMA6B 
and also to validate the expression of additional genes detailed in Figure 5.11A. 
 
Figure 5.11. Several members of the Semaphorin family of molecules are differentially 
expressed in JAM-C KD HUVECs following IL-1β stimulation. 
(A) Control and JAM-C KD HUVECs stimulated with IL-1β were subjected to differential 
expression analysis. Semaphorin and related genes are displayed in the table. 
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(B) Normalised intensities were extracted from the microarray data chips and plotted for 
SEMA3E, SEMA3G, SEMA4F, RGMA and SEMA6B genes. 
 
Figure 5.12. qPCR validation of Semaphorin gene expression in JAM-C KD HUVECs. 
RNA was isolated from control and JAM-C KD HUVECs, both unstimulated and IL-1β stimulated 
and reverse transcribed to cDNA. Primers specific for SEMA3G, SEMA4F and SEMA6B (detailed 
in section 2.4.5) were used to specifically amplify those transcripts. Data is plotted as fold 
change over control cells using the ΔΔCt method, where primers for ACTB and PPIA were used 
as housekeeping controls. Data is representative of at least four independent experiments. 
Error bars represent mean ± SEM. * = p<0.05, **=p<0.01 one-way ANOVA. 
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5.4 Discussion 
The aim of this chapter was to investigate the role of JAM-C in regulation of EC gene 
expression. To achieve this, the model of JAM-C KD in HUVECs described in Chapter 3 
was used, with purified RNA from control and JAM-C KD HUVECs under both 
unstimulated and IL-1β stimulated conditions being submitted to gene expression 
microarray analysis using the Illumina HT-12 expression chips. While next generation 
RNA-sequencing has become the more preferred method for analysing gene 
expression, at the time of this work it was considerably more cost effective to use the 
gene expression microarray approach for the present project. This aspect of my PhD 
was significantly facilitated by the Barts and the London Genome Centre. 
The most commonly used approach to analyse gene expression data is the use of 
differential gene expression analysis. In collaboration with Dr Michael Barnes and Dr 
Claudia Cabrera of the Centre for Translation Bioinformatics (QMUL), differential 
expression analysis of control and JAM-C KD HUVECs was performed. A variety of 
methods can be used to identify thresholds for such analysis in order to select 
significant changes in this model. Indeed, while the use of False Detection Rate (FDR) 
corrected P.Values alone is a popular method, this can be quite restrictive depending 
on the biological question at hand. The use of logFC cutoffs and/or P.Values can 
however provide a wider range of genes to investigate (Dalman et al., 2012). As such, it 
was decided to using a combination of logFC and P.Value cut offs to determine 
significant genes in these comparisons, more specifically, logFC increase/decrease of ± 
0.5 and a P.Value of ≤ 0.05. This approach enabled investigations into moderate 
changes in gene expression and associated pathways that might occur following loss of 
JAM-C in ECs. 
 
5.4.1 JAM-C regulates EC gene expression under basal conditions 
Initial investigations into the effects of JAM-C KD on EC gene expression focussed on 
resting ECs. Using both differential gene expression and subsequent pathway analysis 
models, JAM-C KD HUVECs were found to exhibit increased gene expression associated 
with numerous inflammatory pathways, most intriguing of which were leukocyte 
migration related pathways. This was characterised by increased expression of a 
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number of pro-inflammatory genes, including VCAM1, ICAM1, CXCL1, CCL2 and IL8. 
These are the prototypical molecules whose expression is induced by inflammation in 
ECs to recruit leukocytes, particularly monocytes and neutrophils. In many cases this 
increased expression was observed at two or more fold over that of control HUVECs. 
Further characterisation suggested that these gene expression increases are also 
translated into increased protein levels, as indicated by increased protein levels of 
ICAM-1 and IL-8. This represents a novel finding for the field and demonstrates how an 
EC junctional molecule can control the basal inflammatory status of the cell through 
regulating gene expression. 
From these findings, it could be suggested that loss of JAM-C from ECs results in an 
inflammatory priming of ECs. Intriguing though this is, one must also consider the 
physiological impact of such expression. While this increase in gene expression is 
clearly not as high as the induction detected post stimulation of ECs with IL-1β, it was 
nevertheless a significant response. As such, perhaps JAM-C KD HUVECs might support 
increased rolling and/or adhesion of leukocytes (neutrophils specifically) under basal 
conditions. This analysis could be extended to an in vivo model, using endothelial 
specific JAM-C KO mice to investigate whether they exhibit increased leukocyte rolling 
flux, adhesion and/or transmigration under basal conditions. 
Initial investigations into how loss of JAM-C might induce increased pro-inflammatory 
gene expression under basal conditions focussed on the role of the NFκB pathway. 
Each of the genes discussed here have been shown to be induced through activation of 
the NFκB family of transcription factors and its signalling pathway (van Uden et al., 
2008, Moynagh et al., 1994, Anisowicz et al., 1991). Classically, NFκB is activated in 
response to pro-inflammatory mediators such as IL-1β, TNFα and LPS. Stimulation by 
such mediators triggers signalling that ultimately results in the phosphorylation and 
translocation of NFκB to nucleus where it initiates the transcription of a variety of pro-
inflammatory genes (Christian et al., 2016). In the model of EC JAM-C deficiency used 
in this project, JAM-C KD HUVECs showed significantly increased phosphorylated levels 
of the NFκB subunit p65 under basal conditions, although this was not correlated with 
increased p65 nuclear translocation. This suggests that loss of JAM-C from ECs signals 
through the NFκB pathway to induce expression of pro-inflammatory genes. However, 
activation by protein kinase mediated phosphorylation of the individual NFκB subunits 
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is not the only mechanism by which the pathway is regulated (Oeckinghaus et al., 
2009). Inhibitor of κB (IκB) sequesters NFκB in the cytoplasm to prevent its 
translocation to the nucleus. Upon inflammatory cues, IKK phosphorylates and targets 
IκB for degradation, freeing NFκB for nuclear translocation (Yamamoto and Gaynor, 
2004). As such, phosphorylation of the IκB subunits is also a method for analysing NFκB 
pathway activation and could be used in this model of JAM-C KD to obtain further 
evidence for the involvement of NFκB pathway activation post JAM-C KD. 
As mentioned previously, numerous different signalling pathways can be activated by 
an inflammatory stimulus such as IL-1β, notably the MAPK pathway (Weber et al., 
2010). Hence, it is entirely possible that multiple signalling pathways, such as the 
MAPK pathway, are activated following JAM-C KD, which could contribute to the noted 
pro-inflammatory gene expression. While the activation of two MAPKs, ERK1 and 
ERK2, were unaffected by JAM-C KD, these are not the only MAPKs that are associated 
with inflammatory signalling. Indeed, p38 MAPK and c-Jun N-terminal kinase (JNK) are 
two kinases that should also be investigated in this model. Indeed, p38 MAPK has been 
shown to activate the expression of the candidate genes identified in this model such 
as ICAM1 (Yan et al., 2002) and VCAM1 (Dong et al., 2011). Not only that, but p38 
MAPK has also been shown to increase activation of NFκB (Korus et al., 2002), 
highlighting the complex crosstalk that can occur between intracellular signalling 
pathways. 
In addition to increased pro-inflammatory gene expression, the pathway analysis of 
unstimulated JAM-C KD HUVECs under basal conditions also revealed that pathways 
involved in cellular homeostasis were predicted to be upregulated in JAM-C KD cells. 
Further examination of these pathways revealed two genes in particular, HIF1A and 
HMGB1, with qPCR validating that their expression was significantly upregulated in 
JAM-C KD HUVECs under basal conditions. Hypoxia inducible 1-alpha (HIF1α) protein, is 
a critical part of the cellular response to changing oxygen levels (Bartels et al., 2013, 
Semenza, 2014). In addition to this crucial role, HIF1α is also documented to play a role 
in the inflammatory response (Hellwig-Burgel et al., 2005, Palazon et al., 2014) and it 
has also been shown to be regulated by the NFκB pathway, suggesting that 
upregulation of phosphorylated p65 detected in JAM-C KD HUVECs might also be 
responsible for increased HIF1A expression. HMGB1 has a wide range of functions, 
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including facilitating gene transcription (Lotze and Tracey, 2005), regulating autophagy 
(Tang et al., 2010a) and also in inflammation where it functions as a danger associated 
molecular pattern (DAMP) (Klune et al., 2008). Macrophages and monocytes release 
HMGB1 as a pro-inflammatory cytokine acting as a potentiator of local inflammation 
(Schiraldi et al., 2012). In addition, it has also been shown that epithelial cell derived 
HMGB1 acts as a chemoattractant to induce the recruitment of leukocytes by forming 
a complex with CXCL12 chemokine (Huebener et al., 2015). As such, HMGB1 
represents an exciting candidate molecule for investigation with regards to how JAM-C 
regulates EC biology, particularly given its wide range of known pro-inflammatory 
functions. 
 
5.4.2 JAM-C KD ECs respond aberrantly to cytokine stimulation 
Following the analysis of unstimulated HUVECs, it was hypothesised that JAM-C KD ECs 
may respond to an inflammatory stimulus in a different manner to control cells. To 
investigate this, control and JAM-C KD HUVECs were stimulated with the pro-
inflammatory cytokine IL-1β for 4 hours and then analysed for differential gene 
expression. Rather surprisingly, no difference in expression of any typical EC pro-
inflammatory molecules, such as adhesion molecules, chemokines or cytokines was 
found. In fact, in terms of these molecules, JAM-C KD ECs appear to respond in the 
same way as control cells, at the gene expression level at least. 
Differential expression and cluster analysis of IL-1β stimulated control or JAM-C KD 
HUVECs compared to unstimulated conditions revealed two distinct clusters of gene 
dysregulation in IL-1β stimulated JAM-C KD HUVECs (Figure 5.10). Isolation of the 
genes in these clusters revealed a large percentage (30%) of uncharacterised loci and 
transcripts. This indicates that there is a large amount of the gene expression response 
of ECs to inflammatory stimuli such as IL-1β that remains to be characterised. More 
interestingly, loss of JAM-C seems to disrupt the normal expression pattern of these 
targets and as such highlights a number of potential avenues by which JAM-C might be 
crucial to regulating EC gene expression responses to IL-1β. 
Another important finding from this analysis was that, upon subjection of these 
clusters to GSEA analysis, pathways such as intracellular signal transduction were 
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predicted as potentially being regulated by loss of JAM-C in IL-1β stimulated HUVECs. 
While the investigations into this are still at a very early stage, a number of interesting 
observations were made when examining the genes responsible for these predicted 
pathways. These genes, normally upregulated in HUVECs in response to IL-1β, are not 
induced when JAM-C is lost. Some of the genes dysregulated here include IRF6 and 
IRF7, two members of the IRF family of transcription factors that are part of the JAK-
STAT signalling pathway. Interferon regulatory factor 7 (IRF7) is considered the master 
regulator of type I interferon responses, coordinating signalling responses (Honda et 
al., 2005). It has also been shown to interact with Myeloid differentiation primary 
response gene 88 (MyD88), an important adaptor protein in the IL-1β receptor 
complex (Honda et al., 2005). Indeed, if this reduced gene expression correlates to 
reduced protein levels, perhaps loss of JAM-C might impact EC and tissue responses to 
prolonged inflammation and the subsequent resolution of inflammation. Rather 
intriguingly, the gene for the tight junction molecule ZO-2, TJP2, was also not 
upregulated in JAM-C KD HUVECs. These results provide the first evidence for the 
ability of EC JAM-C to regulate the gene expression of another junctional molecule. 
Overall, JAM-C KD HUVECs seem to exhibit a partial failure to respond to IL-1β in terms 
of their gene expression profile. This dysregulation does not appear to occur in any of 
the typical IL-1β responsive pro-inflammatory genes (such as ICAM1 or CXCL1). 
Therefore, altered gene expression may not account for the disrupted modes of 
neutrophil migration that are observed under conditions of JAM-C loss in vivo. 
Nevertheless, the disrupted gene expression profile is highly intriguing and while 
investigations into this phenotype are at a very early stage, the present finding could 
provide valuable insights into how JAM-C regulates EC gene expression responses to 
inflammatory stimuli such as IL-1β. 
 
5.4.3 JAM-C regulates Semaphorin expression during inflammation 
Expression of some members of the Semaphorin family of molecules was found to be 
differentially regulated in IL-1β stimulated JAM-C KD HUVECs. To date, only SEMA4F 
has been validated by qPCR as showing a significant increase in expression in JAM-C KD 
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HUVECs following stimulation, but others such as SEMA3G and SEMA3E also indicate a 
trend for increased expression. 
Semaphorins and their receptors, while classically studied as axonal guidance 
molecules in nervous system development, have also been shown to be expressed in 
ECs and have been reported to regulate endothelial functions and inflammatory 
responses (Takamatsu et al., 2010, Sakurai et al., 2012, Aghajanian et al., 2014). For 
example, a number of the Semaphorins have been shown to have either pro-or anti-
angiogenic properties (Acevedo et al., 2008, Sakurai et al., 2012, Segarra et al., 2012). 
In addition, Semaphorin 3A has been shown to increase vascular permeability by 
decreasing VE-Cadherin stability. As JAM-C can regulate both angiogenesis and 
vascular permeability (Orlova et al., 2006, Li et al., 2009, Rabquer et al., 2010), it would 
certainly be intriguing to investigate the relationship between JAM-C and endothelial 
semaphorin expression in such endothelial functions. 
Of most interest to our lab are the emerging roles of Semaphorins in inflammatory 
responses and in particular their roles in leukocyte recruitment. Semaphorin 3A 
(SEMA3A) has been shown to have anti-inflammatory effects in models of 
autoimmune arthritis (Catalano, 2010) and conversely to potently recruit monocytes in 
diabetic retinopathy (Sapieha et al., 2015) and promote inflammation. Semaphorin 7A 
(SEMA7A) has been shown to increase neutrophil migration across EC monolayers in 
vitro (Morote-Garcia et al., 2012). Most notably, Semaphorin 3E (SEMA3E) has recently 
been shown to be a negative regulator of neutrophil migration, both in vitro and in 
vivo (Movassagh et al., 2017). Indeed, in this model it was shown that SEMA3E inhibits 
neutrophil migration towards the main neutrophil chemoattractant IL-8 and also 
reduces allergen-induced neutrophil recruitment in the lungs of mice. Differential 
expression analysis in this model found that SEMA3E expression was increased in JAM-
C KD HUVECs following IL-1β stimulation as compared to control HUVECs. As loss of 
JAM-C has been shown to induce increased neutrophil reverse migration back into the 
circulation in response to stimuli such as IL-1β (Woodfin et al., 2011), the increase in 
expression of SEMA3E could potentially provide a crucial link between EC JAM-C 
expression and this phenomenon. Of course, the increased expression of SEMA3E does 
need to be validated at both the RNA and protein level in both JAM-C KD HUVECs and 
in a murine model of endothelial JAM-C deficiency in vivo. 
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Regarding Semaphorin 4F (SEMA4F), to date most of the research on this protein has 
focussed on its role in the nervous system (Parrinello et al., 2008, Armendariz et al., 
2012), where it has been shown to provide an axonal contact inhibitory signal that 
prevents Schwann cell proliferation. To date there have been no reports on its 
expression in the endothelium. As such, the findings in this work indicating SEMA4F is 
expressed in HUVECs and further increased in expression upon loss of JAM-C provide a 
novel candidate for further investigation in EC biology, particularly under inflammatory 
conditions where JAM-C expression is disrupted. Given that Semaphorin 4F acts as an 
inhibitory molecule during axonal growth, it is potentially possible that it may have a 
similar function during EC processes such as EC migration during angiogenesis or 
perhaps even by influencing leukocyte migration in a similar manner to that seen for 
SEMA3E. 
 
5.4.4 Mechanism of JAM-C regulated gene expression in ECs 
At this point it is pertinent to speculate on how loss of the EC tight junctional molecule 
JAM-C may regulate EC gene expression. In basal conditions, while increased activation 
of the NFκB pathway was detected, it is still unknown how loss of JAM-C might 
promote the activation of this pathway. Perhaps JAM-C might interact with regulators 
of the signalling pathway, such as IKK, thus keeping the basal activation of NFκB low by 
preventing degradation of the NFκB inhibitor IκB. In this context, JAM-C has been 
linked to both the MAPK and PI3K pathways and indeed, soluble JAM-C was shown to 
mediate angiogenesis through activation of EC p38 MAPK and PI3K (Rabquer et al., 
2010), while anti-JAM-C blocking antibodies prevented the activation of the MAPKs 
ERK1/2 in lymphoma B cells (Donate et al., 2016). Both MAPK and PI3K have been 
shown to regulate NFκB pathway activation (Bai et al., 2009, Saha et al., 2007) and as 
such might provide mechanistic links for how loss of JAM-C induces activation of the 
p65 NFκB pathway under basal conditions. 
In a more global sense, the apparent profile of inflammatory priming observed under 
conditions of JAM-C KD could be interpreted as the EC being unable to maintain 
homeostasis. In basal, resting conditions, activation of NFκB and therefore expression 
of pro-inflammatory molecules such as ICAM-1 and IL-8 is kept low, maintaining the 
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homeostasis of ECs. This is achieved through the actions of the transcription factor Erg 
(Shah et al., 2016) which has been shown to repress the basal activity of NFκB subunit 
p65 by preventing it from directly binding to the promoter of genes such as ICAM1 in 
HUVECs (Dryden et al., 2012). One can therefore hypothesise that increased NFκB p65 
activation following JAM-C KD in basal conditions is due to dysregulation of Erg activity 
or localisation, a response that could promote increased expression of NFκB 
responsive genes. Interestingly, Erg expression was not changed in this model (log FC = 
-0.24, P.value = 0.08), indicating that perhaps if this is the mechanism then some 
change at the protein level of Erg may be occurring which would need to be 
investigated in future studies. 
While inflammatory priming of JAM-C KD HUVECs was detected under basal 
conditions, no difference in expression of NFκB responsive inflammatory genes was 
noted between IL-1β stimulated control and JAM-C KD HUVECs. As such, other 
potential signalling mechanisms would need to be considered. It could be that loss of 
JAM-C disrupts the intracellular localisation of binding partners, such as ZO-1 (Ebnet, 
2003). ZO-1 is known to inhibit the activity of an associated transcription factor, 
ZONAB, in epithelial cells (Balda et al., 2003). As such, loss of or disrupted expression 
of JAM-C could impact ZONAB localisation and/or activity, therefore providing a 
potential pathway through which some of the observed differential gene expression 
patterns are brought about in ECs. 
 
5.4.5 Summary of key findings 
The results presented in this chapter demonstrate that silencing of JAM-C expression 
has a significant impact on EC gene expression, both at a basal level and also following 
stimulation with the inflammatory stimuli IL-1β. This provides the first evidence that 
JAM-C regulates gene transcription in ECs. More specifically, this chapter has identified 
the following: 
• EC JAM-C KD causes an apparent inflammatory priming of ECs, characterised by 
increased activation of the NFκB subunit p65 and subsequent increase in 
expression of pro-inflammatory genes such as ICAM1, VCAM1 and IL8. 
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• JAM-C deficient ECs respond aberrantly to IL-1β stimulation. Further 
characterisation of the genes regulated in this comparison will provide valuable 
insight into the modes and mechanisms by which JAM-C regulates EC responses 
in inflammation. 
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6 Investigating the role of EC JAM-C in inflammatory mediator 
generation 
6.1 Introduction 
Activation of the endothelium during inflammatory reactions is critical in coordinating 
an effective immune response. Activation by PAMPs/DAMPs or by proinflammatory 
molecules released by the surrounding damaged tissue induces changes in the 
endothelium that ultimately promotes leukocyte recruitment. Of key importance to 
this response is the generation, secretion and/or presentation of cytokines and 
chemokines by ECs. These responses act to facilitate leukocyte recruitment and hence 
promote an efficient inflammatory response. Extensive characterisation of activated 
ECs has revealed that they are able to produce and secrete a wide range of cytokines 
(IL-1, IL-15, G-CSF) and chemokines (IL-8, CXCL1, CCL2) (Krishnaswamy et al., 1999, 
Speyer and Ward, 2011). Depending on the nature and duration of the stimulus, the 
exact make up of this EC response can vary considerably. 
As mentioned in Chapter 1, the production and presentation of chemokines by ECs in 
vivo is crucial for directing infiltrating leukocytes to the damaged/infected tissue. 
Whilst the impact of pro-inflammatory insults on chemokine generation has been 
extensively studied, little is known about how EC junctional molecules regulate this 
process. More specifically, almost nothing is known regarding the impact of disrupting 
EC junctional molecules on the inflammatory response of ECs, such as generation of 
cytokines/chemokines. 
Some chemokines are known to modulate EC junctions themselves, such as CCL2, 
which has been shown to disrupt both tight junctions through induction of Rho kinase 
activity and also to disrupt adherens junctions by stimulating β-catenin reorganisation 
(Roberts et al., 2012, Stamatovic et al., 2003). Some work in the intestinal epithelium 
has shown that disruption of tight junctions by pathogens reduces the intestinal 
barrier integrity and results in increased IL-8 secretion (Chen et al., 2006). In a related 
manner, studies in breast cancer cell lines have shown that the tight junction protein 
ZO-1 is important for regulating IL-8 production (Brysse et al., 2012). However, the 
literature is scarce on the role of EC junctional molecules and more specifically JAM-C 
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in regulating cytokine/chemokine secretion from ECs. A single study has previously 
shown that JAM-C can regulate chemokine secretion from fibroblast reticular cells. 
Here, it was shown that mice treated with anti-JAM-C antibodies exhibited decreased 
lymph node levels of the chemokines CXCL12, CCL21 and CCL19. This was subsequently 
translated into reduced T cell migration out of lymph nodes (Frontera et al., 2011). As 
such, it was hypothesised that JAM-C might have similar functionality in ECs. 
 
6.2 Aims 
Given the recent work from our laboratory in elucidating the role of JAM-C in 
disrupted modes of neutrophil migration (particularly rTEM), it was decided to 
investigate the role of EC JAM-C in inflammatory mediator generation by ECs. 
Specifically, the aims were as follows: 
• To investigate inflammatory mediator generation by JAM-C KD HUVECs in 
response to IL-1β stimulation. 
• To determine whether EC JAM-C KO mice exhibit altered chemokine levels in IL-
1β stimulated tissues. 
• To investigate whether there are altered plasma chemokine levels in EC JAM-C 
KO mice post local administration of IL-1β. 
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6.3 Results 
6.3.1 Effect of JAM-C KD on IL-1β-stimulated HUVEC chemokine generation 
The findings in Chapter 5 indicated that loss of EC JAM-C had no effect on IL-1β 
induced expression of the prototypical inflammatory EC response genes, such as IL8 
and CXCL1. As such, the same model of JAM-C KD HUVECs was utilised to investigate 
the protein levels of inflammatory mediators by ECs and thereby assess their response 
to a pro-inflammatory stimulus. 
Protein levels of the chemokine IL-8 had already been shown to be elevated in JAM-C 
KD HUVECs under basal conditions (Chapter 5), and so this analysis was extended to 
HUVECs stimulated with IL-1β for 4 hours. Both control and JAM-C KD HUVECs showed 
highly significant (p<0.0001) upregulation of IL-8 protein in the cell associated fraction 
(Figure 6.1A, left panel), with no differences seen between the two cell types. Taken 
together with the gene expression findings, these results indicated that loss of JAM-C 
from ECs has no effect on IL-8 production in HUVECs. 
Analysis of the cell culture medium collected post IL-1β stimulation also revealed a 
highly significant increase in secreted IL-8 from both control and JAM-C KD HUVECs. 
However in contrast to the cell lysate analysis, significantly less IL-8 was secreted from 
JAM-C KD HUVECs (29%) following IL-1β stimulation (Figure 6.1A, right panel). 
The same analysis was extended to CXCL1, also a key neutrophil chemoattractant 
produced by ECs. Like IL-8, both control and JAM-C KD HUVECs showed highly 
significant upregulation of CXCL1 protein in the cell associated fraction (Figure 6.1B, 
left panel). In a similar manner to IL-8, and taken together with the findings in 
Chapter 5 showing no difference in IL-1β induced CXCL1 gene expression, this suggests 
that loss of EC JAM-C has no effect on the cellular production of CXCL1 by HUVECs. 
Significant increased levels of secreted CXCL1 were also found from both control and 
JAM-C KD HUVECs post IL-1β stimulation, however unlike IL-8, no difference in 
secreted CXCL1 was found between the two cell types. 
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Figure 6.1. ELISA analysis of IL-1β induced chemokine generation by JAM-C KD HUVECs. 
HUVECs were transfected with either control or JAM-C siRNA and cultured for 72h to reach 
confluence. Cells were then either stimulated with IL-1β (1 ng/ml) for 4h or left unstimulated. 
Cell culture medium and cell lysates were collected for further ELISA analysis of either IL-8 (A) 
or CXCL1 (B) chemokines. Levels of secreted chemokine in cell culture medium were expressed 
as pg/ml. Levels of cell associated chemokine were expressed as pg/mg protein in the cell 
lysate. Statistical analysis performed using one-way ANOVA with Tukeys multiple comparison 
test. Data is represented as mean ± SEM from at least 5 independent experiments. *** = 
p<0.001, **** = p<0.0001, compared to control unstimulated. # = p<0.05 compared to control 
IL-1β. 
 
  
155 
 
Following the findings of reduced IL-8 secretion from JAM-C KD HUVECs, conditioned 
medium from IL-1β stimulated control and JAM-C KD HUVECs was investigated more 
broadly to assess the potential impact of JAM-C on a wider range of 
cytokines/chemokines. For this purpose, the conditioned medium was subjected to 
analysis by cytokine array, where 32 different mediators were analysed. Conditioned 
medium from three independenet experients was pooled and assayed using a 
Proteome ProfilerTM human cytokine array. Membranes were probed with IRDye-
Streptavidin to enable accurate quantification of cytokine expression. Read-outs less 
than 1000 A.U. were considered to be below the range of accurate detection. 
From the 32 proteins analysed, 12 were noted to be secreted in control cells in 
response to IL-1β (all with read-outs > 1000 A.U.). For ease of analysis, these repsonses 
were plotted according to high (Figure 6.2A), mid (Figure 6.2B) or low (Figure 6.2C) 
expression level. Reassuringly, IL-8 showed the same trend of reduction in IL-1β JAM-C 
KD HUVECs as had been previously verified in Figure 6.1. However, very few 
differences were seen in most other expressed cytokines such as IL-15, CCL2, and 
G-CSF. Interestingly CCL1 seemed to indicate a reduction in levels in IL-1β stimulated 
JAM-C KD HUVECs in a similar manner to that observed for IL-8. Overall though, the 
cytokine profile of IL-1β stimulated control and JAM-C KD HUVECs remained very 
similar, with only IL-8 and CCL1 showing a decrease in secretion from JAM-C KD 
HUVECs. 
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Figure 6.2. Cytokine array analysis of secreted mediators from JAM-C KD HUVECs. 
HUVECs were transfected with either control or JAM-C siRNA and cultured for 72h to reach 
confluence. Cells were then either stimulated with IL-1β (1 ng/ml) for 4h or left unstimulated. 
Cell culture medium was collected from three independent experiments, pooled and then 
subjected to cytokine array analysis. Samples were added to Human Cytokine Array Kit (R&D 
systems) and analysed according to the manufacturer’s instructions. Membranes were 
scanned using the Odyssey system (LI-COR). Levels of individual cytokines were expressed as 
net signal intensity and plotted according to high (A), mid (B) or low (C) expression. 
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6.3.2 Mouse model of EC JAM-C deficiency 
To further investigate the role of EC JAM-C in EC inflammatory mediator generation, a 
mouse model of EC JAM-C deficiency was used. Here, mice homozygous for a floxed 
JAM-C allele were crossed with Tie2Cre transgenic mice in which expression of Cre 
recombinase is driven by the endothelial specific Tie2 promoter. As such, this results in 
the deletion of a portion of the JAM-C allele specifically in ECs, thereby generating an 
EC JAM-C KO mouse. Littermate controls (EC JAM-C WT) were Tie2Cre negative JAM-C 
floxed mice. 
To assess the level of JAM-C expression in ECs in this model, cremaster muscles from 
EC JAM-C KD and littermate control (WT) mice were immunostained for JAM-C, 
PECAM-1 and VE-Cadherin (Figure 6.3A). Post-capillary venules from both EC JAM-C 
WT and KO mice showed similar levels and distribution of VE-Cadherin and PECAM-1 
immunostaining, with most expression of these markers localised to the junctional 
compartment. Junctional JAM-C was also clearly visible in EC JAM-C WT mice, adopting 
a similar pattern of expression to VE-Cadherin and PECAM-1. Some non-junctional cell 
surface JAM-C was also observed. Contrastingly, the post-capillary venules of EC JAM-C 
KO mice showed markedly reduced junctional JAM-C expression, with only some 
immunostaining found in a few cells of venular segments. This was suggestive of a 
good level genetic deficiency of JAM-C (about 50-60%), a result that is in accordance 
with other reports of Tie2Cre recombinase efficiency (Ohashi et al., 2010, Kisanuki et 
al., 2001). However, it should be noted here the findings that Tie2 is also expressed in 
endothelial cells and so use of this model as to generate endothelial specific mouse 
knockouts is not strictly true (Tang et al., 2010b). Indeed, in this study it was found 
that nearly all lineages of hematopoietic precursors (including lymphocytes, 
monocytes and granulocytes) were of Tie2 origin. While expression of JAM-C has not 
been observed in mouse leukocyte populations, one should still be cautious when 
analysing this as a strictly endothelial specific JAM-C KO model.  
Quantification of the level of junctional JAM-C deficiency in this model was performed 
by creating an artificial surface on junctional VE-Cadherin using IMARIS software 
(Bitplane). The mean fluorescence intensity of junctional JAM-C and PECAM-1 was 
then calculated for that surface and is shown in Figure 6.3B. Analysis of JAM-C 
expression revealed a 50% reduction in junctional JAM-C, while PECAM-1 was 
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unaffected. This is in agreement with previous published findings from our laboratory 
(Woodfin et al., 2011) that observed a 40-60% KO efficiency in this model. 
 
 
Figure 6.3. Immunofluorescence staining of EC JAM-C in cremaster muscle venules. 
(A) Cremaster muscles were isolated from EC JAM-C KO and littermate control WT mice and 
immunostained ex vivo for JAM-C (green) PECAM-1 (red) and VE-Cadherin (blue). Images are 
representative from n=3 mice per group and 4-7 vessels per mouse. 
(B) Fluorescence intensity of JAM-C and PECAM-1 at EC junctions was quantified using IMARIS 
Bitplane software. Data are displayed as mean ± SEM from n=3 mice per group. 
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6.3.3 Establishment of a mouse neutrophil depletion protocol 
In an acute inflammatory reaction, neutrophils are the primary responding cells that 
act to counter the offending stimulus and also to release a range of cytokines, 
chemokines and other proinflammatory molecules that facilitate the recruitment of 
additional immune cells. As such, when studying the role of EC JAM-C in pro-
inflammatory mediator generation in vivo, neutrophil-derived mediators could 
contribute to the overall results. Thus, to eliminate the potential role of neutrophils, 
and to gain a better insight into the release of mediators from ECs, control and JAM-C 
KO mice were depleted of their circulating neutrophils prior to investigating 
cytokine/chemokine responses in vivo. 
To achieve this, the well documented method of GR1 mediated neutrophil depletion 
was employed. Specifically, mice were injected with low dose (25 μg) anti-GR-1 
antibody for three consecutive days (Voisin et al., 2009). This antibody binds to GR1 
expressed on neutrophils to target them for removal through the 
complement/macrophage pathway. GR1 is also expressed to some extent on 
monocytes and so it was hypothesised that the lower dose treatment regime would 
limit the impact of the protocol on circulating monocytes. 
Following three days of depletion, blood samples were taken and analysed for total 
leukocytes (CD45+), neutrophils (Ly6G+) and monocytes (CD115+) by FACS (Figure 6.4). 
As can be seen in the FACS plots in Figure 6.4A, non-depleted mice showed both a 
population of Ly6G+ neutrophils (left panel) and CD115+ monocytes (right panel). In 
comparison, mice treated with anti-GR1 antibody showed a complete depletion of 
circulating neutrophils, while the monocyte population was unaffected in these mice. 
Quantification of this depletion is shown in Figure 6.4B, where neutrophils and 
monocytes were represented as percentage of total CD45+ cells. This analysis revealed 
that non-depleted mice had on average 9.1% neutrophils and 4.2% monocytes. By 
contrast, GR1 depleted mice had a greater than 98% depletion of circulating 
neutrophils with a small but non-significant increase in the average monocyte count 
(6.1%). This increase is likely due to the loss of the 9.1% of circulating neutrophils. 
This method of neutrophil depletion was obtained from well-established protocols, in 
which a number of reports have compared anti-GR1 and IgG control antibodies to 
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monitor neutrophil responses. However, this model required only the depletion of 
neutrophils to obtain a clearer picture of EC responses in vivo and as such, mice 
treated with IgG control were not used. 
 
Figure 6.4. GR-1 mediated depletion of circulating mouse neutrophils 
(A) Neutrophil depletion of EC JAM-C KO and littermate control (WT) mice was induced by 
intraperitoneal injection of anti-GR1 antibody at 25μg/day for 3 consecutive days. Blood 
samples were collected on the fourth day and analysed by FACS for levels of blood neutrophils 
(Ly6G+, CD115low) and monocytes (Ly6G-, CD115+). 
(B) Quantification of neutrophil depletion by FACS. Levels of circulating neutrophils and 
monocytes in GR1 depleted and non-depleted mice were calculated as percentage of CD45+ 
cells. Data are representative of n=5 independent experiments and 3-8 mice per group. 
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Statistical significance was calculated using two-way ANOVA with Sidak correction for multiple 
comparisons. Data represented as mean ± SEM, ** = p<0.01. 
 
6.3.4 Impact of EC JAM-C deficiency on tissue mediator generation 
To investigate the role of EC JAM-C in generating inflammatory mediators in tissue in 
vivo, neutrophil depleted EC JAM-C KO and WT mice were injected with IL-1β 
intrascrotally to induce cremaster muscle inflammation. After 4 hours, cremasters 
muscles were dissected out, homogenised and assessed for mediator generation using 
a mouse XL Proteome ProfilerTM cytokine array. Samples from three mice per group 
were pooled and assayed using this method. In the same manner as Figure 6.2, IRDye-
streptavidin was used to enable accurate quantification of each cytokine. All signal 
intensities were normalised to total amount of protein added to each membrane, and 
signal intensities lower than 1000 A.U. were deemed as below the range for reliable 
detection. 
Using this method enabled the analysis of over 100 different molecules, not all of 
which could be graphically displayed in Figure 6.5. Candidate molecules were selected 
in a similar manner to that for Figure 6.2, where molecules that showed notable 
upregulation in response to IL-1β in WT mice were analysed. 
As shown in Figure 6.5, the majority of the molecules that showed a response to 
inflammation were chemokines, many of which showed interesting differences 
between WT and EC JAM-C KO mice following IL-1β stimulation. Chemokines such as 
CCL2 (MCP1) and CXCL1 (KC) were elevated in response to IL-1β in both groups, 
however there seemed to be a partial reduction in the levels of both in EC JAM-C KO 
mice. Other chemokines, such as CCL12 (6Ckine) and CXCL5 (LIX) showed a complete 
failure to respond to IL-1β in EC JAM-C deficient mice. Overall, these results indicated 
that reduced expression of EC JAM-C can impact tissue chemokine generation. 
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Figure 6.5. Cytokine array analysis of IL-1β-induced cremaster muscle chemokine 
generation. 
Mouse cremaster muscles of EC JAM-C KO and littermate control (WT) mice were stimulated 
by intrascrotal injection of IL-1β (50 ng in 400 μl PBS) or PBS alone as control. Cremasters were 
exteriorised, dissected out and 162homogenised for analysis of chemokine generation. N=3 
cremasters from each group were pooled and analysed using a Mouse XL Cytokine Array kit. 
Levels of each cytokine/chemokine were expressed as net signal intensity and plotted 
according to high (A) or low (B) expression. 
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To further investigate these findings, a number of chemokines were selected for 
validation by ELISA (Figure 6.6). The findings here largely mirrored that from the 
cytokine array. Tissue KC levels were significantly increase in both WT and EC JAM-C 
KO mice following IL-1β stimulation (Figure 6.6A). CXCL1 levels in EC JAM-C KO mice 
were slightly reduced (≈20%) compared to WT mice, but this was not statistically 
significant (p=0.19). CCL2 was also significantly increased in both WT and KO mice 
following IL-1β stimulation, but unlike CXCL1 no difference between the two mouse 
groups was noted. 
CXCL5 and CCL5 were generated at much lower levels than KC and MCP1 following 
IL-1β stimulation. Nevertheless, CXCL5 showed a 2.5 fold increase in tissue levels 
following IL-1β stimulation in WT mice, though this was variable and did not reach 
significance in this study (p=0.16). EC JAM-C KD mice showed markedly less CXCL5 
following IL-1β stimulation, about 50% of that observed in WT mice, but again this was 
not statistically significant due to varibility (p=0.28). CCL5 was significantly increased in 
WT mice following IL-1β stimulation and this increase was not observed in EC JAM-C 
KO mice. In fact, CCL5 levels in these mice were the same for both PBS and IL-1β 
stimulation. This resulted in a significant reduction in CCL5 levels in EC JAM-C KO mice 
as compared to WT mice post IL-1β stimulation.  
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Figure 6.6. Analysis of chemokine levels in IL-1β-stimulated cremaster muscles as quantified 
by ELISA. 
Mouse cremaster muscles of EC JAM-C KO and littermate control (WT) mice were stimulated 
by intrascrotal injection of IL-1β (50 ng in 400 μl PBS) or PBS alone as control. Cremaster 
muscles were exteriorised, dissected out and homogenised for ELISA analysis of CXCL1 (A), 
CXCL5 (B), CCL2 (C) and CCL5 (D) generation. Data represent mean ± SEM of 6-8 mice per 
group. Statistical significance determined by one-way ANOVA, * = p<0.05, **** = p<0.0001 
compared to WT PBS. # = p<0.05 compared to WT IL-1β. 
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6.3.5 Local administration of IL-1β increased circulating chemokine levels 
As previously stated, ECs are key generators of chemokines following inflammatory 
stimulation, a process crucial for the recruitment of leukocytes. Having established 
that disrupted JAM-C expression in ECs impacts tissue chemokine generation, the 
plasma chemokine profile of these mice following local IL-1β stimulation was also 
investigated. Cremaster inflammation was induced in the same manner as previously 
detailed, by intrascrotal injection of IL-1β into neutrophil depleted WT and EC JAM-C 
KD deficient mice for 4 hours, upon which blood was collected and harvested for 
plasma and analysis of chemokine content by ELISA (Figure 6.7). 
The same four chemokines detailed in Figure 6.6 were analysed for plasma levels. 
Local IL-1β caused a significant increase in circulating plasma levels of CXCL1 (Figure 
6.7A) in EC JAM-C WT mice compared to PBS controls. By contrast, EC JAM-C KO mice 
showed a much smaller increase in CXCL1 post IL-1β stimulation, about 50% of that 
seen in WT mice. This difference did not reach statistical significance at this time due 
to low n numbers (p=0.11, n=3-4). In a similar manner, CCL2 levels were also 
signigicantly increased post IL-1β stimulation in WT mice, whereas in EC JAM-C KO 
mice no such upregulation was observed in IL-1β treated mice (p=0.069 n=3-4). 
CXCL5 plasma levels showed a trend to increase post IL-1β stimulation in WT mice, 
though this was variable and not significant. Nevertheless, the same trend seen for 
MCP1 was also observed here, with no such signal being present in the EC JAM-C KO 
mice. By contrast, plasma CCL5 levels were much lower in this model following IL-1β 
stimulation. A modest increase was seen in WT mice following IL-1β stimulation, with a 
slight decrease seen in EC JAM-C KD mice. The low levels of CCL5, and the noted 
variability in response, make it hard to draw any conclusions regarding this chemokine. 
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Figure 6.7. Analysis of plasma chemokine levels post-IL-1β stimulation of cremaster muscles. 
Mouse cremaster muscles of EC JAM-C KO and littermate control (WT) mice were stimulated 
by intrascrotal injection of IL-1β (50 ng in 400 μl PBS) or PBS alone as control. After 4h, blood 
was harvested and spun down to collect plasma for analysis of CXCL1 (A), CXCL5 (B), CCL2 (C) 
and CCL5 (D) generation. Data represent mean ± SEM of 2-4 mice per group. Statistical 
significance determined by one-way ANOVA, * = p<0.05 compared to EC JAM-C WT PBS. 
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6.4 Discussion 
It has been well established by our laboratory that disrupted expression of EC JAM-C 
leads to increased frequency of disrupted neutrophil TEM in vivo following 
inflammatory stimulations such as that induced by local IL-1β (Woodfin et al., 2011). 
Generation of chemokines and the subsequent formation of chemokine gradients 
following this stimulation are crucial for guiding effective leukocyte recruitment. ECs 
are well known to produce a wide range of cytokines, chemokines and other 
inflammatory mediators in response to proinflammatory stimuli such as IL-1β, hence it 
was hypothesised that disrupted generation of mediators by JAM-C deficient ECs could 
provide a potential mechanism for aberrant neutrophil trafficking that is observed in 
EC JAM-C deficient mice. 
While much is known about how ECs generate and secrete chemokines, little is known 
about how EC junctional molecules may regulate this process. It has previously been 
shown that fibroblast expressed JAM-C is important for controlling chemokine 
generation in lymph nodes in vivo (Frontera et al., 2011), further strengthening our 
hypothesis that EC expressed JAM-C may function in a similar manner. As such, the 
results in this chapter investigated the role of EC JAM-C in this response, utilising both 
the established in vitro model of JAM-C KD HUVECs and also an EC JAM-C KO mouse 
model. 
 
6.4.1 Loss of JAM-C reduces IL-8 secretion from cultured ECs 
Initial studies focussed on using the model of JAM-C KD HUVECs that was established 
in Chapter 3. As subsequently demonstrated in Chapter 5, JAM-C KD HUVECs showed 
no difference in gene expression of the proto-typical EC response genes to IL-1β; 
ICAM1, CXCL1, IL8, CCL2 etc. This chapter extended this work to investigate the protein 
levels of some of those molecules in JAM-C KD HUVECs, particularly the chemokines IL-
8 and CXCL1. In this context, secreted IL-8 levels were found to be significantly lower in 
JAM-C KD HUVECs. IL-8 is important for directing neutrophil recruitment in humans, 
and as such reduced secretion could impact on neutrophil transmigration (Godaly et 
al., 1997, Hammond et al., 1995). Follow up studies could monitor the transmigration 
of neutrophils over control and JAM-C KD HUVEC monolayers that have been 
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stimulated with IL-1β, so as to assess the functional impact of this reduced IL-8 
secretion in the latter. With regards to other cytokines and chemokines, the secretion 
profile of IL-1β JAM-C KD HUVECs was very similar to that of control HUVECs when 
analysed by cytokine array, suggesting that in this model disrupted expression of 
JAM-C has a relatively selective impact upon IL-8 secretion. It is important here to note 
however that HUVECs are macrovascular ECs, and as such it is important to extend this 
work to a microvascular EC culture models. Ongoing work in the lab is currently aimed 
at analysing primary ECs isolated from the lungs of EC JAM-C KO mice with respect to 
cytokine/chemokine responses to IL-1β. 
 
6.4.2 EC JAM-C regulates tissue chemokine production and secretion in vivo 
As a means to investigate the role of EC JAM-C in chemokine production in vivo, 
neutrophil depleted mice were subjected to local IL-1β stimulation of the cremaster 
muscle. In this way, removal of circulating neutrophils enabled a clearer picture of EC 
chemokine signatures to be obtained in EC JAM-C KD mice. Cytokine array and ELISA 
analysis revealed that a number of tissue chemokines were present at reduced levels 
in inflamed tissues of EC JAM-C KD mice. The neutrophil chemoattractants and 
functional mouse homologs of human IL-8, CXCL1 and CXCL5 (Hol et al., 2010, Smith et 
al., 2008), were both partially reduced. Functionally, this could have an impact on total 
neutrophil recruitment and transmigration in response to IL-1β. Indeed, it has been 
shown that mice treated with a JAM-C blocking antibody exhibited a 33% reduction in 
transmigrated neutrophils in response to IL-1β, using the same cremaster 
inflammation model (Woodfin et al., 2011). As such, it is conceivable therefore that 
reduced tissue production of these neutrophil chemoattractants in conditions of 
disrupted or reduced expression of EC JAM-C could cause the reduction in total 
neutrophil extravasation that was observed in this model. 
In addition, chemokines such as CCL21 and CCL5 were shown not to be upregulated in 
EC JAM-C KD mice in response to IL-1β stimulation, significantly in the case of CCL5. 
The reduction in CCL21 production is similar to those findings reported in fibroblast 
reticular cells (Frontera et al., 2011), suggesting JAM-C may be regulating CCL21 
production through a similar mechanism in fibroblasts and ECs. Given that CCL5 and 
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CCL21 are both important T cell chemoattractants (Christopherson et al., 2003, Schall 
et al., 1990), it would be important to investigate T cell recruitment in this model. 
The chemokine levels analysed are representative of the whole tissue environment. As 
such, many different cell types can and will respond to the IL-1β stimulation and 
contribute to the chemokine microenvironment that is created. It is intriguing 
therefore that loss of JAM-C from ECs specifically causes this striking phenotype across 
the tissue as a whole. While ECs might be directly responsible for the reduced levels of 
some of these chemokines (e.g. CXCL1, CXCL5), the loss of JAM-C from ECs could 
conceivably have a paracrine effect on the surrounding tissue cells, thus resulting in 
reduced production of a number of chemokines and inflammatory mediators. 
As well as generation of chemokines in the tissue, secretion of chemokines into the 
lumen of blood vessels can impact directional migration of leukocytes (Speyer and 
Ward, 2011). As such, the plasma chemokine levels following local cremaster IL-1β 
were also investigated in this model using both WT and EC JAM-C deficient mice. 
Collectively, the results demonstrated that chemokine secretion from ECs was 
considerably reduced under conditions of EC JAM-C deficiency. In particular, CXCL1 
plasma levels were reduced by ≈50% in EC JAM-C KD mice, suggesting a defect in 
secretion of CXCL1 from ECs with reduced JAM-C expression. This could disrupt the 
CXCL1 chemokine gradient that is important for neutrophil TEM and as such could 
have two impacts. Firstly, it could contribute to the reduced number of infiltrating 
neutrophils that has already been reported using the same model (Woodfin et al., 
2011). Secondly, it could lead to disrupted chemokine gradients such that disrupted 
modes of neutrophil TEM, particularly rTEM, are induced. 
In this context, it is also important to note the findings of reduced IL-8 secretion from 
JAM-C KD HUVECs earlier in this chapter, given that this is the functional human 
equivalent of mouse CXCL1. Given the importance of these chemokines in neutrophil 
recruitment, it is possible that there exists a common mechanism through which 
JAM-C regulates the secretion of key chemokines from ECs both in vitro and in vivo. 
Interestingly, CCL2 levels were also not elevated by IL-1β stimulation in EC JAM-C KD 
mice. CCL2 is a key chemoattractant for monocytes and as such this suggests loss of EC 
JAM-C could also impact monocyte recruitment in response to IL-1β. Indeed, it is well 
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established that EC JAM-C is important for directing monocyte TEM. Studies have 
shown that blockade of JAM-C reduces monocyte infiltration and also increases 
monocyte rTEM in vitro and in vivo (Bradfield et al., 2016, Bradfield et al., 2007). 
It is easy to assume here that increased levels of plasma chemokine observed post-
IL-1β stimulation is contributed to mostly by ECs, especially considering they produce 
large quantities of both CXCL1 and CCL2 in response to IL-1β (Vernier et al., 1996). At 
this stage though, one cannot rule out the possibility that chemokines derived from 
other cell types, such as tissue resident macrophages, also contribute to plasma levels 
of these chemokines, which are then transported across the endothelium by ECs 
themselves. Indeed, it is well established that ECs are able to transport chemokines 
from basolateral to apical surfaces (Mordelet et al., 2007, Pruenster et al., 2009) and 
as such, disrupted expression of JAM-C could also impact this chemokine transport. 
The results of this chapter highlight the importance of EC JAM-C in regulating 
chemokine production and secretion, particularly in an in vivo setting. These are novel 
findings, providing the first evidence that an EC junctional molecule can regulate 
responses to inflammation by controlling chemokine generation and secretion from 
ECs. In addition, it adds a new role for JAM-C in regulating EC biology beyond those 
already reported for angiogenesis and leukocyte trafficking. At this point it is pertinent 
to speculate on the specificity of this phenomenon to JAM-C, or whether this 
regulation of chemokine secretion is due to a global instability of EC junctions 
following loss of JAM-C. To address this important point, future works should 
investigate the potential role of additional junctional molecules, such as JAM-A and VE-
Cadherin, in regulation of chemokine generation and secretion.  
6.4.3 Key findings 
• JAM-C KD HUVECs secrete significantly less IL-8 than control HUVECs following 
IL-1β stimulation. 
• No other major changes in cytokine or chemokine responses were observed in 
IL-1β-stimulated JAM-C KD HUVECs. 
• EC JAM-C KO mice have reduced tissue levels of a number of chemokines post 
IL-1β stimulation, notably CCL5, CXCL1 and CXCL5. 
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• Local IL-1β stimulation of EC JAM-C KO mice results in markedly lower plasma 
levels of chemokines CXCL1, CCL2 and CXCL5 as compared to responses noted 
in littermate WT controls. 
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7 General Discussion 
7.1 Project overview 
The tight junction adhesion molecule JAM-C, expressed in a range of cell types and 
tissues, has been shown to be important in regulating endothelial and vascular 
processes such as angiogenesis, permeability and leukocyte transmigration (Lamagna 
et al., 2005a, Orlova et al., 2006, Rabquer et al., 2010, Scheiermann et al., 2009, 
Woodfin et al., 2011). However, the cellular roles of JAM-C within ECs remain poorly 
understood. In particular, the mechanism behind the phenomenon of neutrophil rTEM 
that occurs under conditions of disrupted EC JAM-C expression (Colom et al., 2015, 
Woodfin et al., 2011) is not known. As such, this project sought to identify novel 
cellular functions of JAM-C in ECs and more importantly how this might give insight 
into the JAM-C directed endothelial processes. The findings of this work have 
demonstrated a number of novel findings that contribute to our understanding of the 
role of JAM-C in EC functions: 
• JAM-C deficient ECs exhibit increased autophagy under basal conditions. 
• JAM-C deficient ECs show increased pro-inflammatory gene expression under 
basal conditions. 
• EC JAM-C expression regulates semaphorin gene expression following IL-1β 
stimulation in vitro. 
• EC JAM-C expression is necessary for maintaining plasma chemokine levels in 
vivo. 
 
7.2 In vitro KD of JAM-C enabled the functional study of JAM-C in EC biology 
The inherent complexity in using in vivo models to study cellular functions of a specific 
molecule dictated the need for a simplified model of JAM-C deficiency in ECs. As such, 
transfection of cultured HUVECs with JAM-C specific siRNA was utilised to transiently 
KD JAM-C in vitro. Western Blot and immunofluorescence analysis of these HUVECs 
confirmed a significant KD of JAM-C total protein which was also detected at the 
junctional compartment of confluent HUVECs. Furthermore, this KD was specific to 
JAM-C, with expression of other EC junctional molecules such as JAM-A and VE-
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Cadherin unaffected by transfection with JAM-C siRNA. Of course, the expression of 
other junctional markers should also be investigated under these conditions, especially 
ZO-1 which is a known binding partner of JAM-C (Ebnet, 2003). Investigations are 
currently being undertaken in the lab into further analysing the junctional molecule 
expression in both macrovascular (HUVEC) and microvascular (HDMEC and MLEC) ECs 
deficient in JAM-C expression. 
Having established a reliable and robust level of JAM-C KD in HUVECs, these were 
assessed for basic cellular properties such as proliferation and cell death. Use of siRNA 
for gene silencing can have some off-target activity that could lead to such unwanted 
toxicities on the cells. We purposefully used a pool of two siRNA sequences to target 
JAM-C taken from published research (Li et al., 2009) that target two distinct coding 
regions of the JAM-C transcript. Initially, the two siRNAs were tested individually, but 
were then used in combination and in this way, it enabled them to be used in lower 
individual concentrations. This approach was necessary to help avoid unwanted off-
target and non-specific effects of the siRNAs. JAM-C KD HUVECs showed no difference 
in proliferative capacity when compared to control HUVECs, nor did they exhibit 
increased cell death by apoptosis or necrosis. This enabled us to use this model for 
further investigations into the cellular function of JAM-C in ECs. 
 
7.3 JAM-C KD ECs exhibit increased autophagy in vitro 
Using the aforementioned system, initial investigations into the impact of JAM-C loss 
on EC cellular functions focussed on the basal characteristics of these cells. 
Interestingly, JAM-C deficient ECs were found to exhibit significantly higher levels of 
LC3-II than their control counterparts under basal growth conditions. Furthermore, this 
increase in LC3-II was abrogated by treatment with the pan-PI3K inhibitor 3-MA, 
indicating that the canonical pathway that leads to the induction of autophagy is 
increased in JAM-KD HUVECs. This is the first demonstration that an endothelial tight 
junction molecule can modulate such a cellular process. Importantly, these findings are 
consistent with previous unpublished works from our laboratory (Catherine Pickworth) 
which have shown that EC JAM-C deficient mice also exhibit increased EC LC3 positive 
vesicles under basal conditions. 
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Classically, autophagy is a process used by cells to turnover defunct proteins and 
organelles to provide the cell with recycled nutrients in times of cellular stress (e.g. 
starvation, hypoxia). It has also been shown to be increased by numerous other 
cellular stressors (e.g. inflammation, shear stress). As such, our data suggests that loss 
of JAM-C could represent a destabilisation of EC junctions that might in turn induce a 
stress response in ECs, resulting in the upregulation of autophagy. 
This study has not explored the mechanism by which loss of JAM-C results in increased 
EC autophagy. However, some recent findings on the golgi stacking protein GRASP55 
enable us to speculate on a potential mechanism. GRASP55 has been shown to 
interact with JAM-C in germ cells (Cartier-Michaud et al., 2017) and has also been 
shown to be necessary for secretion of IL-1β through an unconventional secretory 
autophagy pathway (Dupont et al., 2011). While an interaction between JAM-C and 
GRASP55 has not yet been identified in ECs, it is plausible to speculate that binding of 
JAM-C to GRASP55 sequesters GRASP55 at EC junctions. Under conditions of JAM-C 
deficiency, GRASP55 could be released enabling it to regulate the autophagy pathway. 
  
7.4 JAM-C controls pro-inflammatory gene expression under basal 
conditions 
To continue characterising JAM-C KD ECs, we performed genome wide expression 
analysis of these cells. Under basal conditions, the expression of a number of pro-
inflammatory genes (e.g. ICAM1, CXCL1, IL8 & VCAM1) were increased in JAM-C KD 
HUVECs, suggestive of a primed or pro-inflammatory state of these cells. Indeed, the 
NFκB pathway was significantly upregulated in JAM-C KD HUVECs under basal 
conditions, a response that could potentially be responsible for the noted increase in 
expression of pro-inflammatory genes. 
To date, there are no reports of JAM family members regulating EC gene expression. In 
fact, the literature is rather scarce on the role of any junctional molecules in regulating 
cellular gene expression responses. The TJ molecule ZO-1 is known to interact with the 
transcription factor ZONAB which is important for regulating gene expression in 
epithelial cells (Lima et al., 2010, Nie et al., 2009). Given the relative lack of knowledge 
of this area, the findings from this thesis are novel additions to the field. Ongoing 
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works are aimed at unravelling how JAM-C regulates pro-inflammatory gene 
expression in ECs and the functional consequences of this. 
At this point it is pertinent to discuss these findings in relation to the observations of 
increased autophagy in JAM-C deficient ECs. Generally speaking, autophagy is an anti-
inflammatory process, functioning to dampen aberrant inflammation and maintain 
cellular homeostasis under basal conditions. In particular, it has been shown that 
autophagy acts to negatively regulate the NFκB signalling pathway by increasing IKK 
protein degradation and hence prevent pro-inflammatory gene expression (Qing et al., 
2006). It is intriguing therefore that JAM-C deficient ECs exhibit both increased 
autophagy and increased NFκB mediated pro-inflammatory gene expression. Why this 
is the case remains unclear, although it is possible that loss of EC JAM-C activates the 
NFκB pathway independently of IKK proteins.  
While the gene expression analysis has identified a number of interesting avenues and 
pathways, there is potential for further interpretations to be made from this data set. 
Indeed, over 500 genes from the unstimulated comparison and nearly 1000 from the 
IL-1β stimulated comparison were defined as differentially regulated by JAM-C in ECs. 
As such, further network and pathway analysis could provide further insight into the 
role of JAM-C in EC functions beyond those already described in the literature. 
 
7.5 JAM-C regulates semaphorin gene expression in ECs 
Expansion of the gene expression analysis to JAM-C KD ECs stimulated with IL-1βs 
highlighted a number of interesting findings. Perhaps one of the most interesting was 
the differential expression of a number of genes in the semaphorin family. In 
particular, SEMA4F and SEMA3G expression was upregulated in JAM-C KD HUVECs 
following IL-1β stimulation. The semaphorin family of molecules were originally 
identified as axonal guidance molecules that regulate the development of the central 
nervous system. More recently however, there is growing evidence for roles for these 
molecules in functions of ECs, where they have been shown to regulate processes such 
as angiogenesis, vascular permeability and also leukocyte TEM (Sakurai et al., 2012, 
Hou et al., 2015, Morote-Garcia et al., 2012, Takamatsu et al., 2010). These findings 
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are the first to indicate that an EC junctional molecule can regulate the expression of 
semaphorin molecules. 
How this increase in expression of semaphorins might relate to JAM-C-dependent is 
unknown. SEMA3E, has been shown to negatively regulate neutrophil migration 
(Movassagh et al., 2017) and was shown to be increased in expression in JAM-C KD 
HUVECs. As such, increased expression of this chemorepellent semaphorin could 
provide a link between loss of JAM-C and the increased frequency of neutrophil 
reverse migration in response to IL-1β stimulation that has been demonstrated by our 
lab (Woodfin et al., 2011). In addition, increased expression of these markers could 
provide insight into the mechanisms by which JAM-C regulates other endothelial 
processes, such as angiogenesis and permeability. A number of semaphorins are 
known to be either pro- or anti-angiogenic, or to modulate vascular permeability. For 
example, Semaphorin 3E is potently anti-angiogenic (Sakurai et al., 2010) and its 
expression is increased in this model, while it has previously been shown that blockade 
of JAM-C reduces angiogenesis in vivo (Lamagna et al., 2005a). As such, it is possible 
that these two findings are intrinsically linked, where increased semaphorin expression 
contributes to the mechanism through which JAM-C blockade inhibits angiogenesis 
(Lamagna et al., 2005a). 
While the investigations into the relationship between JAM-C and semaphorin 
expression are at an early stage, they provide a number of exciting avenues for further 
work. The results detailed in this thesis only describe an increase in gene expression of 
these molecules and future works need to confirm protein levels of these markers, as 
well as investigating the functional impacts of this increased expression on leukocyte 
migration and angiogenesis using in vivo models. 
 
7.6 JAM-C regulates chemokine secretion in vivo 
One of the key aims of this project was to identify potential mechanisms by which loss 
of EC JAM-C results in an increased frequency of neutrophil rTEM, especially post IL-1β 
stimulation. As such, it was hypothesised that disrupted production of chemokines 
from ECs deficient in JAM-C might result in a disrupted chemokine gradient that could 
subsequently account for this phenomenon. 
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This part of the project was investigated mostly in an in vivo setting, taking advantage 
of EC specific JAM-C KO mice to investigate tissue and plasma chemokine levels 
following a local inflammatory stimulation. Neutrophil depleted mice were given an 
intrascrotal injection of IL-1β, following which cremaster muscles and plasma were 
analysed for IL-1β-induced chemokine production. On the whole, tissue chemokine 
levels remained largely unaffected by loss of EC JAM-C, with the exception of CCL5, 
which was not upregulated in EC JAM-C KO mice. As this chemokine is classically 
associated with the chemotaxis of T-cells (Kawai et al., 1999, Schall et al., 1990), this 
could highlight a potential defect in recruitment of T cells JAM-C is shed from ECs. 
Furthermore, this chemokine has also been shown to be chemotactic and activating 
for a number of other leukocyte sub-types, including neutrophils (Di Stefano et al., 
2009), and as such could therefore also impact on their migration in this model also. 
Analysis of plasma chemokine levels revealed a distinctive change in EC JAM-C KO mice 
following a local IL-1β stimulation. In particular, chemokines such as CXCL1, CCL2 and 
CXCL5 were all reduced in the plasma of EC JAM-C KO mice. In concordance, JAM-C KD 
HUVECs showed significantly reduced secretion of IL-8 chemokine, the functional 
human homolog of mouse CXCL1. While this chemokine secretion defect has only been 
described here in response to IL-1β, additional works can investigate whether other 
inflammatory stimuli such as LPS and I/R injury have the same effect in in EC JAM-C KO 
mice and JAM-C KD ECs. 
The results in Chapter 5 detailed that there was no difference in gene expression of 
many pro-inflammatory markers, including chemokines, in cultured JAM-C KD ECs. As 
such, this suggests that this reduction in chemokine levels exists purely at the protein 
level, and more specifically points towards a defect in secretory pathways. The 
mechanism behind this reduced secretion was not investigated in this project due to 
time constraints, but it could be hypothesised that increased EC autophagy, exhibited 
both in vitro and in vivo by JAM-C deficient ECs, could be pivotal to this process. Taking 
these findings together, it can be hypothesised that in JAM-C deficient ECs stimulated 
with IL-1β, chemokines are expressed by the cell, but may be abnormally trafficked to 
autophagosomes, where they might be degraded rather than secreted. Conversely, the 
increase in canonical autophagy might sequester autophagy proteins away from the 
pathway of unconventional secretory autophagy, therefore leading to the decreased 
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secretion phenotype that is observed. While unconventional secretory autophagy has 
so far only been described for the secretion of IL-1β and HMGB1 (Dupont et al., 2011), 
it is not inconceivable that chemokine secretion from ECs could also involve this 
pathway. Alternatively, this defective chemokine secretion could be in part due to 
disrupted polarisation of JAM-C deficient ECs. JAM-C is known to bind to the polarity 
protein partitioning defective 3 homolog (PAR3) and regulate cell polarity (Ebnet, 
2003) and as such, disrupted polarity of JAM-C KD ECs could result in dysregulated 
polarity of protein secretion. 
 
7.7 Future perspectives 
7.7.1 Targeted KD of additional EC junctional molecules and comparison with EC 
JAM-C KD phenotype 
Whilst this project has identified the role of JAM-C in regulating a number of cellular 
functions of ECs, a number of important works need to be done to confirm these 
findings. Of most importance is the comparison of the observed phenotypes in JAM-C 
KD ECs with ECs deficient in other EC junctional molecules, such as JAM-A, VE-Cadherin 
and PECAM-1. Such experiments would be aimed at confirming the specificity of the 
observed phenotypes to JAM-C, and more importantly to confirm that they are not 
due to global junctional instability. As such, evaluation of the key findings in JAM-A 
and/or VE-Cadherin KD ECs in terms of autophagy, gene expression and chemokine 
secretion are required. 
In addition, the majority of the in vitro works in this project were undertaken in 
macrovascular ECs using HUVECs. Additional experiments on JAM-C KD microvascular 
ECs would further increase the understanding of the role of JAM-C in regulating EC 
functions in different vascular cell types. Such works could be undertaken using 
microvascular cells isolated from lungs of EC JAM-C KO mice, that could also help to 
reinforce ongoing associated in vivo works. 
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7.7.2 Investigation into the impact of increased pro-inflammatory gene expression 
under basal conditions 
The results presented here showed an increase in expression of a number of pro-
inflammatory molecules in JAM-C KD ECs, both at the mRNA and protein level, 
including molecules such as ICAM-1 and IL-8. This begs the question as to whether 
JAM-C deficient ECs might support increased rolling, adhesion, or even transmigration 
of leukocytes under basal conditions, thus providing a functional readout to these 
findings. This could be investigated in both an in vitro and in vivo setting. Human 
neutrophils and monocytes could be perfused over control and JAM-C KD HUVECs 
cultured in transwell plates, an assay that would enable the monitoring of rolling, 
adhesion and transmigration. In addition, brightfield IVM experiments could be used 
to monitor the rolling and adhesion of leukocytes in EC JAM-C KO mice, whilst confocal 
microscopy of whole mount tissues could be used to monitor leukocyte transmigration 
in unstimulated EC JAM-C KO mice. 
In addition, it would be interesting to analyse the naïve circulating leukocyte numbers 
of EC JAM-C KO mice under unstimulated conditions. The increased expression of 
chemokines that was observed in JAM-C KD HUVECs could be translated to an effect 
on the level of circulating neutrophils and/or monocytes in EC JAM-C KO mice. Indeed, 
increased basal tissue expression of such chemokines such as CXCL1 and CCL2 might 
induce increased leukocyte mobilisation into the circulation. Analysis of this could be 
achieved through FACS analysis of whole blood from EC JAM-C KO mice and littermate 
controls to identify leukocyte subsets. 
 
7.7.3 Physiological impact of increased EC autophagy in JAM-C deficient ECs 
The data in this project has shown that JAM-C KD ECs have increased autophagy under 
basal conditions. The consequence of this increased autophagy on endothelial 
functions is yet to be identified and as such represents an important next step for this 
project. Work is currently ongoing to investigate the level of autophagy in JAM-C KD 
ECs following inflammatory stimulation, such as with IL-1β and LPS. This will be 
performed both in vitro, using the established JAM-C KD HUVEC model, and also in 
vivo, using EC JAM-C KO mice. In addition, it would also be useful to perform rescue-of-
function experiments and investigate whether the overexpression of an siRNA 
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resistant or mouse JAM-C construct in JAM-C KD HUVECs restores the basal level of 
autophagy. 
Following this, additional studies could be conducted using EC ATG5 KO mice, a model 
of autophagy deficiency in ECs. Such a mouse colony could be used to identify the role 
of autophagy in leukocyte migration, which could be conducted by brightfield and 
confocal IVM using the cremaster model of inflammation. As blockade of JAM-C with 
functional blocking antibodies achieves a similar increase in autophagy to that seen in 
EC JAM-C KO mice, this method could also be used to investigate whether abrogating 
autophagy when JAM-C is disrupted affects neutrophil rTEM phenotype in response to 
IL-1β stimulation.  
 
7.7.4 Mechanism of reduced chemokine secretion and impact on neutrophil TEM 
As discussed in section 7.6, the mechanism by which the reduced chemokine secretion 
from JAM-C deficient ECs occurs is not known. As such, future experiments could use 
the EC ATG5 KD mice to investigate chemokine secretion into the plasma following 
inflammatory stimulation. This could be confirmed by using ATG5 KD HUVECs and 
evaluating levels of secreted chemokines such as IL-8, which is known to be reduced 
from JAM-C KD HUVECs. Following this, a double KD of both JAM-C and ATG5 in vitro 
could be used to see if abrogating autophagy in JAM-C KD ECs restores the normal 
secretory phenotype. While this is difficult to replicate in an in vivo setting, one 
approach could be to use JAM-C blocking antibodies in EC ATG5 KO mice, thus enabling 
the investigation in vivo into whether reduced autophagy in ECs with disrupted JAM-C 
expression rescues the plasma levels of chemokines. 
The effect of JAM-C KD on the polarised secretion phenotype of ECs could be 
investigated in an in vitro setting. Using a transwell system, JAM-C KD HUVECs and 
MLECs isolated from EC JAM-C KO mice could be assessed for apical and basolateral 
secretion of chemokines, to investigate whether depolarised secretion is responsible 
for decreased plasma chemokine levels in EC JAM-C KO mice. 
On the other hand, the physiological impact of this reduced chemokine secretion in 
vivo needs to be addressed. In particular, investigations should be undertaken to 
identify whether the reduced plasma chemokine levels in EC JAM-C KO mice are 
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connected to the phenomenon of increased neutrophil rTEM that is observed in these 
mice. As such, experiments could be designed by which WT mice are given intrascrotal 
injection of IL-1β to induce inflammation and then analysed for neutrophil and/or 
monocyte transmigration events by confocal IVM. It would also be interesting to try to 
mimic the reduced plasma chemokine levels from EC JAM-C KO mice in WT mice. One 
approach could be to use blocking antibodies to KC and LIX that could be injected in 
low doses intravenously following IL-1β stimulation, in order to achieve a partial 
reduction in the circulating levels of these chemokines. Confocal IVM could then be 
used to assess leukocyte migration dynamics in this model. 
 
7.8 Wider implications of this work 
The aim of this project was to deepen our understanding of the role of JAM-C in EC 
biology, so that this can be translated to human conditions where JAM-C is known to 
be important. The mouse model of ischemia reperfusion, which results in disrupted 
and reduced EC JAM-C expression (Woodfin et al., 2011), can be clinically linked to 
many forms of major human trauma. Here the hypoxic environments created by the 
trauma affect tissues and organs is key in the pathogenesis of disease, such as stroke, 
myocardial infarction, or major traumatic events. It has been shown by our group that 
in such inflammatory reactions, cleavage of JAM-C by neutrophil elastase (NE) leads to 
reduced endothelial JAM-C expression (Colom et al., 2012) as well as increased soluble 
JAM-C in the plasma of mice, and subsequently an increase in reverse migrated 
neutrophils. In a similar manner, major trauma patients also exhibit increased serum 
levels of JAM-C. Increased frequency of neutrophil rTEM is associated with increased 
second organ injury, a phenomenon which occurs with high frequency in major trauma 
patients, where susceptibility to developing conditions such as acute respiratory 
distress syndrome (ARDS) not related to the original trauma are high (Bakowitz et al., 
2012, De'Ath et al., 2012). As such, the findings presented in this thesis are crucial in 
unravelling the mechanisms by which such phenomenon occur and provide the 
groundwork for investigating the link between neutrophil rTEM and secondary organ 
injury. This work also opens up potential for new biomarkers in the pathogenesis of 
JAM-C related diseases, such as trauma, as described earlier. For example, JAM-C 
itself, or rather soluble levels of JAM-C, could also be a potential predictive biomarker 
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for disease severity in these patients. Cleavage of JAM-C by neutrophil elastase during 
neutrophil TEM increases circulating levels of sJAM-C in mice and correlates with 
distant organ injury. This concept which is currently being investigated in the lab, 
where serum samples of trauma patients with varying disease severities and distant 
organ injury are being analysed for sJAM-C. 
JAM-C is also known to be important for the pathogenesis of other human conditions, 
such as Rheumatoid Arthritis, where JAM-C expressed on both the endothelium and 
synovial fibroblasts acts to recruit and retain leukocytes in the synovium, so 
progressing the state of this disease (Rabquer et al., 2008). As such, it has been 
postulated that targeting JAM-C in this model would be beneficial in preventing 
leukocyte retention. However, our findings here dictate that more considerations need 
to be taken before applying such methods as treatment.  For example, the data in this 
thesis suggests that while targeting EC JAM-C expression could impact plasma 
chemokine levels, this may also be the mechanism by which increased neutrophil rTEM 
is brought about. As such, targeting of JAM-C in this model, while potentially limiting 
local leukocyte infiltration, might also have the unwanted adverse effect of increasing 
second organ injury as a result of increased reverse migrated neutrophils. 
Atherosclerosis models have proposed a role for JAM-C in retention of monocytes in 
atherosclerotic plaques and that blockade of JAM-C reduces the number of 
atherogenic monocytes by increasing their rTEM out of the plaques (Bradfield et al., 
2016). As such, JAM-C again provides an attractive target for treatment in this disease 
but considering our findings this should also be approached with caution. While 
targeting JAM-C in this model might achieve the desired effect of monocyte rTEM out 
of atherogenic plaques and so halting disease progression, such treatment might also 
potentially have adverse effects. Indeed, atherosclerotic patients are also likely to be 
at higher risk of events such as stroke and myocardial infarction, episodes in which a 
JAM-C targeted therapy could exacerbate the disease and increase likelihood of 
secondary organ inflammations such as ARDS.  
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7.9 Conclusions 
In conclusion, this study undertook rigorous investigations into the cellular role of EC 
JAM-C, with the aim to identify potential mechanisms behind the functional 
consequences of its disrupted expression that can occur during various inflammatory 
situations. We have identified a novel role for JAM-C in regulating both EC autophagy 
and EC pro-inflammatory gene expression under basal conditions. Furthermore, we 
have also identified a new relationship between the level of JAM-C expression and 
expression of semaphorins in ECs, an exciting and novel concept. And finally, this 
project has also begun to unravel the role of JAM-C in inflammatory responses, in 
particular how it is important in regulating EC chemokine secretion, an avenue that 
needs further investigation within the context of leukocyte migration. Taken together, 
the results presented in this thesis highlight the importance of JAM-C in EC biology at 
multiple novel angles. 
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Appendices 
Appendix 1. Isotype control antibody staining for JAM-C. Untransfected HUVECs were 
cultured for 48-72 h to reach confluence and then fixed for 15 mins in 4% PFA at room 
temperature. Cells were then immuno-stained for VE-Cadherin and DRAQ5 (lower 
panel) and with either Rabbit anti-JAM-C (top-left panel) or Rabbit IgG control 
antibodies (top-right panel). Images were taken using a Zeiss LSM800 confocal 
microscope. 
 
  
185 
 
Appendix 2. Isotype control antibody staining for LC3. Untransfected HUVECs were 
cultured for 48-72 h to reach confluence, then subjected to 2 hours of starvation 
treatment with addition of Bafilomycin A1 (100 nM) to induce LC3 puncta formation, 
then fixed for 3-5 mins in 100% methanol at -20oC. Cells were then immuno-stained for 
VE-Cadherin and DRAQ5 (lower panel) and with either Rabbit anti-LC3 (top-left panel) 
or Rabbit IgG control antibodies (top-right panel). Images were taken using a Zeiss 
LSM800 confocal microscope. 
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Appendix 3. List of chemorepulsive genes from pathway analysis. 
 
Gene Molecule name 
BDNF Brain-derived neurotrophic factor 
BMP7 Bone morphogenic protein 7 
CXCL12 Chemokine CXCL12 
CXCR4 Chemokine Receptor CXCR40 
cAMP Cyclic AMP 
FLT1 VEGFR1 
FYN Fyn kinase 
GDF7 Growth differentiation factor 7 
GDNF Glial cell derived neurotrophic factor 
NRCAM Neuronal cell adhesion molecule 
NRP1 Neuropilin 1 
NRP2 Neuropilin 2 
NTN1 Netrin-1 
PKA Protein kinase A 
PLXND1 Plexin D1 
PTPRZ1 Receptor-type tyrosine-protein phosphatase ζ 
RHOD RhoD 
ROBO1 Roundabout guidance receptor 1 
ROBO2 Roundabout guidance receptor 2 
SCN1B Sodium channel subunit β1 
SCN2B Sodium channel subunit β2 
SEMA3A Semaphorin 3A 
SEMA3B Semaphorin 3B 
SEMA3D Semaphorin 3D 
SEMA3E Semaphorin 3E 
SEMA3F Semaphorin 3F 
SLIT2 Slit homolog 2 protein 
TNR Tenascin-R 
UNC5A Netrin receptor 5A 
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